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 One of the hallmarks of cancer is genomic instability driven by DNA damage. Cells 
respond to these genetic insults through chromatin-based mechanisms that repair the 
damage. Chromatin plays a pivotal role in protecting cells from genome and epigenome 
instability that drive cancer progression. Chromatin, a highly dynamic complex of DNA 
and proteins, undergoes structural and functional changes in response to cellular factors 
that are essential for replication, transcription, DNA damage responses (DDR) and repair. 
Chromatin structure and function are highly dependent on histone modifications. 
Histones are modified on distinct amino acids by post-translational modifications 
(PTMs). Delineating chromatin-regulated processes are fundamental for understanding 
the nuclear pathways that regulate access to, and protection of, our genetic and epigenetic 
information. The first part of my project focused on analyzing the contribution of a 
chromatin domain, the nucleosome acidic patch in regulating histone H2A/X 
ubiquitination and the DDR using in vitro and in vivo approaches. I established 
techniques to biochemically purify human recombinant histones and reconstituted 
nucleosome core particles (NCPs) containing WT or acidic patch mutant H2A/X for in 
vitro Ub assays with purified E3 ligases, RNF168 and RING1B/BMI1. Both E3s 
ubiquitinated H2A/X within WT NCPs but not mutant NCPs. Thus, this assay confirmed 
our hypothesis that the effect of the acidic patch mutation on H2AX/ H2Aub is direct and 
that it mediates site-specific ubiquitinations. I showed that the acidic patch interacting 
peptide LANA could compete with RNF168 and RING1B/BMI1 dependent H2AX/H2A 
 viii 
Ub. In the second project, I tested how chromatin alters targeting of an anticancer drug 
using a cisplatin derivative that acts on the genome. I identified that cotreatment of 
cisplatin and the clinically approved drug Vorinostat/SAHA generated clusters of lesions 
that co-localized with translesion synthesis factors. However, I found that activated 
translesion synthesis no longer acted as a bypass mechanism but instead promoted 
apoptosis. These results demonstrated that pharmacological alterations of chromatin 
reprograms genome targeting with platinum drugs and, concomitantly, drug response.  
The third project for my thesis work involves functional analysis of the bromodomain 
containing TRIM proteins in DDR. These proteins belong to the bromodomain (BRD) 
family, which are the readers of PTM acetylation. I identified specific domains in 
TRIM24 required for its recruitment to damaged DNA and its dependency on other 
chromatin associated factors, namely, SUV39H1, KAT6B, TRIM28, TRIM33 that 
regulate TRIM24 dynamics in the context of DNA damage. I validated some interactors 
of TRIM24, TRIM28 and TRIM33 including the FACT and MCM complex. In summary, 
knowledge gained from these studies will help to understand how these BRD reader 
proteins promote the DDR within acetylated chromatin to preserve genome stability. 
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CHAPTER 1: INTRODUCTION 
 
THE DNA DAMAGE RESPONSE 
Maintenance of genomic integrity through the preservation of genetic information 
is crucial for organismal survival and homeostasis. Genomic instability can be caused by 
high incidences of DNA damage that occur frequently in cells as a consequence of 
recurrent exposure to genotoxic cellular processes and agents including replication stress, 
reactions involving production of metabolic by-products, transcription-associated 
damage, and exposure to external factors including UV radiation, environmental agents, 
and clinical treatments like radiotherapy and chemotherapeutics (1, 2). DNA damage 
must be detected and repaired in a timely and efficient manner to avert genomic and 
cellular alterations that can cause diseases, including cancer (2). To combat the harmful 
effects posed by DNA damage, cells use a highly coordinated network of DNA damage 
response (DDR) pathways to detect the damaged DNA lesion, signal its presence to 
downstream effector proteins, which orchestrate the appropriate cellular responses and 
DDR pathways to repair the lesion by damage-specific repair pathway such as double 
strand break repair, nucleotide exchange repair, base excision repair or mismatch repair 
(1, 2). Nuclear eukaryotic DNA is bound by histone proteins and structurally organized 
 
Portions of this chapter have been published as follows: 
Ø Poonam Agarwal and Kyle M. Miller (2016) The nucleosome: orchestrating DNA 
damage signaling and repair within chromatin. Biochemistry and Cell Biology 
94: 1–15. (Contributions: P.A. and K.M.M. wrote the manuscript together). 
Ø Poonam Agarwal and Kyle. M. Miller  (2016) Book chapter: Chromatin 
Dynamics and DNA repair in Chromatin Regulation and Dynamics, Elsevier 
     (Contributions: P.A. and K.M.M. wrote the manuscript together). 
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into chromatin through the formation of nucleosomes, the basic unit of chromatin which 
consists of ~146 bp of nuclear DNA wrapped around the octameric histone core. 
Chromatin therefore constitutes the legitimate in vivo substrate in which all processes 
involving DNA occur, including DNA replication, transcription, and repair. Thus, the 
DNA damage response and repair machinery that operates at the sites of DNA damage 
must function within the context of chromatin (Figure 1.1). It is well established that a 
 
Figure 1.1 Chromatin and the DNA damage response  
Nuclear DNA in eukaryotes is organized into nucleosomes and packaged in higher-order 
chromatin structure that regulates several DNA-based processes including DNA repair. 
 DNA damage occurs within chromatin where specialized DNA repair pathways detect, 
signal and  promote an appropriate DNA-damage repair pathway in order to maintain 
genome integrity. DNA damage response pathways (DDR) cooperate with various 
chromatin pathways to orchestrate DNA repair within the context of chromatin (3).  
multitude of DNA repair factors are recruited to chromatin upon DNA damage and that 
chromatin features, including chromatin architecture, histone modifications, histone 
variants and chromatin remodeling complexes, shape the epigenetic landscape to 
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orchestrate DNA repair reactions within the chromatin environment (4-7). What is less 
clear however is how specificity for chromatin binding and modification of histones by 
DDR factors is achieved within chromatin to promote DNA damage signaling and repair. 
 
CHROMATIN DYNAMICS AND DNA DOUBLE-STRAND BREAK REPAIR 
DNA double-strand breaks (DSB) are considered a particularly dangerous DNA 
lesion, as failure to repair the broken ends accurately can promote genomic instability 
through chromosome loss, rearrangements and (or) mutations. DSBs are repaired by 2 
prominent repair pathways in mammalian cells, namely, homologous recombination 
(HR) or non-homologous end-joining (NHEJ) (8). The two repair pathways differ in their 
requirement for a homologous template DNA and in the fidelity of DSB repair. HR uses 
an undamaged sister chromatid sequence as a template to faithfully repair the DSB, while 
NHEJ is a potentially more error-prone pathway that repairs the break through ligating 
the broken ends together. In mammalian cells, NHEJ is the predominant repair pathway 
active throughout the cell cycle, while HR is restricted to S/G2 phases, cell cycle stages 
in which a sister chromatid is available for repair (9-11). Control of these two pathways 
necessitates the regulation of chromatin/nucleosome modifications that take place 
surrounding the break. Histone post-translational modifications (PTMs), histones 
exchange, and nucleosome remodeling complexes participate in altering the chromatin 
landscape to facilitate DDR activities, which ultimately lead to the repair of the damaged 
DNA. Whether the damaged lesion is repaired by NHEJ or HR pathway, detection of the 
damaged DNA and initiation of either of these DSB repair processes requires recruitment 
of chromatin-modifying enzymes for remodeling of the damaged chromatin. Histone 
modifications serve as one mechanism that opens or condenses the chromatin structure by 
changing the nucleosome-DNA, nucleosome-nucleosome and (or) nucleosome/ 
chromatin protein interactions. ATP-dependent chromatin remodelers alter the chromatin 
 4 
 
Figure 1.2 Various pathways involved in chromatin dynamics and DNA repair  
(A) Histone modifications. (B) Histone PTM modifying and binding proteins that 
“write,” “erase,” and “read” chromatin marks. (C) Histone variants. (D) Histone 
chaperones, and (E) Chromatin remodeling complexes that regulate nucleosome and 
chromatin dynamics through activities including sliding and eviction of nucleosomes. A 
limited set of examples for each category is provided (3). 
landscape by sliding, evicting, or exchanging histones, including variants or modulating 
nucleosome–DNA interactions to promote DNA damage signaling and repair (4, 12-16) 
(Figure 1.2 A-E). The collective utilization of these pathways is essential for maintaining 
genome integrity and averting diseases including cancer. 
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HISTONE POSTTRANSLATIONAL MODIFICATIONS (PTMS) IN 
CHROMATIN REGULATION AND THE DDR 
Histone PTMs can impact chromatin structure to provide DNA accessibility to 
DDR factors to facilitate repair. Eukaryotic genomes contain multiple chromatin states 
that change depending on cell type and cell-cycle phase as well as the processes that act 
upon a particular region of the genome at any given time. For example, active 
transcription correlates with an “open” chromatin configuration (i.e. euchromatin) while 
transcriptionally repressed regions results in a more “closed” chromatin state (i.e. 
heterochromatin). A mechanism that regulates chromatin states is the PTMs that decorate 
histones. The basic charge of histones is due to the high proportion of positively charged 
lysine and arginine residues that are found in all histone proteins. Negatively charged 
DNA interacts electrostatically to regions of the histone that contain these amino acids. 
Modifications of either lysines or arginines have the potential to disrupt DNA/protein and 
protein/protein interactions by changing the charge of the modified amino acid (17, 18). 
Histone PTMs, including phosphorylation, ubiquitination, methylation, and 
acetylation, can also serve as molecular DSB recognition signals for PTM “reader” 
proteins that selectively recognize and bind to these modifications on chromatin (4, 12, 
19-21). For example, the first histone signaling event identified upon DSB induction was 
the phosphorylation on serine-139 of the histone variant H2AX (called γH2AX) (22). 
This modification is triggered by the activation of the DDR kinases, including ATM and 
DNA-PK that are themselves recruited to and activated by signaling processes that 
include DNA ends of the DSB. Although initiated at the DSB, the γH2AX modification 
spreads over a megabase of chromatin flanking the DSB site by an amplification loop 
involving the binding of γH2AX by the phospho-reader MDC1, which interacts with 
MRN complex to recruit and further stimulate ATM activity on chromatin (Figure 1.3) 
(16, 23-30). Focal accumulation of γH2AX promotes the accumulation of DSB factors to 
the break site, thereby promoting chromatin responses to DNA damage (5, 28, 31-35). In 
 6 
addition to γH2AX, modification of nucleosomes by other DDR factors act to coordinate 
the complex signaling events of the DDR network that are involved in DNA repair of 
DSBs (Table 1.1). Several E3 ubiquitin ligases, including RNF8, RNF168, BRCA1, 
RNF20/40, RING1B and BMI1 are recruited to DNA lesions and ubiquitinate histones 
and chromatin factors to promote the DDR (36, 37). For example, phosphorylation of 
mediator of DNA-damage checkpoint1 (MDC1) protein by ATM recruits RNF8, which  
 
 
Figure 1.3 DNA damage signaling within chromatin  
The MRN complex senses the DSB and recruits and activates ATM resulting in 
phosphorylation of H2AX (i.e., γH2AX). γH2AX is bound by MDC1, which interacts 
with MRN-ATM, which sets up an amplification signal on chromatin. Phosphorylated 
MDC1 recruits the Ubiquitin E3 ligase RNF8 that targets H1 linker histones. 
Ubiquitinated H1 promotes recruitment of the ubiquitin E3 ligase RNF168. RNF168-
dependent ubiquitination of H2A and H2AX promotes accumulation of DSB repair 
proteins to sites of damage. P = phosphorylation, Ub = Ubiquitination, MRN = Mre11-
Rad50-Nbs1 complex (38).  
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 (Continued in next page) 
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Table 1.1 Histone PTMs associated with DSB repair in mammalian cells 
N.D. = Not determined. This table was adapted from (38). 
has recently been shown to ubiquitinate the linker histone H1 (39). RNF168 is recruited 
to damage sites through ubiquitin-dependent interactions to promote further 
ubiquitination of histones by this E3 ligase, which are required to regulate DSB repair by 
53BP1 and BRCA1 (5, 24, 37, 40, 41) (Figure 1.3). Interestingly, recognition of damaged 
chromatin by 53BP1 requires binding to H4K20 methylation as well as histone H2A/ 
 9 
H2AX K15 ubiquitination (17, 42). 53BP1 recruitment to chromatin upon DNA damage 
is also regulated by histone acetylation. Histones are acetylated by histone 
acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs). Many of 
these enzymes are recruited to DSBs to regulate specific acetylated residues on histones 
to promote either HR or NHEJ (43). For 53BP1, acetylation of H4K16 at DSBs by the 
TIP60 HAT occludes the ability of the tudor domain within 53BP1 to recognize H4K20 
methylation. 
When H4K16 is acetylated, this inhibits 53BP1 binding, which promotes BRCA1 
binding and HR (44, 45). Histone marks can also act as high affinity binding sites for 
proteins that contain binding domains that recognize histone PTMs. Histone binding 
domains exists for many PTMs including phosphorylation, methylation and acetylation. 
For instance, twin-BRCT domains can bind phosphorylated histones, chromodomains 
have binding preferences for methylated lysines and bromodomains can specifically 
interact with acetylated lysine residues (12, 20, 46). For example, transcription-associated 
H3K36 trimethylation (H3K36me3) by SETD2 promotes DNA repair by homologous 
recombination (47-49). H3K4me3 creates a binding site for transcriptional complexes, 
leading to gene activation and euchromatin formation. Thus, different chromatin states 
and functions found throughout the genome can be regulated and established by the 
modification of context specific amino acid residues on histones. 
Although the primary function of many histone PTMs in DSB repair signaling are 
well characterized, it is still unclear how writers of these marks, including ubiquitin E3 
ligases and HATs, recognize their histone substrates within the nucleosome to promote 
site-specific modifications of their target lysine residues (Figure 1.4). Recent studies are 
beginning to provide mechanistic insights into how nucleosome recognition is achieved 
to promote chromatin-based DDR events. Accumulating evidence suggests that key stru- 
 10 
 
Figure 1.4 Damage-induced histone ubiquitinations on the nucleosome 
X-ray crystal structure of a nucleosome core particle of Xenopus was retrieved from 
protein data bank (PDB code 1AOI) and modeled in Pymol. Locations of lysine residues 
on the exposed nucleosomal surface are marked in dark blue. Histone tails are structurally 
unresolved so are not depicted. Known damage-induced ubiquitinated lysines are 
indicated as Ub. DNA, grey; histones, pale cyan; lysines, dark blue; ubiquitin (Ub), light 
blue (38). 
-ctural features of the nucleosome serve to mediate chromatin targeting by DDR factors 
to promote DNA damage signaling within chromatin (50-54). This information is starting 
to reveal important new ideas for how the “histone code” is encoded and read at DSB 
sites by DDR factors. 
THE NUCLEOSOME: BASIC UNIT OF CHROMATIN 
In the mammalian genome, billions of bases of DNA are organized by chromatin 
into the nuclear volume of the cell. Within this environment, specific gene regulatory 
networks must be highly regulated to maintain cellular function and identity. Dynamic 
transitions from compact and inaccessible chromatin states to decompacted and 
accessible structures allow control of gene expression. The presence of DNA damage 
within these environments necessitates the use of similar chromatin dynamics to 
coordinate DNA damage signaling and repair. The basic unit of chromatin is the 
nucleosome, which forms linear arrays of DNA–protein complexes that resemble an 
extended “beads on a string” structure in its most relaxed state. The nucleosome core 
 11 
particle (NCP), a structure consisting of a core histone octamer, is composed of 2 copies 
of each core histone protein H2A, H2B, H3 and H4, containing around 146 bps of DNA 
(55-57). The overall sequence of histones and structure of NCPs containing the canonical 
histones is highly conserved from yeast to mammals, suggesting resistance to structural 
alterations, implying significant functionality for the NCP across different species (58). 
Histones H2A, H2B, H4 and histone variant H2AX have been shown to be ubiquitinated 
at distinct lysine residues upon damage induction to signal and activate DSB repair (59-
65) (Figure 1.4). However, a mechanistic understanding of how site-specific epigenetic 
marks on these histone residues are achieved by writer enzymes and how these marks are 
recognized by their reader proteins within the context of the nucleosome is poorly 
understood. While most studies have focused on chromatin DDR factors and histone 
modifications involved in the DDR, very few studies have asked how these pathways are 
regulated at the level of the starting template, the nucleosome. While many of these 
protein–nucleosome interactions are mediated by histone PTMs, some regulatory 
proteins, including writers of these histone PTMs interact with specific residues, surface 
domains, or structured regions of the nucleosome. One such structured domain is the 
nucleosome acidic patch present in the histone H2A-H2B dimer (66-69). This indicates 
that the nucleosome does not merely act as a static packaging mechanism for DNA within 
cells but rather serves as a dynamic interface for chromatin-mediated processes that 
regulate the chromatin landscape to orchestrate DNA damage signaling and repair within 
specialized chromatin surroundings. 
NUCLEOSOME ACIDIC PATCH AND DNA REPAIR 
Solving the X-ray crystal structure of the NCP using reconstituted Xenopus 
recombinant histones revealed for the first time that in contrast to the largely basic nature 
of the core histones, the H2A-H2B dimer in the NCP consists of a unique negatively 
charged region on the surface of the nucleosome called the acidic patch (57). A group of 
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8 negatively charged residues constitute the acidic patch, 6 residues from histone H2A 
(E56, E61, E64, D90, E91, E92) and 2 from histone H2B (E102 and E110), all of which 
are localized on the nucleosome surface (Figure 1.5). Numerous studies suggest that the 
acidic patch serves as an interaction or recognition site for other chromatin proteins (54, 
66, 67, 70). Although the overall structure of the NCP is conserved among species, in 
higher eukaryotes alternative H2A isoforms exist that can affect chromatin structure and  
 
Figure 1.5 Involvement of the nucleosome acidic patch in the DDR 
Structural position of the negatively charged acidic patch residues (shown in red) within 
the nucleosome (PDB 1AOI). The structure was colored and modeled in Pymol. Right 
panel: Sequence alignment of acidic patch containing segment (50–101 amino acids) of 
histone H2A and its variants. The acidic patch residues of H2A (E56, E61, E64, D90, 
E91and E92) are highlighted in red. Residues that are conserved among all the four H2A 
variants are marked in brown boxes (38). 
stability when incorporated into NCPs and in turn regulate the chromatin-association of 
various factors (71-73). With the exception of H2A.Bbd, the nucleosome acidic patch is 
conserved in other human H2A variants, including H2AX, macroH2A, and H2AZ 
(Figure 1.5).  
Interestingly, the acidic patch within H2AZ nucleosome is slightly extended as 
opposed to the other H2A and variant nucleosomes (71, 73, 74), which may alter its 
functionality, compared to other H2A species. Recent studies have identified the acidic 
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patch of the nucleosome as a critical chromatin component for DSB sensing and repair. 
The involvement of the acidic patch in DSB repair was first identified in the Jackson and 
Miller labs by a systematic mutation screen for H2AX that analyzed over 70 mutations in 
H2AX and how they affected its PTMs, including phosphorylation, sumoylation, and 
ubiquitination (50). Surprisingly, mutations within the acidic patch of H2AX or H2A 
abolished all detectable ubiquitination modifications of the mutant histone protein. 
However, the functional consequences of these mutations on the DDR require further 
investigation.  
ACETYLATION READER PROTEINS AND THE DDR 
Acetylation signaling is an integral component of the DDR machinery in human 
cells as evident by around 17 histone acetyltransferases (HATs) and 18 histone 
deacetylases (HDACs) that are recruited to DNA damage to regulate DDR-related 
acetylation signaling (75).  Histone acetylation regulates DNA and histone binding, as 
shown by H4K16Ac that interrupts histone interactions in order to promote chromatin 
relaxation (76). The HAT, TIP60 promotes HR by acetylating H4K16 that in turn 
interferes with chromatin binding of the NHEJ factor 53BP1 to reduce NHEJ (77, 78). 
Acetylated histone and non-histone proteins can be recognized and bound by specific 
domains within proteins including BRD proteins, which contain the acetyl-lysine binding 
bromodomain (BRD) (19, 79) (Figure 1.6).  
BRD-containing proteins are involved in a wide range of function such as several 
of them serve as HATs that catalyze histone acetylation, components of ATP-dependent 
chromatin remodeling complexes and various other transcription regulators. BRD, the 
principal acetylation reader domain is present in 42 human proteins containing one or 
more BRD domains (79, 80). All BRD domains consist of four α-helices (αZ, αA, αB, 
αC), linked by different loops of various lengths. The ZA and BC loops form a hydroph- 
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Figure 1.6 Acetylation mark on histones and their readers 
HATs catalyze the addition of an acetyl (Ac) moiety on the e-amino group of a lysine 
residue, and HDACs reverse this reaction. Acetylated lysines on histones is recognized 
and bound by proteins containing BRD domains and other acetyl-lysine binding domains 
(not shown here). This figure was adapted from (81). 
-obic cavity that specifically recognizes acetyl-lysines. BRD proteins are grouped 
according to their functions such as HATs, components of ATP-dependent chromatin 
remodeling complexes and transcriptional regulators (79, 82, 83). Mutated or abnormally 
expressed BRD proteins leading to their dysfunction have been identified in different 
types of diseases, including cancer (84). BRD proteins represent an attractive drug target 
due to their unique structure and druggability and efforts to design small molecule 
inhibitors of these proteins as putative cancer therapies have already been FDA approved 
or being evaluated in pre-clinical and clinical trials (85-87). 
BRD proteins are generally classified as transcriptional regulators and recent 
studies have shown several BRD proteins (e.g. p300, BAZ1B and BRD4) to be involved 
in the DDR (88-91). The BRD protein TRIM28 (KAP1) was one of the first identified 
heterochromatin DSB repair factors (92-94). The Miller lab previously reported the 
involvement of one-third of the 42 human BRD proteins in the DNA damage response 
(DDR) (82). They identified ZMYND8 BRD protein as a new DDR factor that recruits to 
DNA damage and in a TIP60 mediated histone acetylation dependent manner recruits the 
NuRD chromatin-remodeling complex to damaged chromatin (82) to repress 
transcription and facilitate DNA repair by HR. Of the newly identified DNA damage 
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associated BRD factors by the Miller lab, a part of my thesis project focuses on studying 
the TRIM-BRD proteins (TRIM24-TRIM28-TRIM33) that represent a large family of 
tripartite motif-containing (TRIM) proteins and have been linked to cancer but their 
individual or collective roles in the DDR are unclear. Functional analysis of TRIM-BRD 
proteins in the DDR will help to gain mechanistic insights into chromatin-based DDR 
through understanding the ability of BRD proteins to read and transmit information 
contained within acetylated chromatin. 
REGULATION OF DNA DAMAGE-INDUCING ANTICANCER TREATMENTS 
BY CHROMATIN 
Although DDR and chromatin pathways cooperate to promote genome stability to 
suppress mutations that can drive cancer, once the DDR is deregulated, a common 
situation is cancer cells; it renders the cells chemo- and radio-sensitive. The cytotoxic 
nature of DNA damage is exploited to kill cancer cells through DNA damage-inducing 
treatments such as anti-cancer drugs and radiotherapy (95, 96). Indeed, the first 
chemotherapeutic drug in the 1940s treated cancer by damaging DNA. This pioneering 
discovery set the stage for developing DNA damaging agents as anticancer drugs that are 
still amongst the most commonly-prescribed cancer treatment owing to their ability to 
promote DNA damage and cell death. Based on these successes, genome and epigenome 
targeting drugs including DNA alkylators, intercalators (actinomycin), cross linkers 
(cisplatin, mitomycin) etc. represent a large class of compounds being actively developed 
for therapeutic purposes (97-102). Importantly, different agents are associated with 
unique drug-induced cell phenotypes that vary between cancers and cell types. Discovery 
of mutated or dysregulated epigenetic modifiers and altered epigenomes in cancers could 
contribute to these effects (103). Indeed, the dynamic nature of genome and epigenome 
makes it challenging to predict and control chromatin-targeting drug responses. Besides, 
emerging evidence suggests that functional interactions between these small molecule 
compounds and the genome are non-stochastic and are influenced by a dynamic interplay 
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between DNA sequences and chromatin states(101). As chromatin regulates transcription 
through protein targeting at specific genomic loci, these chromatin states can also 
influence target accessibility and binding of small molecules (Figure 1.7).  
 
Figure 1.7 Chromatin regulates genome targeting by small molecules  
The open state (euchromatin) and closed state (heterochromatin) of chromatin are shown. 
This figure was adapted from (104). 
Unbiased genome-wide approaches to identify functional targets of small 
molecules in cells are being developed to identify drug effects across the genome. For 
instance, the use of drug labeling and genome-wide sequencing to reveal unanticipated 
drug mechanisms for a G-quadruplex (G4) binding small molecule, PDS has been shown 
(105). This work localized G4 structures with a known G4 binding protein, PIF1, which 
provided the strongest evidence of G4 structures in cells. The use of ChIP-Seq 
(chromatin-immunoprecipitation followed by sequencing) of DNA damage chromatin 
mark (γH2AX) identified unanticipated gene targets, including the proto-oncogene SRC 
that was 90% downregulated by the drug.  This study provided a powerful example of 
how innovative chemical tagging techniques coupled with genome-wide strategies can 
provide novel insights into drug responses in human cells. Nonetheless, methods such as 
ChIP–seq and gene expression profiling provide indirect readouts of genomic sites of 
action of small molecules, which may preclude an in-depth understanding of drug 
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responses. Another technique, Chem-seq, was developed by the Bradner, Young and 
Rosenfeld labs that used bulky biotin tagged small molecules to isolate nucleic acids 
followed by sequencing to identify biologically relevant genomic target sites but there 
were technical limitations due to drug modifications that reduced the biological activity 
of the drug(106, 107). These studies highlight the importance of identifying genomic 
target sites; responses and properties of genome and epigenome drugs and to test the role 
of chromatin in these processes to better predict and control drug responses as a step 
towards personalized medicine.  
Front line cancer therapies such as platinum drugs including cisplatin treatment 
readily result in the development of chemoresistance through multiple mechanisms(108).  
Importantly, cisplatin resistant cancer cells can be resensitized to cisplatin by combined 
treatment with other epigenetic drugs (109). For example, the two FDA approved 
epigenetic drugs; histone deacetylase inhibitors (HDACi) and DNA methylation inhibitor 
5-azacytidine are being evaluated for combinatorial use with DNA damage for cancer 
treatments(110). Orchestration of drug targeting by chromatin might also shed light on 
intrinsic resistance or sensitivity of cancer cells to drug treatments and acquired drug 
resistance, which represent serious obstacles for therapeutic applications. Taken together, 
it is critical to evaluate whether chromatin reprogramming can modulate drug target site 
accessibility and drug responses.  
HYPOTHESIS AND AIMS 
Ubiquitination of proteins regulate the DDR with at least 6 E3 ubiquitin ligases 
recruited at DNA damage sites. In particular, the histone H2A/X are ubiquitinated by 
RING1B/BMI1 and RNF168 on K118/119 and K13/K15 respectively that mediate the 
chromatin association of both NHEJ and HR repair factors. A mechanistic view of how 
multiple Ub on H2A/X crosstalk between each other, as well as with other histone marks 
on H2A/X to coordinate and execute the DDR is undefined. Previous work from the 
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Miller lab has identified that key functional residues in H2AX that form the nucleosome 
acidic patch mediates H2A/X ubiquitination. I tested the hypothesis that the chromatin 
domain, nucleosome acidic patch, is required for both RNF168 and RING1B/BMI1 
dependent H2A/X ubiquitinations in response to DNA damage. Secondly, the BRD 
chromatin reader proteins interact with damage associated acetylation to promote the 
DDR and genome maintenance. I tested our hypothesis that the TRIM-BRD proteins that 
are readily detectable as damage-recruited participate in the DDR. These experiments 
were designed to comprehensively assign functions to the TRIM-BRD proteins through 
acetylation signaling and their interacting factors. Mechanistic details of the DDR and 
chromatin would provide insights into novel therapeutic targets and therapies because 
these pathways are currently targeted by anti-cancer chemotherapeutic treatments in the 
clinic. Thirdly, chromatin represents a major target of drug substances used to treat 
cancer. Emerging evidence suggests that functional interactions between small molecules 
and the genome are non-stochastic and are influenced by a dynamic interplay between 
DNA sequences and chromatin states. As chromatin regulates transcription through 
protein targeting at specific genomic loci, these chromatin states can also influence target 
accessibility and binding of small molecules. In the second part of my thesis project, I 
tested the hypothesis that genome targeting by  DNA-damaging agents is regulated by 
chromatin, which influences drug targeting, efficacy and  responses. This study involved 
the development of innovative tools and strategies for interrogating chromatin-drug 
mechanisms, which has the potential to better predict and control these responses in 
cancer and its treatments as a step towards personalized medicine. These goals were 
pursued by these projects as outlined below: 
Project 1. Investigate the role of nucleosome acidic patch in promoting H2A/X 
and H2AZ ubiquitination mediated DNA damage signaling. (A) Determine whether both 
RNF168 and RING1B/BMI1 E3 Ub ligases require the acidic patch for their activity by 
using a dual approach of in vivo and in vitro analyses (using reconstituted nucleosomes). 
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(B) Test whether nucleosome acidic patch interacting peptides (e.g. LANA) inhibit 
H2A/H2AX ubiquitinations and the DDR by in vitro Ub assays and in vivo analysis.  
Project 2: Determine how chromatin regulates genome targeting of the cisplatin 
derivative, APPA. (A) Optimize chemical labeling of APPA in cells for visual detection 
of platinated lesions. (B) Identify how chromatin influences the drug targeting of 
platinated drugs using combinatorial treatment of APPA and chromatin modulators in 
cells. 
Project 3: Determine the function of human TRIM-BRD proteins in the DDR. (A) 
Interrogate how damage-recruitment of TRIM-BRD proteins is regulated by upstream 
factors of the DDR pathway (B) Examine roles of histone acetylation in TRIM24 
recognition of damaged chromatin; (C) Identify and validate TRIM-BRD proteins 
interactome using MS data for functional assignment of TRIM-BRDs in the DDR. 
Collectively, these studies have contributed to deciphering chromatin-regulated 
processes that are paramount for understanding the nuclear pathways that regulate access 
to, and protection of our genetic and epigenetic information. 
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SUMMARY 
During my graduate studies at the University of Texas at Austin, my dissertation 
project focused on understanding the mechanisms of chromatin involved in DDR and in 
chemotherapeutic responses. I also worked on delineating the function of acetylation 
reader BRD TRIM proteins in promoting chromatin-based DDR. My projects can be 
divided into several parts as follows:  
1. I established methods to biochemically purify recombinant human histones and 
optimized protocols for reconstitution of nucleosome core particles in order to 
utilize them for in vitro assays. (Chapter 3).  
2. I identified that the chromatin domain nucleosome acidic patch regulates both N’- 
and C’- H2A and H2AX ubiquitination reactions catalyzed by RNF168 and 
RING1B/BMI1 E3 ubiquitin ligases respectively to promote DDR signaling for 
efficient DNA repair. (Chapter 3).  
3. I studied how chromatin states influence genome targeting of anticancer Pt drugs 
using a cisplatin analogue (APPA) that can be chemically labeled and visualized 
in cells. I identified that the clinically approved drug, Vorinostat (SAHA), a 
known inhibitor of histone deacetylases, when used as a combinatorial treatment 
with APPA formed clusters of DNA lesions that co-localized with translesion 
synthesis factors and activated this pathway. I found that the activated damage 
bypass translesion synthesis pathway no longer acted as a bypass/resistance 
mechanism but instead promoted apoptosis after cotreatment demonstrating that 
pharmacological alterations of chromatin reprograms genome targeting with 
platinum drugs and, concomitantly, the response to these drugs. (Chapter 4). 
4. I performed functional analysis of the TRIM-BRD proteins that are recruited to 
sites of DNA damage. I identified the specific domains in TRIM24 that are 
required for its recruitment to sites of DNA damage and its dependency on other 
chromatin associated factors, namely, SUV39H1, KAT6B, TRIM28, TRIM33 
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that regulate TRIM24 dynamics in the context of DNA damage. I validated some 
of the interactors of TRIM24, TRIM28 and TRIM33 including the FACT and 
MCM complex family members to delineate their role in the DNA repair 
pathway. (Chapter 5). 
Knowledge gained from these studies helped to delineate the role of an essential 
chromatin domain the acidic patch, interplay between three TRIM-BRD reader proteins 
in the DDR and chromatin-regulated processes that are paramount for regulation and 
protection of our genetic and epigenetic information. Since mutations in BRD reader 
proteins including the TRIM family cause genome instability and defective acetylation 
signaling that has directly been linked to cancer, future investigations to gain mechanistic 
insights into how these pathways function in regulating the cellular response to DNA 
damage is warranted. Given the increasing development and potential of epigenetic drugs 
targeting cancer pathways, these studies could provide additional candidates for 
development of small molecule inhibitors as well as new therapeutic targets in diseases 
including cancer. Besides, studies performed on how chromatin influences drug-genome 
interactions are informative for interrogating drug mechanisms and acquired drug 
resistance to better predict and control these responses in cancer and its treatments. 
In addition to my main projects, I also participated in other collaborative projects, 
which are not included in this dissertation, but summarized as follows: 
1. I identified the H2A histone variant H2AZ to be a substrate of the E3 ubiquitin 
ligase RNF168. 
2. I purified nucleosomes containing the histone variant macroH2A and performed 
biochemical assays demonstrating that RNF168 and RING1B/BMI1 both 
ubiquitinate this histone variant. 
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CHAPTER 2: MATERIALS AND METHODS 
CELL CULTURE CONDITIONS AND TREATMENTS 
Most of the cell lines used in this study were cultured in standard conditions in 
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) supplemented with 10% 
fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml 
streptomycin. HEK293T and BOSC23 cells were cultured in RPMI 1640 medium 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. WT and 
H2AX deficient MCF10A cells were cultured in DMEM/F12 medium supplemented with 
5% horse serum, EGF (20 ng/ml), hydrocortisone (0.5 mg/ml), cholera toxin (100 ng/ml), 
insulin (10 mg/ml) and 1% penicillin/streptomycin. A2780 cells (cisplatin sensitive) were 
purchased from Sigma-Aldrich (#93112519) and maintained in RPMI-1640 medium 
containing 2 mM L-glutamine and 10% FBS. HCT116 RAD18 KO cells were kindly 
provided by Junjie Chen’s Lab (MD Anderson). Cells were kept at 37°C in a humidified 
incubator containing 5% CO2. Cells stably expressing GFP-tagged TRIM proteins were 
established and maintained in medium with 10mg/ml Blasticidin. The chemical drugs and 
treatment conditions are listed in Table 2.1 on the next page. 
 
Portions of this chapter have been published as follows: 
Ø Justin W. Leung*, Poonam Agarwal*, Marella D. Canny, Fade Gong, Aaron D. 
Robison, Ilya J. Finkelstein, Daniel Durocher, Kyle M. Miller (2014) Nucleosome 
acidic patch promotes RNF168- and RING1B/BMI1-dependent H2AXand H2A 
ubiquitination and DNA damage signaling. PLOS Genetics 10(3): e1004178. (* 
co first authors 
Ø Emmanouil Zacharioudakis1, Poonam Agarwal1, Alexandra Bartoli, Nathan 
Abell, Lavaniya Kunalingam, Valerie Bergoglio, Blerta Xhemalce, Kyle M. 
Miller* and Raphael Rodriguez* (2017) Chromatin regulates genome targeting 
with cisplatin. Angew. Chem. Int. Ed. 2017, 56, 1–6. ( 1co first authors, * co 
corresponding authors) 
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Picoplatin, APPA and APP were prepared in the Rodriguez laboratory as described in 
(111). Suberoylanilide hydroxamic acid (SAHA), cisplatin, MS-275 and hydroxyurea 
(HU) were purchased from Sigma. Stock solutions of APPA, picoplatin, and cisplatin 
were prepared at a concentration of 10 mM in DMF for cell viability assay. A fresh stock 
solution of 1 mM in 0.9% w/v NaCl was freshly prepared for APPA and cisplatin for use  
 
Full name Abbreviation Work Conc. Treatment time 
2-aminomethylpyridine 
(dichloro) platinum (II) azide APPA 250 μM 3-24 hrs 
5-Bromo-2′-deoxyuridine BrdU 10 μM 24 hrs 
Cisplatin - 10-500 μM 3-24 hrs 
Azacytidine 5-Aza 10 μM 24 hrs 
Taxol - 1 μM 6 hrs 
Trichostatin A TSA 1 μM 24 hrs 
5,6-Dichlorobenzimidazole 
riboside DRB 100 μM 1-2 hrs 
KU55933 ATMi 1 μM 2 hrs 
Shield-1 - 0.5 mM 3 hrs 
4-Hydroxytamoxifen 4-OHT 1 μM 3 hrs 
Doxycycline Dox 1 μg/ml 3 hrs 
Olaparib PARPi 1 μM 2 hrs 
5-ethynyl uridine 5-EU 1 mM 1 hrs 
Suberoylanilide hydroxamic 
acid SAHA 1-10 μM 3-26 hrs 
Pyridostatin - 10 μM 6 hrs 
Picoplatin - 10-100 μM 3 hrs 
NU7441 DNA-PKi 2 μM 4 hrs 
MS-275  5 μM 5 hrs 
GW7647 USP1 DUB 50 μM 3 hrs 
Camptothecin CPT 1 μM 4 hrs 
Doxorubicin - 100 nM 24 hrs 
Etoposide Etop 25 μM 4 hrs 
Hydroxyurea HU 2 mM 3-24 hrs 
JQ1 BRD inhibitor 1 μM 5 hrs 
Garcinol HATi 10 μM 24 hrs 
Remodelin - 10 μM 24 hrs 
Tranylcypromine - 10 μM 24 hrs 
JIB-04 HDMTi 10 μM 24 hrs 
SGC0946 HMTi 10 μM 24 hrs 
DZNep HMTi 10 μM 24 hrs 
Table 2.1 Small molecules, chemical drugs and treatment conditions used in this study 
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in cell imaging and pull-down experiments. Unless stated otherwise, cells were treated 
with APPA (250 μM) or cisplatin (10 μM). For co-treatments, SAHA (2.5 μM) was 
added to cells 2 h prior to treatment with APPA or cisplatin. 
DOT BLOT ASSAY 
U2OS cells were cultured in 15 cm dishes and treated with APP or APPA for 3 h. 
Total genomic DNA was isolated from cells using DNeasy Blood and Tissue kit (Qiagen; 
#69506) according to the manufacturer protocol. DNA was reacted with Alexa Fluor 488 
alkyne using a click reaction buffer according to the manufacturer protocol 
(ThermoFisher Scientific; C10337). Labeled DNA was mechanically sheared using a 
bioruptor (Diagenode), 15 mins, 10 sec on/off at 4°C. DNA was then purified using 
QIAquick PCR purification kit (Qiagen, #28106) according to the manufacturer protocol. 
2 μg of total DNA were loaded on Hybond nylon membranes (GE Healthcare). Samples 
were air-dried and visualized using a Bio-Rad Molecular Imager ChemiDoc XRS+ 
system. 
DNA PULL-DOWN ASSAY 
U2OS cells were treated with APPA alone or in combination with SAHA. After 
treatment, total genomic DNA of each sample was purified using DNeasy Blood and 
Tissue kit (Qiagen, #69506). Pure link RNaseA (Invitrogen) was used to remove RNA 
during genomic DNA extraction. Click-reaction was performed on the isolated DNA 
using Biotin-PEG4 alkyne (Sigma-Aldrich, #764213) and incubated for 1 h protected 
from light at room temperature. The click-reaction was quenched using 4 mM EDTA. 
The DNA was fragmented up to ~ 100-350 bp size using Diagenode Bioruptor 300 and 
purified using QIAquick PCR purification kit (Qiagen, #28106). To capture the biotin 
tagged DNA-ACP conjugates, each sample was incubated with Dynabeads® MyOneTM 
Streptavidin T1 (Invitrogen, #65602) followed by washing with a buffer containing 1 M 
NaCl, 5 mM Tris-HCl, pH 7.5 and 0.5 mM EDTA. Beads were then washed with 8 M 
 25 
urea followed by three washes using the above washing buffer with 100 mM NaCl. After 
washing, beads were incubated in 1.8 M thiourea for 48 h at 37°C. DNA was purified 
using QIAquick PCR purification kit (Qiagen) and quantified using Qubit. 
RNA-SEQ SAMPLE PREPARATION 
Total RNA was extracted from cells untreated or treated with APPA, SAHA or in 
combination of SAHA and APPA using RNeasy Mini Kit (Qiagen, #74106) following 
the manufacturer’s protocol. Residual DNA was removed by DNase I on column 
digestion. RNA concentration was determined using Nanodrop and sent for RNA-seq 
library preparation and deep sequencing at the NGS facility, MD Anderson Cancer 
Center. All datasets were analyzed with FastQC to confirm a lack of sequencing 
abnormalities. No adapter contamination was detected. rRNA and tRNA sequences were 
filtered and remaining sequences were aligned to the most recent build of the human 
genome (hg38) using Tophat2/Bowtie2 with sensitive parameters. Alignments with a 
mapping quality score of less than 5 or that were flagged as secondary were removed and 
files sorted and indexed. Read counts per gene were calculated from the remaining 
alignments using HTSeq with the Gencode v21 comprehensive genome annotation and 
results were exported into a raw counts expression matrix. Differentially expressed genes 
were identified using edgeR with default parameters except for two modifications: first, a 
gene was required to have an expression value of at least 1 count per million reads in at 
least one sample to be tested and second, a differentially expressed gene was required to 
have both an absolute fold change of 1.5 or greater and a statistically significant FDR-
adjusted P-value <0.01. All final results were exported to Excel and all downstream 
plotting and analysis was performed with custom scripts in R using the ggplot2 graphics 
package. The heatmap was generated and hierarchically clustered by row and column 
using Pearson correlation as a distance metric and mean centered and normalized by row. 
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TRANSCRIPTION REPRESSION ASSAY 
Nascent transcription detection by 5-EU monitoring was performed with 1 mM 5-
EU added 1 h post-treatment. 5-EU was detected by Click-iT RNA imaging kit 
(Invitrogen). Samples were imaged and analyzed with Z-stacked settings using the FV10-
ASW3.1 software on a Fluoview 1000 confocal microscope (Olympus). 
TRANSFECTION IN MAMMALIAN CELLS AND RETROVIRAL INFECTION 
Mammalian expression vectors were transfected into U2OS cells by Fugene HD 
(Promega) or using lipofectamine 2000 according to manufacturer’s instructions. For 
HEK293T cells, transient transfections were carried out with pEI (Polyethylenimine, 
Sigma). Analyses for transient plasmid transfection were performed 24-48 h after 
transfection. HA-Flag-retroviral expression constructs were cotransfected with pCL-
ampho in BOSC23 cells using Lipofectamine2000 (Invitrogen). Viruses were harvested 
and filtered at 48 h and 72 h after transfection. MCF10A H2AX-/- cells were transduced 
by virus containing medium and selected by puromycin (2 mg/ml). The GFP-LANA (1–
32 a.a) or GFP-LANA-8LRS10 constructs were transfected into U2OS cells using 
HilyMax (Dojindo) following manufacturer’s instruction. Transfections for siRNA were 
carried out with lipofectamine RNAiMax (Invitrogen) following manufacturer’s 
instructions. Analyses for siRNA treated cells were performed 48-72 h after transfection. 
The sequences of siRNA used in this study are list in Table 2.2. 
 
Target gene siRNA sequence or Order information Source 
TRIM24 ON-TARGETplus SMARTpool: L-005387-00-0005 GE Dharmacon 
TRIM28 ON-TARGETplus SMARTpool: L-005046-00-0005 GE Dharmacon 
TRIM33 ON-TARGETplus SMARTpool: L-005392-00-0005 GE Dharmacon 
TIP60 ON-TARGETplus SMARTpool: L-006301-00-0005 GE Dharmacon 
MOF GCAAAGACCAUAAGAUUUA Sigma 
LigaseIV AGGAAGUAUUCUCAGGAAUUA Sigma 
CtIP GGUAAAACAGGAACGAAUC Sigma 
SUV39H1 ON-TARGETplus SMARTpool: L-009604-00-0005 GE Dharmacon 
KAT6B ON-TARGETplus SMARTpool: L-019563-01-0005 GE Dharmacon 
Table 2.2 List of siRNA sequences or order information used in this study 
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IR treatment: Untransfected cells or 24 h post transfection, cells were treated with 2 Gy 
IR and processed 2 h post-treatment. A Faxitron X-ray machine (Faxitron X-ray 
Corporation) was used for gamma irradiation (IR). 
CELL VIABILITY ASSAY 
Cell viability assays were carried out by plating U2OS human osteosarcoma cells 
(2,000 cells/well) in 96-well plates. Cells were treated with the relevant drug for 72 h and 
incubated with CellTiter-Blue® (20 μL/well) for 1 h before recording fluorescence 
(560(20) Ex/590(10) Em) using a PerkinElmer Wallac 1420 Victor2 Microplate Reader.  
Experiments were performed in triplicate and the fluorescence of each treated sample was 
normalized against untreated samples in order to obtain the percentage of viability for 
each treatment. GI50 values (the concentration of drugs that reduces by 50% the 
fluorescence that is emitted compared to untreated samples) was calculated and plotted 
on a graph. 
CLONING AND PLASMIDS 
RNA was extracted from U2OS cells or HEK293T cells for cDNA synthesis. 
cDNAs of human proteins used in this study were cloned into entry vector pDONR201 
by attB recombinant sites. Point mutation or internal deletion constructs of the chosen 
protein were performed as per the site-directed mutagenesis standard protocols using 
primers designed for the indicated mutation or deletion. All plasmid inserts and mutations 
were confirmed by DNA sequencing. WT and mutant human H2AX cDNAs were cloned 
into gateway compatible entry vector (pDONR201). 5’-biotin tagged 601 nucleotide 
sequence was generated by PCR using the primer pairs: 5’(Btn) 
CTGGAGAATCCCGGTGCC (F’ primer) and 5’ACAGGATGTATATATCTGACACG 
(R’ primer) to be used for reconstitution of nucleosomes. The N-terminal 32 amino acids 
of LANA were amplified using PCR with the following primers:  
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F’: 5’TTGTCGACATGGCGCCCCCGGGAATGCGCCTGA-3’ and R’: 5’- 
TTTCTAGACTATCTTTCCGGAGACCTGTTTCG-3’ and cloned into eGFP-C1 
(Clontech) vector using 5’-SalI and 39-XbaI restriction sites to create GFP-LANA (1–32 
a.a.). Primers for mutating 8RLS10 to AAA of LANA have been described by a previous 
study and were used to mutate GFP-LANA (1–32 a.a.) to GFP-LANA-8LRS10 (112).  
The expression plasmids used in this study are listed in Table 2.3.   
 
(Continued in next page) 
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Table 2.3 Expression vectors used in this study   
PROTEIN EXTRACTS AND WESTERN BLOTTING 
For whole cell extracts, cells were washed once with PBS and collected with 2X 
Laemmli buffer (4% (v/v) SDS, 20% (v/v) glycerol and 120 mM Tris-HCl, pH 6.8). 
Samples were sonicated using a Diagenode Bioruptor 300 for 10 min followed by boiling 
for 5 min at 95°C before loading onto SDS-PAGE gel using 3X protein loading buffer 
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(4% (v/v) SDS, 30% (v/v) glycerol, 150 mM Tris-HCl (pH 6.8), 350mM beta-
mercaptoethanol and 0.075% bromophenol blue). For chromatin fractions, cells were pre-
extracted by CSK buffer (10 mM PIPES, pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM 
MgCl2, 1 mM EGTA, 0.5% (v/v) Triton X-100) for 5 min on ice to remove the soluble 
proteins. After two washes with PBS, chromatin extracts were collected with Laemmli 
buffer and subjected to sonication and boiling steps before loading. Protein samples were 
resolved by SDS-PAGE, transferred to nitrocellulose membrane (GE Healthcare), 
incubated overnight in primary antibodies as indicated, followed by 1h of incubation in 
HRP-conjugated secondary antibodies. Signal on western blots were detected by standard 
chemiluminescence (GE Healthcare, Amersham ECL Prime system) using a Bio-Rad 
molecular imager ChemiDoc XRS+ system. Secondary antibodies used were: anti-rabbit 
IgG, HRP-linked (Cell Signaling, #7074) and antimouse IgG, HRP-linked (Cell 
Signaling, #7076). Primary antibodies used in this study are listed in Table 2.4.  
(Continued in next page) 
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Table 2.4 Primary antibodies used in this study.  
IF: immunofluorescence; IP: immunoprecipitation; WB: Western blotting, FACS: 
Fluorescence assisted cell sorting 
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LASER MICRO-IRRADIATION AND LIVE-CELL MICROSCOPY ANALYSIS 
U2OS cells were plated on glass-bottomed dishes (Wilco Wells). Cells were 
presensitized with 10 μM of 5-bromo-2’ deoxyuridine (BrdU) in normal DMEM medium 
for 20 h. Laser micro-irradiation was carried out with a Fluoview 1000 confocal 
microscope (Olympus). Laser setting and protocols were as previous described (113). For 
quantification of laser damage recruitment, after laser microirradiation, the fluorescence 
intensity at the damage site as well as an undamaged control region of the same size from 
the same cell were directly recorded by the FV10-ASW3.1 software in real-time. 
Variation of the fluorescence intensity was quantified as the difference between the 
average fluorescence intensity in the damaged region versus the average fluorescence 
intensity in an undamaged region from the same cell. Each curve corresponds to data 
obtained from at least 10 independently analyzed cells. Experiments were performed in a 
heated environmental chamber with 5% CO2 on a Fluoview 1000 confocal microscope 
(Olympus).  
IMMUNOFLUORESCENCE (IF) ANALYSIS 
After incubation with the indicated treatments, cells were washed with PBS (3X) 
and processed for IF as previously described (52). Briefly, cells were pre-extracted with 
CSK buffer for 5 min on ice. Cells were then washed with PBS (3X) and fixed with 2% 
(v/v) formalin (PFA) for 15 min at room temperature. For APPA click labeling with 
Alexa Fluor® 488 alkyne (Life Technologies; #A10267) was performed based on a 
previously published procedure (105). Cells were blocked with PBS containing 3% BSA. 
For specific treatments without pre-extraction, cells were permeabilized with 0.5% (v/v) 
Triton-X for 10 min between fixing and blocking steps. After blocking, cells were 
incubated with indicated primary antibodies overnight. Primary antibodies used for IF are 
listed in Table 2.4. After incubation with primary antibodies, cells were washed with PBS 
(3X) and incubated with appropriate mouse or rabbit secondary antibodies made in 
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blocking solution for an hour at room temperature. Secondary antibodies used for IF are 
as follows: Alexa Fluor 488 goat anti-rabbit IgG, Alexa Fluor 488 goat anti-mouse IgG, 
Alexa Fluor 594 goat anti-rabbit IgG, and Alexa Fluor 594 goat anti-mouse IgG, Alexa 
Fluor 594 anti-goat IgG, Alexa Fluor 647 anti-rabbit IgG and Alexa Fluor 647 anti-mouse 
IgG along with Hoechst 33258 to visualize cell nuclei. After incubations, coverslips with 
cells were washed with PBS (3X) and mounted on glass slides using mounting medium. 
Cells were imaged and analyzed with Z-stacked settings using the FV10-ASW3.1 
software on a Fluoview 1000 confocal microscope (Olympus). Data were analyzed with 
ImageJ. For IRIF quantification, >500 or >100 cells were counted for all conditions from 
at least two independent experiments. Data was analyzed in Prism and graphs were 
plotted from the data obtained.  
FACS ANALYSIS 
U2OS cells were transfected with GFP-LANA, Myc-LANA or a control vector 
for 8 h or with the indicated siRNA. 24 h after plasmids transfection or 72 h of post 
siRNA transfection, cells were harvested and fixed with 80% ethanol overnight. The 
fixed samples were washed 3X with PBS containing 1% FCS and incubated with 
phospho-histone H3 (S10) primary antibody for 2 h followed by incubation of goat anti-
rabbit secondary antibody for 2 h at room temperature for the mitotic index assay. For 
DNA content analysis, the cells were washed and stained with propidium iodide (PI) and 
processed on a BD Accuri C6 flow cytometer (BD Biosciences) for cell cycle analysis. 
IN VITRO ASSAYS 
NUCLEOSOME CORE PARTICLE (NCP) RECONSTITUTION 
Recombinant human histones were expressed in E.coli BL21 (DE3)/RIL cells 
from pET21 vectors and extracted from inclusion bodies as described (114-116). All 
histones were purified under denaturing conditions on 5 ml HiTrap Q and HiTrap SP 
cation exchange columns (GE Healthcare). Peak fractions were confirmed using SDS-
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PAGE and fractions containing pure histones were pooled and dialyzed extensively into 
10 mM Tris-HCl (pH 8.0) before lyophilization. Octamers were refolded from purified 
histones by mixing the four histones in equimolar ratios (10% more of H2A/H2B relative 
to H3/H4), followed by dialysis into 2 M NaCl and then purified on a Superdex 200 
(16/60) size exclusion column (GE Healthcare). NCPs were reconstituted by salt 
deposition as described (116). The 147 bp ‘601’ DNA was biotinylated and used to wrap 
the mononucleosomes. NCP formations were confirmed on 6% native TBE gels by gel 
mobility shift assays. 
HUMAN HISTONE PURIFICATION 
I. Expression and Purification of Human Histone H2A 
Lysis Buffer: 100 mM NaPO4 pH 8.0, 8 M Urea, 10 mM DTT   
Wash Buffer: 100 mM   NaPO4 pH 8.0, 7 M Urea, 10 mM DTT  
Elution Buffer: 100 mM NaPO4 pH 8.0, 1 M NaCl, 7 M Urea, 10 mM   DTT 
Note: Deionized urea was used to prepare the above buffers by stirring with 25 g/L AG 
501-X8 resin (Cat. No. 142-6424, Bio Rad) or Amberlite MB-150 (Sigma A5710) for at 
least 30 min at RT or over night at 4°C.  
For 4 L culture pellet, 100 ml of Lysis buffer, 120-150 ml Wash buffer and 30 ml elution 
buffer were prepared.  
Buffers for FPLC: SAU-200 Buffer: 20 mM Na-acetate pH 5.2, 7 M Urea, 200 mM 
NaCl, 1 mM EDTA 5 mM β-Mercaptoethanol.  
SAU-600 Buffer: 20 mM Na-acetate pH 5.2, 7 M Urea, 600 mM NaCl, 1mM EDTA, 5 
mM β-Mercaptoethanol   
Note: The above buffers were prepared from a freshly made 8 M urea stock solution that 
had been deionized. Leftover buffer solution from the gel filtration buffer preparation can 
be stored over night at 4°C and used the next day to prepare SAU-200 and SAU-600 for 
the ion exchange purification. 
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Day 1: H2A Expression: (Procedure for 4 L of culture)  
1. Human histone H2A was expressed from pET21b (+) vector by transforming the 
plasmid into BL21 (DE3)/codon plus RIL cells or streaked frozen stock on LB containing 
Ampicillin (Amp) plates and incubated at 37°C overnight.  
2. Next day in the evening: 40-50 ml LB Amp was inoculated with several colonies and 
placed on shaker at 37°C overnight. 
3. Next day in the morning: 1 L LB Amp/Chloramphenicol was inoculated with 10 ml 
overnight cultures each. After reaching OD600 = 0.6, histone expression was induced 
with 0.2 mM IPTG and flasks were incubated at 37°C for 3 h. 
4. Uninduced and induced samples on a 15% SDS-PAGE gel by coomassie staining.  
5. The culture broth was centrifuged at 5000 g for 15 min at RT and pellet was stored at -
20°C. H2A pellet can be frozen and stored at -20°C directly without the addition of 
buffer or used straight away for the SP-Sepharose capturing step. 
Day 2: Capturing H2A from E. coli Extracts on SP-Sepharose Beads and gel filtration  
Human Histone H2A does not form inclusion bodies and is captured from E. coli extracts 
on SP-Sepharose beads and purified by denaturing gel filtration and ion exchange 
chromatography.  
A. In the morning: 1.5 L of SAU-200 buffer was made from a freshly prepared deionized 
8 M urea stock solution. Superdex-200 (16/60) gel filtration column (GE Healthcare) was 
equilibrated first with ~120 ml ddH2O (while preparing urea and buffer) and then with 
~150 ml SAU-200 buffer during the day.  
B. In the afternoon: H2A was captured from E. coli extracts on SP-Sepharose beads as 
follows:  
1. Cells were harvested or frozen cells were thawed and the pellet was resuspended in 
100 ml Lysis Buffer. This results in a final concentration of ~7 M urea.  
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2. The cell suspensions were distributed into ~25 ml aliquots in 50 ml Falcon tubes and 
each aliquot was sonicated 4 x 30 sec on ice to prevent samples from heating. 
3. The sonicated lysates were centrifuged for 30 min at 20000 g and RT (Beckman JLA-
16.25 rotor or equivalent).  
4. For 4 L culture broth, 8 ml (bed volume) SP-Sepharose Fast Flow (GE Healthcare) was 
packed in a 100 ml gravity column by marking 8ml and pouring the slurry up to that 
mark. Sepharose beads are supplied in 10% ethanol. Hence 8 ml bed volume beads were 
washed with 10 column volumes (i.e., 80 ml) of water.  
5. The column was equilibrated with 10 column volumes of wash buffer.  
6. Supernatant (100 ml) was added to the equilibrated SP-Sepharose Fast Flow and 
rotated for 30 min at RT.  
7. The beads were allowed to settle down by loading onto a gravity flow (OR by gently 
centrifuging the beads at 1000 g and RT) and washed once with 40 ml wash buffer.  
8. Excess wash buffer was allowed to drain and then the protein was eluted 5X with 5 ml 
Elution buffer each time. All elutions/eluate was pooled to a get a total volume of 25 ml.  
C. In the evening: The eluted sample was loaded directly onto the gel filtration column. 
The sample was loaded into a 50 ml super-loop and separated over a Superdex-200 
column equilibrated in SAU-200 buffer. Gel filtration (size exclusion chromatography) 
was done in SAU-200 buffer at 0.5-1 ml/min overnight at RT (or 12°C) by injecting the 
sample and 2-3 ml fractions were collected using the fractionator.  
Note: Deionize urea before use and do not leave proteins in urea buffer for extended 
periods of time (>24 h) in order to prevent carbamylation of proteins. Purification will 
also work at 4°C but buffer is close to precipitation at this temperature.  
Day 3: Purification 
1. The fractions from gel filtration were checked on a 15% SDS-PAGE gel.  
2. H2A containing fractions were combined (usually 40 ml total volume).  
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3. A 5 ml HiTrap Q and a 5 ml SP ion exchange column (GE Healthcare) were set up in 
tandem (alternatively only a 20 ml SP-Sepharose HP 16/20 column-GE Healthcare can be 
used). The columns should be arranged so that the protein sample passes through the Q 
column first.  
4. The columns were equilibrated with SAU-200 (can be made using leftover deionized 
urea from the buffer prep for gel filtration).  
5. The combined fractions were loaded directly onto the Q/SP tandem columns at a flow 
rate of 0.5-1 mL/min with a super loop.  
6. Washes were done for several column volumes (at least 15-20 ml) after which the Q 
column was removed. Elution was done with a gradient from 0% - 100% SAU-600 over 
20 CV (Buffer A: SAU-200; Buffer B: SAU-600). 1.5-3 ml fractions were collected.  
7. The fractions were checked on a 15% SDS-PAGE gel and pure histone fractions were 
combined and dialyzed extensively using 7,000 MWCO dialysis tubing against H20/1 
mM DTT overnight at 4°C.  
Day 4: Determination of H2A concentration and storage by lyophilization 
The concentration was determined by measuring the OD280nm of the undiluted protein 
solution against water or comparing with known protein concentration by Coomassie 
staining/Bradford assay. Aliquots of 1.2 ml each were made in eppendorf tubes. Tiny 
holes were poked using twizzers in the center of the lids of eppendorf tubes containing 
the histones before lyophilizing to allow moisture evaporation during freeze drying and 
tubes were freeze dried overnight (For lyophilization, 0.5 L liquid nitrogen was 
purchased from UT core facility). 
Day 5: Lyophilized vials were stored at -20°C and condensed water accumulated in the 
lyophilizer was wiped clean for the next user. 
Expected yields are: H2A: ~20 mg for 4 L of culture  
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II. Expression and Purification of Histones: H2B, H3 and H4 
Buffers and reagents:  
1. LB broth supplemented with 34 μg/mL chloramphenicol and 1 μg/mL carbenicillin; 1 
M IPTG (isopropyl β-d-1-thiogalactopyranoside).  
2. TW buffer for pellet resuspension: 50 mM Tris–HCl (pH 7.5), 100 mM NaCl, 1 mM 
EDTA.  
3. TW buffer for inclusion bodies: 50 mM Tris–HCl (pH 7.5), 100 mM NaCl, 1 mM 
EDTA, 5 mM β-mercaptoethanol (βME), 1 mM benzamidine, and 1% (w/v) Triton X-
100.  
4. Urea buffer: 10 mM Tris–HCl (pH 8.0), 7 M urea, 1 mM EDTA, 5 mM βME, and 100 
mM NaCl for wt and HA-tagged H2B, 200 mM NaCl for wt and HA-tagged H3 and H4, 
or 100 mM for all FLAG. Deionize these buffers with 25 g/L AG 501-X8 resin (Cat. No. 
142-6424, Bio Rad) for at least 30 min at RT or overnight at 4°C before adding NaCl. A 
1.0 mm Whatman paper was used to remove AG 501-X8 resin after deionization.  
5. Unfolding buffer: 20 mM Tris–HCl (pH 7.5), 7 M guanidinium-HCl, and 10 mM DTT.  
6. Buffer A: 10 mM Tris–HCl (pH 8.0), 7 M urea, 1 mM EDTA, and 1 mM DTT.  
7. Buffer B: 10 mM Tris–HCl (pH 8.0), 7 M urea, 1 mM EDTA, 1 mM DTT, 1 M NaCl. 
8. Tris dialysis buffer: 10 mM Tris–HCl (pH 8.0) with and without 5 mM βME.  
9. Protein purification columns: 5 mL HiTrap Q and SP ion exchange columns, and 
Superdex 200 (16/60) gel filtration column, all purchased from GE Healthcare.  
10. Dialysis tubing: 7,000 MWCO.  11. Lyophilizer (Labconco). 12. Microtip sonicator.  
Day 1: Expression of Human H2B, H3 and H4 
1. Human histones were expressed from pET21b (+) vector by transforming the plasmid 
into BL21 (DE3)/codon plus RIL cells and incubated at 37°C overnight. Alternately, E. 
coli Rossetta strain or BL-21 (DE3) pLysS for protein expression can be used. 
2. Bacteria were grown at 37°C in LB broth with 1 mg/mL ampicillin.  
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3. Induction was performed at OD600 = 0.6 – 0.8 using 200 uL of 1 M IPTG (0.2mM 
IPTG working stock) per 1 L of culture, and growth was continued for 3 h at 37°C.  
4. Cells were harvested by centrifugation at 5000g for 15-20 min at RT. Cell pellet was 
resuspended in 25 mL TW buffer 1 per 1 L culture and then frozen at −80°C.  
5. Samples (uninduced and induced) were analyzed for histones overexpression by SDS-
PAGE and Coomassie staining before proceeding to next step.  
Day 2: Inclusion Body Purification 
The following procedures pertain to wt histones, histones bearing a single FLAG or HA 
tag, and histone H3 bearing a 3xFLAG tag.  
1. TW buffer was added to the cell suspensions up to 35mL total volume and sonicated 
on ice for 2 min (10 s on and 50 s off) with 40% output.  
2. Centrifugation was done at 20,000 × g for 20 min at 4°C to harvest inclusion bodies.  
3. The resulting protein pellet was rinsed with TW buffer by resuspending as much as 
possible with agitation.  
4. Centrifugation and resuspension were repeated two more times using TW buffer 
without Triton X-100 and the protein pellet obtained was frozen at −80°C.  
The following procedures pertain to histones H2B and H4 tagged with 3xFLAG.  
1. The cell suspensions were sonicated and spun down as described above for WT 
histones, but this time the supernatant was kept and pellet was discarded.  
2. 0.27 g of ammonium sulfate/mL of supernatant was added and stirred at 4°C for 1 h.  
3. The suspension was centrifuged at 20,000 × g for 30 min at 4°C and protein pellets 
frozen at −80°C. 
Days 3 – 4: Histone Purification 
1. Deionized urea buffer was prepared as mentioned above. 
2. To dissolve WT histones, histones with 3XFLAG tag or HA tag, 0.2 ml dimethyl 
sulfoxide (DMSO) per 1L culture was added and the pellet was minced using a spatula.  
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3. 6.5 mL unfolding buffer per 1 L culture was added to dissolve the pellets and gently 
agitated for 1 h at RT.  
4. Remaining cell debris was removed by centrifugation at 20,000 × g for 20 min at 4°C 
and the supernatant was collected. This step can be done by dispensing the suspension in 
1.5 ml microfuge tubes.  
5. The remaining pelleted material was rinsed again with 1.5 mL unfolding buffer, spun 
down at 20,000 × g for 20 min at 4°C, and the supernatants were combined. 
6. Dialysis of the resulting histones against 1–2 L urea buffer was done using 7,000 
MWCO dialysis tubing with two buffer changes for several hours at RT or at 4°C if 
overnight. For each histone, appropriate urea buffer should be used as mentioned in 
buffer preparation.  
7. Q and SP ion exchange columns were set up in tandem. The columns were arranged so 
that the protein sample passes through the Q column first.  
The columns were equilibrated with 10% buffer B for H2A and H2B and all tagged 
histones, and with 20% buffer B for wt H3 and H4.  
8. Dialyzed sample was loaded onto the Q/SP tandem columns at a flow rate of 0.5–1 
mL/min with a superloop and washed with several column volumes. The Q column was 
removed and protein was eluted over 20 column volumes 10–40% buffer-B for H2B and 
all tagged histones, over 15 column volumes for 20–50% buffer-B for wt H3 and H4.  
Note: H4 is eluted slower than other histones with a flow rate no greater than 0.4 mL/min 
or 0.2 mL/min if eluted overnight.  
9. Peak fractions were confirmed using SDS-PAGE and combined.  
10. The histone was dialyzed over several hours against Tris dialysis buffer using 7,000 
MWCO dialysis tubing with several times buffer changes at 4°C. The final two buffer 
changes were done without βME.  
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11. Protein concentration was measured by taking OD at 280 nm, aliquoted into 
microfuge tubes and the dialyzed histone was lyophilized. This step can require up to 2 
days. The lyophilized histone was store at −20°C.  
H2B: ~30 mg for 4 L of culture, H3.1: ~40 mg for 3 L of culture, H4: ~10-15 mg for 3 L 
of culture. 
5’-BTN 601 DNA AMPLIFICATION 
For 100 μl reaction: DNA (150 ng), dNTP (10 mM) 2 μl, F’ primer (10 mM) 5 μl, 
R’ primer (10 mM) 5 μl, Phusion polymerase 0.5 μl, MgCl2 (50 mM) 2 μl, Water: total to 
100 μl. Master Mix can be made for 8 reactions. PCR program: Standard Phusion PCR. 
Purify using PCR purification kit by using 2 spin columns for purifying 800 μl of the 
PCR product. Final elution was done in 40 μl (30+10) of water. 
NUCLEOSOME RECONSTITUTION 
1. The molar concentrations of 601 DNA and octamer were calculated as follows:  
a. Concentration of the octamer using nanodrop was noted. For actual conc. of the 
octamer, added MW of all four histones x 2 = Total MW and sum up if all the individual 
histones’ extinction coefficients was done. The actual concentration was calculated to be 
= Octamer concentration from Nanodrop X Total MW / Sum of extinction coefficients. 
The value obtained was then converted into micromolar (μM). 
2. The volume of DNA and octamer was calculated to make them equimolar. 
To use DNA: octamer = 1:1.7 
Total volume = 100 μl which should also include TE with 1.5M NaCl. 
3. 10,000 MWCO dialysis buttons were placed in water for 30 min to remove glycine and 
purified octamer was thawed on ice. 
4. A ratio of 1:1.7 :: DNA: octamer in 1X TE (pH 8.0) was mixed with 1.5M NaCl on ice 
to make a total volume of 100 μl. 
5. The mixture was incubated on ice for 30 min and transferred to dialysis button. 
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6. Gradually the NaCl concentration was reduced by step dialysis at 4°C for 2h in 1X TE 
(pH 8.0) containing 1M NaCl, 0.8M NaCl, 0.6M NaCl, 0.4 M NaCl. 
 
Reagents for 1 
L of each 
TE+ 1M 
NaCl 
TE+ 0.8M 
NaCl 
TE+ 0.6M 
NaCl 
TE+ 0.4M 
NaCl 
TE+ 0.2M 
NaCl 
4M NaCl 250 ml 200 ml 150 ml 100 ml 50 ml 
1M Tris pH 8.0 10 ml 10 10 10 10 
0.5M EDTA 2 ml 2 2 2 2 
Water Make upto 1L Make upto 1L Make upto 1L Make upto 1L Make upto 1L 
Table 2.5 Step dialysis for NCP reconstitution 
7. A final dialysis step was done overnight in 1X TE (pH 8.0) with 0.2 M NaCl. Dialysis 
steps longer than 2h can be done but shorter dialysis times will lower the reconstitution 
efficiency. 
8. The nucleosomes were transferred into 1.5 ml tubes and stored in 4°C for several 
weeks (upto 6 months). 
9. Formation of nucleosome core particles (NCP) was confirmed by running 2-4 μl of the 
NCP on a 4-6% native polyacrylamide gel. 
NATIVE GEL TBE 
Native PAGE separations were run in non-denaturing conditions. Detergents are used 
only to the extent that they are necessary to lyse lipid membranes in the cell. Complexes 
remain, for the most part, associated and folded as they would be in the cell. One 
downside, however, is that complexes may not separate cleanly or predictably, since they 
cannot move through the polyacrylamide gel as quickly as individual, denatured proteins. 
Recipe for 6% gel is as shown in Table 2.6 below. TBE gel was pre-run for 10 minutes at 
80V in 0.5X TBE buffer (see below TBE buffer recipe). This ensures acrylamide would 
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not react with protein samples and it also heats up the gel so that the DNA stays 
denatured while running the sample.  
 
 
 
 
 
Table 2.6 Native gel preparation 
Sample loading and gel run: Mix 2-3 μl of NCP + 2 μl 6X non-SDS dye + 3 μl water. 
Samples are not boiled before loaded onto the gel.  
Gel run: The gel is run at 80V for 50-60 minutes. Be sure to watch the solvent front. The 
gel was removed from the casing and soaked for 15-20 minutes in 0.005% Ethidium 
bromide (in water). Gel is gooey and was handled with care. 
After gel run, the gel was removed from ethidium bromide and rinsed with water 5 times. 
Gel was let soaked in water for 15 minutes and imaged as done for an agarose gel. 
TBE buffer for native gels: 5X stock solution in 1 L of H2O: 54 g of Tris base, 27.5 g of 
boric acid, 20 mL of 0.5 M EDTA (pH 8.0). TBE was prepared and stored as a 5X or 
10X stock solution. The pH of the concentrated stock buffer was adjusted to ~8.3. The 
concentrated stock buffer was diluted just before use and gel solution and electrophoresis 
buffer were prepared from the same concentrated stock solution.  
Note: Some investigators prefer to use more concentrated stock solutions of TBE (10X as 
opposed to 5X). However, 5X stock solution is more stable because the solutes do not 
precipitate during storage. Passing the 5X or 10X buffer stocks through a 0.22-μm filter 
would prevent or delay formation of precipitates.  
To make 1 L of 0.5X running buffer: 100ml of 5X to 900ml of water is to be added. 
Resolving Layer 6% (2 gels) 
 H2O (ml)  6.15 
5X TBE (ml)  0.825 
40% Acryl (ml) 1.24 
10% APS (ml)  82.5 
TEMED (μl)  3.3 
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PROTEIN PURIFICATIONS 
E3 Ub ligase enzymes used in the in vitro Ub assays were His6 tagged RNF168 
(1–113) construct expressed in Rosetta 2 (DE3) pLysS cells and purified over a Ni-NTA 
column (Qiagen) and stored in elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 
mM imidazole, pH 8.0) containing 10% glycerol. The pET24b(+)-Bmi1-His6 (1–108) and 
pGEX-6P-1-RING1B (1–116) expression plasmids were co-transformed in Rosetta2 
(DE3) pLysS cells and the proteins were purified as a complex as described in (117) with 
exact details provided below: 
A.  RNF168 expression and purification 
1. Lysis Buffer: Preparation 100 ml 
50 mM NaH2PO4    0.78 g 
300 mM NaCl   (7.5 ml of 4M NaCl stock) 
10 mM Imidazole  68 mg  
pH was adjusted to 8.0 using 10M NaOH and the volume made up to 100 ml with water. 
2. Wash Buffer: 100 ml 
50 mM NaH2PO4    0.78 g 
300 mM NaCl   (7.5 ml of 4M NaCl stock) 
20 mM Imidazole  136 mg 
pH was adjusted to 8.0 using 10M NaOH and the volume made up to 100 ml with water.  
3. Elution Buffer: 25 ml 
50 mM NaH2PO4    0.195 g 
300 mM NaCl   (1.875 ml of 4M NaCl stock) 
250 mM Imidazole  425 mg 
pH was adjusted to 8.0 using 10 M NaOH and volume made upto 25 ml with water. 
4. Storage buffer: 50 mM Tris-HCl pH7.5, 1mM EDTA, and 10 % glycerol. 
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The RNF168 bacterial expression vector (residues 1-113) was cloned into pPROEX Hta 
(Invitrogen) using the BamH1 and Spe1 sites. His6-RNF168 (1-113) was purified on Ni-
NTA agarose (Qiagen) as follows:  
1. RNF168 containing plasmid was transformed into Rosetta or BL-21 cells and plated on 
LB ampicillin (and chloramphenicol for Rosetta cells). A colony was picked and 
inoculated in 10 ml LB with antibiotics for overnight incubation at 37˚C. 
2. Next day 500mL LB media with antibiotics was inoculated with 5 mL of overnight 
grown culture to an OD600= 0.6 and then protein expression was induced with 0.5 mM 
IPTG overnight at 16˚C. 
3. Next day, cells were pelleted and can be stored at -20˚C if not processed for the next 
step immediately. 
4. Cell pellet was thawed for 15 min on ice and resuspended in 35 ml of cell lysis buffer. 
5. Lysozyme was added to 1 mg/ml and incubated on ice for 30 min. 
6. The cell suspension was sonicated on ice using six 10s bursts at 100W with a 10s 
cooling period between each burst and placed on a shaker at 4˚C for 30 min. 
7. The lysate was centrifuged at 10,000g for 25 min at 4˚C to pellet the cellular debris 
and the supernatant (clear lysate) obtained was collected.  
8. 1ml Ni-NTA beads slurry was washed with water and equilibrated with 5 ml of lysis 
buffer twice. 
9. Equilibrated Ni-NTA beads were added to the filtered lysate and nutated for 1h at 4˚C. 
10. The mixture was centrifuge at 100rpm/2min and the supernatant was collected. The 
beads were stored with some supernatant left at 4˚C to avoid drying the beads. 
11. 1 ml of pre equilibrated Ni-NTA beads was added to the supernatant and nutated 
overnight at 4˚C to obtain the remaining previously unbound RNF168 protein in the 
supernatant. 
12. The beads were pooled together by centrifugation and removing the supernatant. The 
beads were washed twice with 10 ml wash buffer. 
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13. The protein was eluted thrice with 0.5 ml elution buffer each time and buffer 
exchange was done into storage buffer via a PD-midi trap G-25 column which was 
preequilibrated with storage buffer (i.e., final product was obtained in 1.5 ml storage 
buffer).  
Quantity of eluted protein using this method is about ~0.89 mg/ml (64.6 μM) 
B. BMI1/RING1B expression and purification  
Buffer A: 10 mL of 1 M Tris pH 7.5 (50 mM working stock), 6 mL of 5 M NaCl (150 
mM) and 200 μL of 1 M DTT (1mM) to make a total of 200 mL 
Buffer B: 2.5 mL of 1 M Hepes, pH 7.5 (50 mM), 1.5 mL 5 M NaCl (150 mM), 50 μL of 
1 M DTT (1 mM) to make a total of 50 mL 
Buffer C: Buffer B + 0.05% Tween-20 
Buffer D: 50 mM Tris pH 7, 150 mM NaCl, 1 mM EDTA, 1 mM DTT 
Purification: 
1. 2 μl (~100 ng) DNA each of Bmi1-His and GST-Ring1B plasmids were 
simultaneously cotransformed into Rosetta-1 cells and plated on LB plates containing 
Ampicillin/Kanamycin/Chloramphenicol antibiotics.           
2. Next day, the plates were scraped to inoculate 1 L LB media with antibiotics to an 
OD600 of ~0.02 and grown at 37°C to reach an OD of about OD600 = 0.6. For induction 
of protein expression 0.3 mM IPTG was added and the culture was incubated on a shaker 
overnight at 18°C. 
3. Next Day: Cells were pelleted and resuspended in 40 mL Buffer A (+ protease 
inhibitors).  The suspension was sonicated  (using six 10 s bursts at 100W with a 15 s 
cooling period between each burst) to lyse the cells, 21 mg lysozyme was then added to 
the lysate and nutated for 30 min at room temp (RT). 
4. The cell lysate was cleared by centrifuging 18k rpm, 40 min, 4 °C and filtered through 
a 0.45 μm syringe filter to obtain a clear lysate. 
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5. 2 mL Ni-NTA slurry was added (Qiagen, and I don’t bother washing the storage buffer 
out of the slurry) to the filtered lysate and nutated for 1 h, RT. 
6. The flow through (FT) was collected and beads were washed with 60 mL Buffer A + 
30 mM imidazole (0.123 g). 
7. The complex was eluted in 15 mL of Buffer A + 250 mM imidazole (60 mL + 1.02 g). 
8. Eluted sample was concentrated to 2 mL (30 kDa MWCO) and buffer exchanged into 
Buffer B via a PD-10 column, pre-equilibrated with 25ml of Buffer B (eluting in 3.5 mL) 
and stored at 4°C over night. 
9. Next Day: The precipitate was spun and 2-3 mL washed glutathione sepharose beads 
(GE) was added after washes with water and Buffer B. It was nutated at 4°C for 2 h.   
FT was collected and beads were washed with 20 mL each of Buffer B, then C, then D.  
At this point, I ran some of the beads on a gel just to make sure that I had each protein 
and that it was washed enough. 
10. 5 μL of 10 mg/mL Pre-Scission protease was added to beads (still on the column, 
with about 0.5 mL Buffer D on top of beads) and allowed to cleave overnight, 4°C, on 
stand (i.e., I did not nutate the sample at this point). 
11. Next Day: Some beads (~5 μL) were run on a gel to check for efficiency of cleavage.  
I observed about 50% cleaved protein, but it made for plenty of protein in the end.  FT 
was collected and beads were washed with Buffer D.  The eluted protein (10kDa 
MWCO) was concentrated and checked on a 15% gel.  The preparation was clean and 
~1.8 mg of complex was obtained from this 1 L prep. 
IN VITRO UB ASSAY 
Assays were performed essentially as described (17). Briefly, 2.5 mg of 
recombinant mononucleosomes were incubated in a 50 ml reaction buffer containing 50 
mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 mM ZnOAc, 1 mM DTT, 30 nM 
ubiquitin activating enzyme E1 (Boston Biochem), 1.5 mM ubiquitin conjugating enzyme 
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UbcH5a (Boston Biochem), 4 mM RNF168 (1–113) or RING1B/BMI1 complex, 22 mM 
ubiquitin (Boston Biochem) and 3.33 mM ATP at 30°C for 4 h. The reaction was 
terminated by addition of SDS-PAGE loading buffer. Assays with free histones were 
carried out with 10 mM of H2A or H2AX and the reactions were incubated overnight at 
30°C. The samples were boiled and loaded on 15% SDS-PAGE gels, transferred to a 
nitrocellulose membrane, probed using specific antibodies and detected as described. 
IN VITRO METHYLATION ASSAY 
2.5 mg of recombinant mononucleosomes were incubated at 30°C for 2 h in a 50 
ml reaction containing 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 mM 
ZnOAc, 1 mM DTT, 0.1 mM S-adenosyl methionine (NEB), and 100 ng recombinant 
human Set8 (Active Motif). The reaction was terminated by addition of SDS-PAGE 
loading buffer. Western blots were probed using indicated antibodies.  
LANA COMPETITION ASSAY 
 In vitro Ub assays were set up as described above, except with 3, 10, 30, 50, 100 
or 150 mM of the indicated peptide. The peptides were synthesized by Bio Basic: LANA 
(Biotin-Mini-PEG-MAPPGMRLRSGRSTGAPLTRGSY) and 8LRS10 (Biotin-Mini-
PEG–MAPPGMRAAAGRSTGAPLTRGSY) and were based on data presented 
previously (118).  
TANDEM AFFINITY PURIFICATION (TAP) 
Tandem affinity purification (TAP) was performed as previously described with 
minor modifications (119). Briefly, HEK293T cells were seeded in 10 cm dishes and 
transiently transfected with SFB (S-protein, 2xFlag, streptavidin-binding peptide) tagged 
constructs. After 24 h of transfection, 10 dishes of cells with transfection plus 10 dishes 
of cells without transfection were collected and combined together. Cells were lysed with 
NETN buffer (150 mM NaCl, 1mM EDTA, 10 mM Tris-HCl, pH 8.0, and 0.5% NP-40) 
for 30 min at 4°C. Cell lysates were cleared by 15000 rpm centrifugation for 30 min at 
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4°C. The supernatants were collected as the soluble fraction. The pellets were digested 
with NETN buffer containing TurboNuclease (Accelagen) and 1 mM MgCl2 for 1 h at 
4°C. Cell lysates were then centrifuged to collect the supernatants as the chromatin 
fraction. Both soluble and chromatin fractions were incubated with 300 μl of streptavidin 
beads (GE Healthcare) for at least 1 h at 4°C. Next, the beads were precipitated by 2000 
rpm centrifugation and washed one time with NETN buffer. The bound proteins were 
eluted with 750 μl of NETN buffer containing 2 mg/ml biotin (Sigma) twice. The eluted 
supernatants were incubated overnight with 40 μl of S-protein beads (Novagen). The 
precipitated beads were washed three times with NETN buffer. Protein mixtures were 
eluted by boiling with Laemmli buffer, and resolved by SDS-PAGE. The purification 
efficiency was checked by silver stain (Calbiochem) following manufacturer’s 
instruction. The remaining samples were subjected to Mass Spectrometry (MS) 
identification.  
MASS SPECTROMETRY (MS) ANALYSIS 
For MS experiments, the raw data for TRIM samples were obtained from Dr. 
Brodbelt’s laboratory at the University of Texas at Austin. For MS data analysis in this 
study, only those proteins identified with at least two peptides for each experiment, were 
considered as potential interactors.  
IMMUNOPRECIPITATION (IP) ANALYSIS 
Untreated cells or with indicated treatments were collected and lysed with NETN 
buffer containing 1 mM MgCl2 and TurboNuclease by nutating on a roller for 1 h at 4°C. 
Cell lysates were cleared by centrifugation at 15,000 rpm for 30 min at 4°C. 
Overexpressed SFB tagged proteins were pulled down using 30 μl of streptavidin beads 
(GE Healthcare) by nutating for at least 1 h at 4°C. Similarly, ectopically expressed GFP 
tagged proteins were pulled down with 30 μl GFP-Trap beads (Chromotek) by nutating 
the tubes for at least 2 h at 4°C. Endogenous proteins were immunoprecipitated by adding 
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1 μg of indicated antibodies or following dilutions suggested in manufacturer’s 
instructions. The lysate-antibody mix was incubated by nutating the tubes overnight at 
4°C. Next day, 30 μl of IgG & IgA Dynabeads (Invitrogen) slurry or Protein A beads 
(Millipore) was added to each tube and nutated at least for 2 h at 4°C. Beads were 
washed 4X with NETN buffer. Protein mixture was eluted by boiling with Laemmli 
buffer and then subjected to the standard WB analysis with indicated antibodies (Table 
2.4).  
CLONOGENIC CELL SURVIVAL ASSAY 
U2OS cells (~500 cells per well) seeded in 6-well plates were treated with 
indicated dosages of different DNA damaging agents such as IR, hydroxyurea (HU), 
mitomycin C and camptothecin (CPT). Cells were left to form colonies for 10 to 14 days 
at 37°C. Formation of colonies was checked under the microscope and plates were 
washed once with 1X PBS and stained with 0.5% (w/v) crystal violet and 20% (v/v) 
ethanol for 30 min at room temperature. After staining, plates were gently washed with 
flowing water and let to air dry before the colonies were counted. Results were 
normalized to plating efficiencies of untreated cells for each treatment. 
HOMOLOGOUS RECOMBINATION ASSAY 
An integrated HR reporter DR-GFP-containing U2OS cell line was used as 
described previously [109]. One day after indicated siRNA treatments, U2OS DR-GFP 
cells were transfected with I-SceI expressing vector (pCAG-I-SceI) or control vector 
(pCAG). 48 h following I-SceI transfection, cells were trypsinized, washed once with 
PBS, and then resuspended in Sodium Citrate solution without fixation. Resuspended 
cells were filled into Falcon 5 ml Polystyrene round-bottom tubes through the cell-
strainer caps. The percentage of GFP positive cells was determined by a BD Accuri Flow 
Cytometer (BD biosciences). All samples were normalized with the siControl sample 
transfected with pCAG-I-SceI vector. 
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NON-HOMOLOGOUS END JOINING ASSAY 
Experiments were performed as previously described (77). Briefly, 24 h after 
siRNA transfection, U2OS cells were transfected with linearized pEGFP-C1 (BamHI and 
XhoI treatment). The next day, GFP positive cells were counted to calculate transfection 
efficiency. The cells were then trypsinized, counted and plated into two duplicated plates. 
One plate with 0.5 μg/ml G418 (as NHEJ events), and the other without (as plating 
efficiency) were incubated for two weeks at 37°C to allow colony formation. Colonies 
were stained as described in the clonogenic cell survival assay methods. Random-plasmid 
integration events were calculated using transfection and plating efficiency normalized to 
siControl.    
REVERSE TRANSCRIPTION AND QUANTITATIVE PCR (QPCR) 
After indicated treatments, total RNA for each sample was purified using the 
RNeasy mini kit (Qiagen, 74106) and treated with RNase-Free DNase I (Qiagen) 
following the manufacturer’s protocol. 2 μg of total RNA for each sample was used to 
synthesize cDNA by the SuperScript III first strand synthesis system (Invitrogen). 
Quantitative PCR (qPCR) was performed on the StepOnePlus Real-Time PCR system 
(Applied Biosystems) using SYBR green master mix (Applied Biosystems) with the 
indicated primers. To analyze mRNA expression levels of candidate genes, gene-specific 
qPCR primer pairs were designed as obtained. For normalization, the qPCR primer pair 
for GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used. The qPCR primer 
pairs used in this study are listed in Table 2.7 (in the next page). 
CRISPR TARGETING FOR GENE KNOCKOUT 
USOS cells with TRIM24, TRIM28 or TRIM33 knockout and HeLa cells for 
TRIM24 or TRIM28 knockout were generated using CRISPR/Cas9 system following 
standard protocol (120). sgRNA sequences used are: GGCCCGGACTCGGAGCGCGG, 
CATGCGTGATAGTGGCAGCA for TRIM28 and AGTGCCCACTGAGGCCGCAG 
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for TRIM33. The Cas9 nuclease vector is pSpCas9(BB)-2A-Puro. Successful knockout of 
the indicated genes was validated by Western blot. 
 
Target Sequences 
CXCL8 F’ TCCTGATTTCTGCAGCTCTGT 
R’ AAATTTGGGGTGGAAAGGTT 
IL11 F’ GGACAGGGAAGGGTTAAAGG 
R’ CTCAGCACGACCAGGACC 
AREG F’ ACGAACCACAAATACCTGGC 
R’ TTTCACTTTCCGTCTTGTTTTG 
EREG F’ AGGAGGATGGAGATGCTCTG 
R’ CACAGTTGTACTGAGGACTGCC 
RRAD F’ CAACAAGAGCGACCTGGTG 
R’ CCGCTGATGTCTCAATGAACT 
ATOH8 F’ TCAGCTTCTCCGAGTGTGTG 
R’ ACAGTGGTGGCCTTGGTCTT 
UCN2 F’ CTGCCTTACCCCAGAAGCA 
R’ ACTCTGCCCAACATCAGGAC 
DRD1 F’ AGCGAAGTCCACATTCCAAG 
R’ ATGTCTTCTCGCTCCTCCAA 
HTR2A F’ CCGCTTCAACTCCAGAACTAA 
R’ GAATCGTCCTGTAGCCCAAA 
BMF F’ AAGGTTGTGCAGGAAGAGGA 
 R’ CAGTGCATTGCAGACCAGTT 
GAPDH F’ CAATGACCCCTTCATTGACC 
 R’ GATCTCGCTCCTGGAAGAT 
MDC1-1 F’ CTTCATGTTGACTCCACCCC 
 R’ AATGGCTGTGTAGCCAGGAC 
MDC1-2 F’ TGGAGGATGAACCTACCCAG 
 R’ AGAATGGCTGTGTAGCCAGG 
KAT6B-1 F’ GCCTTCTACCCCATGAGAAA 
 R’ GCCACAATCTGCACAAGAGA 
KAT6B-2 F’ TTTGTGTCCCCCTGTTGTTGT 
 R’ GACTCCATTGGGCTGTAATCAGT 
TIP60 F: TCAAGCCGTGGTACTTCTCC 
 R: ATCTCATTGCCTGGAGGATG 
MOF F: TCAAGCCGTGGTACTTCTCC 
 R: ATCTCATTGCCTGGAGGATG 
Table 2.7 qPCR primers used in this study 
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CHAPTER 3: NUCLEOSOME ACIDIC PATCH PROMOTES 
RNF168- AND RING1B/BMI1-DEPENDENT H2AX AND H2A 
UBIQUITINATION AND DNA DAMAGE SIGNALING 
Eukaryotic DNA is bound by histone proteins and organized into chromatin, the 
true in vivo substrate of transcription, replication and DNA repair, processes that are 
important in preserving genome integrity. Chromatin structure and function are highly 
regulated by histone post-translational modifications (PTMs) (12). Histones are modified 
on distinct amino acid residues by different PTMs, such as phosphorylation, acetylation 
and ubiquitination, including several that are involved in DSB repair (4). Upon DSB 
formation, H2AX is phosphorylated on Ser-139 within its C-terminal tail by the PIKK 
family kinases ATM, ATR and DNA-PK, to yield γH2AX (22). γH2AX can be generated 
over a megabase of chromatin surrounding DSBs, thus creating microscopically-visible 
ionizing radiation-induced nuclear foci (IRIF) (26, 34). γH2AX creates a binding site for 
the DNA damage protein MDC1, which promotes the localization of other DNA damage 
factors to damage sites (4). Numerous E3 ubiquitin ligases including RNF8, RNF168, 
BRCA1, RING1B and BMI1 are recruited to DNA lesions (121, 122). Collectively, these 
DNA damage factors orchestrate the DNA damage response (DDR) that is a complex 
signaling network that is critical in regulating DNA damage signaling and repair (2, 5, 
121). Ubiquitin-mediated responses to DNA damage include histone H2A and variant 
H2AX ubiquitinations (H2A/H2AXub). Indeed, H2A/H2AXub is ubiquitinated by 
RNF168, which targets Lys-13/15 within the N-terminal tail (17, 59, 62), and RING1B/  
 
Portions of this chapter have been published as follows: 
Ø Justin W. Leung*, Poonam Agarwal*, Marella D. Canny, Fade Gong, Aaron D. 
Robison, Ilya J. Finkelstein, Daniel Durocher, Kyle M. Miller (2014) Nucleosome 
acidic patch promotes RNF168- and RING1B/BMI1-dependent H2AXand H2A 
ubiquitination and DNA damage signaling. PLOS Genetics 10(3): e1004178. 
      (* co first authors) 
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BMI1 that ubiquitinates C-terminal Lys-118/119 of H2A/H2AX (60, 123-125). 
Ubiquitinated histones H2AX and H2A mediate the chromatin association of both the 
mediator protein 53BP1 and the repair factor BRCA1. These interactions occur through 
binding to Ubiquitin-interaction motif (UIM) domains in 53BP1 and in the BRCA1-
interacting protein RAP80 (126, 127). Thus, site-specific histone ubiquitinations mediate 
critical signaling events that promote sensing and repair of DNA damage in mammalian 
cells (4, 121, 128). Although the role of histone ubiquitination is well established in DNA 
damage signaling, it is unclear how the ubiquitin E3 ligases recognize their specific 
lysine targets on histones within the context of the nucleosome. Whether the nucleosome 
itself is involved in mediating the site -specific ubiquitin modifications on histones in 
response to DNA damage or other biological signals involving histone ubiquitinations 
has not yet been established. In this study, we find that the nucleosome acidic patch is 
required for RNF168- and RING1B/BMI1-dependent H2A and H2AX ubiquitination.  
RESULTS/DISCUSSION 
The acidic patch promotes H2AX/H2A ubiquitination  
Ubiquitination of histones has emerged as a critical component of the DNA 
damage signaling pathway in mammalian cells (121). We previously identified several 
mutations that reduced H2AX ubiquitin levels in undamaged cells (50). One such 
mutation, H2AX-E92A resided in the acidic patch region of the nucleosome.  Expression 
of tagged versions of human H2AX and H2A in human HEK293T cells revealed a full-
length protein species of predicted size as well as a slower migrating ubiquitinated form 
for both human H2AX and H2A (Figure 3.1A-B). Mutation of glutamic acid 92 to 
alanine (E92A) reduced H2AX and H2A ubiquitination (H2AX/H2Aub, Figure 3.1A-B). 
These results identify the amino acid E92 of human H2AX/H2A as an important residue 
for H2AX/H2Aub. 
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Figure 3.1 Mutation of the acidic patch impairs human H2AX/H2Aub 
(A and B) E92A mutation in the acidic patch reduces H2AX/H2Aub. WT or E92A 
H2AX/H2A constructs were transfected into HEK293T cells and analyzed by western 
blotting with the indicated antibodies. Arrows indicate ub forms. (SFB = S-tag, Flag 
epitope tag, and streptavidin-binding peptide tag; e = endogenous; tub = tubulin loading 
control). Molecular mass (kDa) is indicated on the left of each panel. HEK293T cells 
were used for all cellular assays. (This figure was prepared by J.W.L.)  
We next sought to define the contribution of the acidic patch region of the 
nucleosome towards H2AX/H2Aub and the DDR. H2AX/H2A is specifically 
ubiquitinated on the N-terminal Lys-13/15 by RNF168 (17, 59, 62), as well as on the C-
terminal Lys-118/119 by RING1B/BMI1 (60, 123-125). Therefore, an important question 
was to determine which sites on H2AX rely on the acidic patch for ubiquitination. To 
answer this question, we first created a lysine-free human H2AX where all lysine 
residues were mutated to arginines. These mutations maintain the basic charge at each 
amino acid location but are unable to be ubiquitinated (Figure 3.2A). As expected, 
expression of H2AX-allR in HEK293T cells confirmed that this mutant lacked any 
detectable ubiquitination, similarly to H2AX-E92A (Figure 3.2B). Unlike these H2AX 
derivatives, mutation of the DNA damage induced phosphorylation site on H2AX (S139) 
to an unphosphorylatable residue (S139A) did not affect H2AXub (Figure 3.2B). Having 
identified a mutant H2AX derivative that lacked ubiquitination, we then reverted specific 
arginine residues in this mutant back to lysine residues that are contained in WT H2AX 
(Figure 3.2A). This strategy allowed us to unambiguously identify site-specific ubiquitin- 
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Figure 3.2 H2AX/H2A N’- and C’-ub require functional nucleosome acidic patch 
(A) Schematic of all H2AX lysines (K) and mutant derivatives. allR represents an all K to 
arginine (R) version of H2AX. Additional site-specific reversions from arginine to lysine 
within the allR H2AX derivate are indicated. (B) H2AX-allR and acidic patch mutation 
E92A reduces H2AXub. WT or E92A H2AX/H2A constructs were transfected into 
HEK293T cells and analyzed by western blotting with the indicated antibodies. Arrows 
indicate ub forms. (SFB = S-tag, Flag epitope tag, and streptavidin-binding peptide tag; e 
= endogenous). Molecular mass (kDa) is indicated on the left of each panel. HEK293T 
cells were used for all cellular assays. (C) H2AX-K13/15 dependent ubiquitination 
requires the acidic patch. H2AX and derivatives were expressed in HEK293T cells (-) or 
(+) ionizing radiation (IR, 20 Gy). Samples were analyzed as in A 6 hr post-IR treatment. 
(D) H2AX-K13/15 and K118/119-dependent ubiquitination requires the acidic patch. 
Cells were co-transfected with H2AX and derivatives along with myc- RNF168 and 
analyzed as in C. (E) Phospho-competent H2AX S139 is not required in cis for H2AX 
K13/15ub. Cells were analyzed as in C. tub = tubulin loading control. (This figure was 
prepared by J.W.L with the assistance of K.M.M.) 
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-ations within H2AX. As expected, H2AX mutants lacking K118/119 exhibited a large 
reduction in mono-ubiquitination (Figure 3.2C). This confirmed previous work showing 
that these sites on H2AX/H2A are the major lysine acceptor sites for mono-ubiquitination 
(4, 129). Interestingly, we observed ubiquitination of the H2AX derivative containing 
only K13/15 as acceptor sites for ubiquitin (Figure 3.2C). We also observed an increase 
in K13/15ub on this H2AX derivative upon DNA damage, which is consistent with 
previous studies showing that a small fraction of H2AX becomes ubiquitinated on 
K13/K15 following DNA damage by the E3 ubiquitin ligase RNF168 (17, 59, 62). To 
assess the contribution of the acidic patch towards H2AX K13/15ub, we tested whether 
an E92A mutation would affect H2AX K13/15ub.  Combining the E92A mutation within 
the H2AX derivative that could only be ubiquitinated on K13/15 abolished any detectable 
ubiquitination at these sites within H2AX (Figure 3.2C). We next tested whether the 
acidic patch also affected the ubiquitination of K118/119 of H2AX. Analysis of an H2AX 
derivative that could only be ubiquitinated on K118/119 showed that this protein was 
readily ubiquitinated and mutation of the acidic patch diminished H2AXub at these 
specific lysine sites (Figure 3.3).  
RNF168 is a limiting factor within the DDR and overexpression of RNF168 
increases H2AX-K13/15ub levels but not H2AX-K118/119ub levels (17, 59, 62, 130). In 
agreement with these studies, we observed that overexpression of RNF168 increased 
H2AX-K13/15ub but not H2AX-K118/119ub (Figure 3.2D, 3.3). In accordance with our 
results from Figure 3.2C), mutation of the acidic patch decreased H2AX-K13/15ub 
levels; even under conditions where RNF168 is overexpressed and not limiting (Figure 
3.2D). H2AX-K13/15ub is mediated by RNF168 whose recruitment to sites of DNA 
damage requires MDC1 and RNF8 (30, 40), which in turn require H2AX phosphorylation 
on S139 (30, 131-133). Collectively, these findings suggest that γH2AX may be required 
for H2AX-K13/15ub. To test this possibility, we mutated S139 within the H2AX-allR-
R13/15K derivative to monitor specifically H2AX-K13/15ub in either the presence or 
 58 
absence of S139. While E92A abolished H2AX-K13/15ub, the S139A mutation did not 
affect ubiquitination at these sites (Figure 3.2E). These results show that S139 is not 
required in cis for H2AX-K13/15ub under these conditions. We note that these 
experiments were performed in cells containing WT H2AX that could provide functional 
residues in trans for H2AX-K13/15ub. These experiments were done in the presence of 
overexpressed RNF168, which could bypass the requirement for S139 phosphorylation 
for its recruitment to chromatin. In overexpression conditions, RNF168 accumulates at 
sites of endogenous DNA damage marked by 53BP1 (130), which we note requires 
K13/15ub on H2A/H2AX (17). Regardless, under either limiting or non-limiting 
conditions for RNF168, we find that the acidic patch is required for H2AX-K13/15ub 
(Figure 3.2C-E).  
 
Figure 3.3 H2AX-K118/119ub requires the acidic patch and is unaffected by over 
expression of RNF168  
H2AX derivatives were transfected into HEK293T cells with or without myc-RNF168 
and either (-) or (+) IR treated with 20 Gy and allowed to recover for 6 h. Samples were 
taken and analyzed by western blotting with the indicated antibodies. Arrows indicate 
H2AXub. (SFB = S-tag, Flag epitope tag, and streptavidin-binding peptide tag, e = 
endogenous). (This figure was prepared by J.W.L.) 
Nucleosome acidic patch is required for H2AX/H2Aub in vitro 
Our results strongly suggested that the acidic patch is required for both K13/15 
and K118/119 H2AX/H2Aub. We next sought to test whether the effect of the acidic  
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Figure 3.4 RING1B/BMI1- and RNF168-dependent H2AX/H2Aub requires the 
nucleosome acidic patch in vitro 
(A) Schematic for in vitro reconstitution of nucleosome core particles (NCPs). (B) 
Bacterially expressed and purified human histones. Histones were expressed, purified and 
reconstituted as described in experimental procedures. (C) Analysis of in vitro 
reconstituted NCPs. The 147 bp 601 DNA fragment was analyzed alone or after NCP 
reconstitution. DNA ladder indicates size (bp). (D and E) RING1B/BMI1 and RNF168 
readily ubiquitinate H2AX within WT NCPs but not NCPs containing a mutation in the 
acidic patch (H2AX-E92A). In vitro Ub assays (4 h) were performed as described in 
experimental procedures. (F) RNF168 ubiquitinates WT H2AX and H2AX-E92A 
similarly when assayed in the context of free histones. Assays were performed as in E 
except with free histones and reactions were performed overnight. (G and H) 
RING1B/BMI1 and RNF168 readily ubiquitinate H2A within WT NCPs but not NCPs 
containing a mutation in the acidic patch (H2A-E92A). Experiments were performed as 
in D and E using H2A. (I) RNF168 ubiquitinates free WT H2A and H2A-E92A similarly. 
Experiments performed as in F. 
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patch mutation on H2AX/H2Aub was direct, as well as to analyze the role of the acidic 
patch in mediating site-specific ubiquitinations with their associated E3 ligases. To assess 
these questions, we reconstituted H2AX and H2A nucleosome core particles (NCPs, 
Figure 3.4A-C) with or without the acidic patch mutation (i.e. E92A) and subjected them 
to in vitro ubiquitination (Ub) assays. Previous studies have established that bacterially 
expressed and purified RNF168 and RING1B/BMI1 complexes catalyze the specific 
addition of ubiquitin on H2AX/H2A NCPs at K13/15 and K118/119 respectively (17, 
62). Using the same constructs and experimental conditions, we performed in vitro Ub 
assays with H2AX NCPs with or without the E92A acidic patch mutation. As expected, 
RING1B/BMI1 and RNF168 ubiquitinated H2AX within WT NCPs (Figure 3.4D-E). In 
contrast, both E3 ligase complexes were unable to efficiently ubiquitinate NCPs 
containing E92A mutation in H2AX (Figure 3.4D-E). These effects appear to occur 
within the context of the nucleosome as RNF168 could ubiquitinate the free form of 
H2AX whether it was WT or contained the acidic patch E92A mutation (Figure 3.4F). 
We performed identical experiments with H2A WT and E92A NCPs and obtained the 
same results (Figure 3.4G-I). As another control, we subjected H2AX and H2A WT and 
E92A NCPs to in vitro methylation assays with SET8, a methyltransferase that is active 
only within the context of the nucleosome for methylating H4K20 (134).  The acidic 
patch mutation did not affect nucleosome specific SET8 methylation suggesting the 
E92A mutation does not overtly disorder the NCP (Figure 3.5). These in vitro results are 
consistent with our in vivo data and demonstrate that RNF168 and RING1B/BMI1 
require the nucleosome acidic patch of H2AX/H2A to promote site-specific 
ubiquitination of H2AX/H2A K13/15 and H2AX/H2A K118/119 respectively. 
Nucleosome acidic patch is required for H2AZub in vitro 
We next performed experiments with NCPs reconstituted with histone H2A variant 
H2AZ to examine the functional importance of the H2AZ nucleosome acidic patch in 
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related functions in the DDR. Crystal structure of the H2AZ-containing nucleosome has 
revealed several unique properties of this H2A variant (73). Compared to other H2A con- 
 
Figure 3.5 The acidic patch does not affect SET8 methylation of NCPs 
WT, H2AX-E92A (A) and H2A-E92A (B) NCPs were subjected to methylation assays 
with Set8. Samples were analyzed by western blotting with specific antibodies against 
H2AX, H2A and H4K20me1, a SET8-dependent methylation mark. The methylation 
reactions were performed for 2 h at 20 C. The different apparent molecular weight of WT 
H2A is due to a 6XHis tag on WT H2A compared to untagged H2A-E92A. SAM = S-
Adenosyl methionine. (This figure was provided by M.D.C.) 
-taining NCPs, the extended acidic patch domain of H2AZ creates an altered acidic 
pocket on the H2AZ–nucleosomal surface. Mutational studies have shown that this can 
be functionally significant for DSB repair. For instance, euchromatic H2AZ shows higher 
chromatin folding than H2A, as a consequence of its extended acidic patch (135). 
Acetylation of histone H4 tail promotes chromatin relaxation by blocking the binding of 
H4 tail of one nucleosome to the acidic patch on the surface of an adjacent nucleosome 
(57, 66, 136, 137). The histone variant H2AZ is transiently loaded into NCPs at DSB 
sites. This step is mediated by the p400 ATPase subunit of the NuA4 HAT complex to 
stabilize and maintain a compact chromatin state by increasing the interaction between 
the H4 tail and the extended acidic patch of H2AZ immediately after DSB induction (51, 
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138). Since human RNF168 is a key mediator of ubiquitin signaling in DNA double-
strand break repair, in collaboration with the Huibregste lab and using the UBAIT 
technique and MS analysis, we identified H2AZ, a histone H2A variant involved in DNA 
repair as a new target of RNF168. RNF168 ubiquitinated H2AZ in vitro in H2AZ-
containing reconstituted nucleosome core particles (NCPs) (Figure 3.15). The D94A 
mutation in H2AZ disrupts the extended acidic patch in H2AZ that is required for repair 
activity suggesting that the nucleosome acidic patch region of H2AZ is required for 
RNF168-dependent ubiquitination (139). The analogous mutation in H2A blocks 
recruitment of RNF168 to nucleosomes (52), and this mutation also prevented in vitro 
ubiquitylation of H2AZ in NCPs (Figure 3.6).  
 
 
Figure 3.6 RNF168 ubiquitinates H2AZ-containing NCP  
Purified WT H2AZ-containing NCPs (first two lanes) were incubated with RNF168, 
UBCH5a, and ubiquitin, without or with E1 enzyme (lanes 1 and 2, respectively) in an in 
vitro Ub assay. Third lane contains D94A-containing NCPs, incubated with RNF168, 
UbcH5a, ubiquitin, and E1.  
Negative charge and mass of the nucleosome acidic patch is required for histone Ub 
In order to further assess whether the charge and/ or mass of the amino acids that 
comprise the acidic patch plays the critical role in these specific ubiquitin reactions, we 
substituted the WT acidic glutamic acid E92 in H2AX into another acidic negatively 
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charged residue, aspartic acid, i.e., E92D to retain the same charge and performed 
additional biochemical analyses. In addition, for retaining the mass of amino acids similar 
to the WT glutamic acid (E92), we substituted E92 with glutamine, i.e., E92Q and 
reconstituted individual nucleosomes with these residues on H2AX (Figure 3.7A). In 
vitro ubiquitination assays showed that RING1B/BMI1 E3 ligase mediated ubiquitination 
of E92Q containing NCP was completely abolished whereas RNF168 mediated 
ubiquitination had a marked reduction (Figure 3.7B). These results demonstrate that the  
 
Figure 3.7 Negative charge and mass of the nucleosome acidic patch regulate H2A/Xub  
(A) Point mutations of acidic patch were used to analyze the effect of its mass and charge 
on the histone H2A/X ubiquitinations and DDR signaling. (B) In vitro ubiquitination 
assay using the acidic patch mutants containing NCPs and either of the E3 Ub ligases 
RNF168 or RING1B/BMI1. 
negative charge on the acidic residue glutamic acid is critical for the specificity of the 
acidic patch mediated chromatin reactions. Substitutions made for maintaining the 
negative charges and altering mass of the amino acids also showed defective 
ubiquitinations as compared to WT NCPs mediated by either RING1B/BMI1 or by 
RNF168. Collectively, these results highlight that both the charge and mass of the acidic 
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patch residues are determining factors for this chromatin domain to mediate the histone 
PTMs on site-specific lysines and thereby promote DDR signaling. 
Although the acidic patch within H2A-H2B is the most notable interaction 
platform on the nucleosome, there are other potential structured regions on the 
nucleosome that may be of functional significance. For instance, investigations of other 
structural domains on the nucleosomal surface led to novel findings that include the 
presence of a structured and negatively charged region adjacent to the H2A-H2B acidic 
patch. This acidic pocket is composed of 3 residues within H3 and one residue from H4 
residues (140). Thus, the presence of a distinctive acidic patch region on the nucleosome 
prompted us to explore the requirement of other structural domains or residues on the 
nucleosome surface for regulating these ubiquitination reactions. To this end, we used the 
protein structural biology tool, Pymol, to shortlist 4 residues on H2AX which reside on  
 
Figure 3.8 Nucleosome surface serves as a chromatin domain to regulate various PTMs  
(A) Crystal structure of the NCP highlighting the non-acidic patch mutations on the 
nucleosome surface. (B) Non-acidic patch mutant L65A.L93A reduces levels of H2AX 
diubiquitination mediated by RNF168 as compared to control NCP.  
the nucleosomal surface to be mutated to alanine and analyze how these modifications 
would affect H2AX ubiquitination in the NCP (Figure 3.8A). The mutation L65A on 
H2AX showed reduced monoubiquitination and completely abolished the diubiquitinated 
H2AX which otherwise is observed in ubiquitination reactions using WT NCPs (Figure 
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3.8B). On mutating another negatively charged residue in H2B that constitutes the acidic 
patch to a basic arginine (i.e., H2B E106R) we observed similar results as obtained with 
the E92A mutant (Figure 3.9).  
 
Figure 3.9 Affect of H2B acidic residue mutant on H2Aub 
Mutation of acidic patch residue on H2B, E106R reduces RNF168 mediated H2A 
ubiquitination and completely abolishes RING1B/BMI1 mediated ubiquitination in vitro. 
Mutations in RNF168 and RING1B/BMI1 affect their E3 ligase activity 
Chromatin interaction motifs within both RNF168 and RING1B/BMI1 have been 
identified. For example, RNF168 contains multiple ubiquitin-binding domains (Figure 
3.10A) that target RNF168 to chromatin (141) and the RING1B/BMI1 complex contains 
DNA binding activity that is critical for histone ubiquitination (117). Similar to the 
bivalent reading of histone marks by 53BP1, our results suggest that the histone ubiquitin 
writers, RNF168 and RING1B/BMI1, utilize multivalent chromatin interactions, 
including the nucleosome acidic patch, to write their “histone code.”  
Key mechanistic insights explaining these chromatin Ub reactions have been 
provided by the X-ray structure of the RING1B/BMI1-UbcH5c E3-E2 complex (the 
PRC1 ubiquitylation module) bound to the NCP. This enzyme–NCP co-crystal structure 
revealed that the basic residues of RING1B/BMI1 heterodimer interact with the histone 
surfaces on the NCP, including amino acids within H2A-H2B acidic patch (142). H2A-
type histones residue E92 and RING1B residues K97, R98 and to a lesser extent K93 
contribute to the RING1B-nucleosomal interface. Validation of the structural predictions 
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through mutagenesis experiments in solution confirmed that the RING1B residue R98 
inserts into the acidic pocket generated by H2A residues E61, D90, and E92, making 
charged hydrogen bonds with each of the amino acid side chain carboxylates within the 
acidic patch. Besides arginine R98, other positively charged RING1B residues also 
interact with the acidic patch extending the RING1B-nucleosome interaction surface. The 
BMI1 subunit of this E3 ubiquitin ligase heterodimer has weak nucleosome binding 
affinity but makes contact with the H3 N-terminal tail, which is crucial for binding and 
proper orientation of the PRC1 complex on the nucleosomal surface (68, 143). 
Collectively, like RNF168, exposure of the nucleosome surface is necessary for 
RING1B/BMI1 to make contacts with the nucleosome to promote its site-specific activity 
on H2A histones. Unlike RNF168, how RING1B/BMI1 are targeted to DNA damage 
sites is unclear. While RNF168 contains Ub binding domains that recognize damage-
induced ubiquitinated targets, it is unclear how the heterodimeric RING1B/BMI1 
complex accumulates at damage sites. This question warrants further investigation, as 
answers to this question could reveal additional mechanistic understanding of how this 
complex targets damaged chromatin to promote the DDR. 
To test the importance of a few basic residues on the E3 ligases RNF168 and 
BMI1/RING1B, we purified mutant RNF168 and BMI1/RING1 containing aspartic acid 
or alanine substitutions of their basic residues and performed in vitro ubiquitination of 
H2AX containing NCPs using these as the E3 Ub enzyme. Consistent with previously 
published reports mentioned above, RNF168 R57D mutant was defective in catalyzing 
H2AX ubiquitination. However, additional RNF168 mutants that completely abolished or 
reduced these ubiquitinations on H2AX NCP were detected (R63D, R108D and K112D 
respectively) (Figure 3.10A-B). Similar results were obtained using BMI1 mutant  
(K62A.R64A) or RING1B mutant (K97A.R98A or E substitutions) (Figure 3.10C). 
Taken together, these results highlight the importance of the key residues on the E3s that 
are critical for perfoming the specific ubiquitination reactions on NCP to mediate DDR. 
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Figure 3.10 Mutations on RNF168 and RING1B/BMI1 residues affect their E3ub ligase 
activity on nucleosomal substrates 
(A) Domain structure of full length RNF168 full length. N’-RNF168 (1-113) is zoomed 3 
folds in the schematic. Mutations (aspartic acid substitutions) of amino acid positions are 
indicated. (B and C) In vitro ubiquitination assay using WT H2AX NCPs with (B) 
RNF168 mutants or (C) RING1B/BMI1 mutants. 
Nucleosome acidic patch of H2AX and the DNA damage response 
Our findings show that the nucleosome acidic patch mediates both H2AX/H2A K13/15ub  
by RNF168 and H2AX/H2A K118/119ub by RING1B/BMI1. Several studies have 
shown that RING1B/BMI1 participates in the DDR although a clear function for 
H2AX/H2A K118/119ub is as yet unidentified (60, 123-125, 144-146). In contrast, the 
function of H2AX/H2A K13/15ub by RNF168 was recently elucidated and is well 
defined (17). Indeed, RNF168-dependent H2AX/H2A K15ub is selectively recognized by 
the ubiquitination-dependent recruitment motif (UDR) of 53BP1 that, together with its 
Tudor domain, reads a bivalent ubiquitin-methylation signal at DNA damage sites to 
recruit the DDR factor 53BP1.  A clear prediction of this mechanism is that 53BP1 
recruitment to sites of DNA damage would be perturbed in the absence of H2AX-
K13/15ub and/or H2A K13/15ub. We chose to next focus on the role of the acidic patch 
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in regards to RNF168-dependent H2AX/H2A K13/15ub in vivo since we could utilize 
53BP1 foci formation as an in vivo read-out for functional H2AX/H2A-K13/15ub.  
Because RNF168 specifically targets H2AX-K13/15, we sought to characterize 
further our H2AX derivatives where K13/15 are the only lysines available for 
ubiquitination and to ascertain the contribution of both the acidic patch and RNF168 
expression levels on H2AX-K13/15 ubiquitin levels. Expression of SFB-tagged WT 
H2AX resulted in clearly identifiable mono-ubiquitinated species whose electrophoretic 
mobility was retarded as expected due to the presence of a 9 kDa ubiquitin protein 
(Figure 3.11A). Rendering WT H2AX unmodifiable by ubiquitin on all but K13/15 
resulted in an almost complete loss of mono-ubiquitinated H2AX (Figure 3.11A). This 
reduction was also observed when the acidic mutation E92A was added to this H2AX 
derivative. To analyze the contribution of both RNF168 and the acidic patch on H2AX-
K13/15ub, we repeated these experiments in the presence of overexpressed Myc-tagged 
RNF168. Although we still observed reduced H2AXub in K13/15 only H2AX derivatives 
compared to WT H2AX, we now were able to specifically detect H2AX-K13/15ub using 
this H2AX derivative that only contained K13/15 (Figure 3.11A). Interestingly, we were 
able to detect a small increase in H2AX-K13/15ub upon DNA damage suggesting that 
this H2AX derivative was functioning within the DDR in cells (Figure 3.11A). Under 
these optimized conditions for specifically detecting H2AX-K13/15ub, mutation of the 
acidic patch (i.e. E92A) resulted in a large reduction in H2AX-K13/15ub levels either in 
the presence or absence of DNA damage (Figure 3.11A). Thus, we could detect DNA 
damaged induced H2AX-K13/15ub in the presence of RNF168, and in all conditions 
tested, H2AX-K13/15ub required the acidic patch.  
Having now characterized H2AX derivatives for their ubiquitination on K13/15, 
K118/119 or in the absence of lysines, we sought to determine whether H2AX 
ubiquitinations were required in vivo for the DDR and more specifically for 53BP1 foci 
formation. Up to now, all of our experiments analyzing H2AX derivatives were perform- 
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Figure 3.11 The acidic patch regulates H2AX-K13/K15ub by RNF168  
(A) Maximum H2AX-K13/15ub levels (-) or (+) RNF168 is dependent on the acidic 
patch. HEK293T cells were transfected with H2AX and derivatives either (-) or (+) 
RNF168 and analyzed as in Figure 3.2D. (B) Human H2AX and derivatives reconstituted 
in MCF10A H2AX-/- cells. Western blot analysis of the indicated MCF10A H2AX-/- 
stable cell lines. (C) H2AXub is dispensable for 53BP1 foci formation after DNA 
damage. Reconstituted MCF10A H2AX-/- cells stably expressing H2AX and H2AX 
mutants were analyzed by immunofluorescence (IF) with the indicated antibodies. Cells 
were treated with 3 Gy IR and analyzed by IF 2 h post-IR. (This figure was provided by 
J.W.L.) 
-ed in the presence of WT H2AX. To overcome this limitation, we turned to a human cell 
line deleted for H2AX, MCF10A H2AX-/-, that we previously characterized (50). In order 
to test the contribution of H2AXub for 53BP1 IRIF, we stably reconstitutedMCF10A 
H2AX-/- with WT H2AX and derivatives to compare the ability of site-specific mutations 
in ubiquitinated sites on H2AX to complement the defect of 53BP1 IRIF that occurs in 
these cells in the absence of H2AX. We first created stable cell lines expressing H2AX 
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constructs to be tested and selected clones for each that expressed H2AX in the majority 
of cells and to similar protein levels as the WT H2AX reconstituted cell line (Figure 
3.11B, 3.12 and data not shown). To assess 53BP1 IRIF, we analyzed several H2AX 
derivatives for their ability to rescue defective 53BP1 IRIF in MCF10A cells lacking 
H2AX. As we previously reported, MCF10A H2AX-/- and MCF10A H2AX-/- + H2AX 
S139A are unable to support equivalent recruitment of 53BP1 into IRIF compared to WT 
MCF10A cells (Figure 3.11C). Surprisingly, all H2AX derivatives tested, including a 
lysine-less H2AX (allR) that cannot support ubiquitination on either K13/15 or 
K118/119, were able to fully support 53BP1 IRIF (Figure 3.11C). Thus, although S139 
phosphorylation is required for 53BP1 IRIF in these cells, H2AXub (including K13/15 or 
K118/119), as well as the H2AX acidic patch, is dispensable for 53BP1 IRIF (Figure 
3.11C). As DNA damage dependent H2A-K13/15ub also occurs, these results suggest 
that gH2AX could function in trans to promote H2A- K13/15ub that would be sufficient 
to mediate 53BP1 recruitment to sites of DNA damage. One hypothesis could be that 
DNA damage induced H2AX phosphorylation on S139 could mediate an initial 
ubiquitination on H2AX-K13/15 that would be required to amplify RNF168-dependent 
H2Aub. Similarly, the nucleosome acidic patch of H2AX could initiate the recruitment 
and activation of RNF168 that would in turn trigger the start of this ubiquitin-dependent 
signaling pathway. However, our results argue against these hypotheses and instead 
suggest that the acidic patch of H2A, as well as H2Aub, can compensate for H2AXub in 
the DDR to support 53BP1 IRIF. Testing the role of the H2A acidic patch and H2Aub in 
vivo is extremely challenging due to the unavailability of a mutation system for H2A in 
human cells.  Regardless, our findings establish that the acidic patch of H2AX, as well as 
H2AXub, is dispensable for 53BP1 IRIF in human cells.  
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Figure 3.12 IF analysis of H2AX derivatives expressed in MCF10A-/- cells 
Cells analyzed in Figure 3.11C were probed with a-Flag to detect tagged-H2AX 
derivatives and DAPI identifies nuclear DNA. Cells were processed for IF as described in 
experimental procedures (52).  
Nucleosome acidic patch is required for the DDR in vivo 
To overcome the limitations of studying histone mutants in vivo and to validate the 
requirement of the nucleosome acidic patch in promoting H2AX/H2Aub and subsequent 
DDR signaling, we sought to identify an experimental approach to target the acidic patch 
regions of both H2A and H2AX in vivo. The nucleosome acidic patch of H2A has been 
shown to interact with several proteins including histone H4, the Kaposi’s sarcoma–
associated herpesvirus (KSHV) protein LANA, IL-33, HMGN2 and RCC1 (118, 147-
150). The finding that several proteins interact through this nucleosome region has 
suggested that the nucleosome acidic patch acts as a “chromatin platform” to mediate 
various cellular signals via their interactions with chromatin through the acidic patch. As 
our data has identified the nucleosome acidic patch of H2AX and H2A as a requirement 
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for RNF168- and RING1B/BMI1-dependent H2AX/H2Aub in vitro and in vivo, we set 
out to test whether expression of a known acidic patch interacting protein could interfere 
with these DDR factors. This experimental approach has the advantage of blocking both 
H2A and H2AX acidic patch regions, a potential necessity for uncovering the function of 
this nucleosome domain in the DDR. Results from these experiments would further 
define the role of the nucleosome acidic patch of both H2A and H2AX in the DDR and 
would allow us to test our hypothesis that the acidic patch of H2A and H2AX functions 
in the DDR in vivo, at least in part by promoting H2AX/H2A-K13/15ub. 
   The KSHV latency-associated nuclear antigen (LANA) interacts with the 
nucleosome acidic patch of H2A to tether episomes to chromosomes (118).  The first 32 
amino acids of LANA comprise the acidic patch interacting region and expression of a 
GFP fusion with this minimal region in cells is sufficient to target this small truncated 
region of the protein to mitotic chromosomes (118). Additionally, mutation of the 8-10 
amino acid region (named 8LRS10) of this 32 amino acid LANA peptide abolishes the 
interaction of LANA with the nucleosome acidic patch. To assess whether this acidic 
patch interacting peptide from LANA could compete with RNF168- and RING1B/BMI1-
dependent H2AX/H2Aub, we synthesized the minimal acidic patch interacting peptide 
from LANA along with the 8LRS10 mutant peptide and analyzed the effects of these 
peptides on our previously characterized in vitro Ub assays.  
Interestingly, the acidic patch binding LANA peptide reduced H2Aub that was 
catalyzed by both RING1B/BMI1 and RNF168 in a concentration-dependent manner 
(Figure 3.13A, 3.14). The reduction of H2Aub by the LANA peptide required the ability 
to bind the acidic patch as the 8LRS10 mutant peptide was unable to compete away 
H2Aub.  These results supported our previous findings that the acidic patch was directly 
promoting histone ubiquitination by these E3 ligases and also suggested that the LANA 
peptide could interfere with this reaction in cells.  
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Figure 3.13 The KSHV LANA peptide inhibits histone ub in vitro and in vivo 
(A) The acidic patch interaction region of LANA inhibits RNF168- dependent H2Aub in 
vitro. In vitro Ub assays were performed (-) or (+) either LANA peptide or a mutant 
LANA peptide (8LRS10) that does not interact with the nucleosome acidic patch. Assays 
were performed as in Figure 3.4 with increasing concentrations of peptides (mM) as 
indicated (4 h reactions). (B) Expression of GFP-LANA (1-32a.a.) reduces H2AXub. 
HEK293T cells were transfected with the indicated constructs and analyzed by western 
blotting as in Figure 3.2B. (C) GFP-LANA (1-32a.a.) reduces H2AXub at K118/119. 
Experiments were performed as in B using H2AX-allR-R118/119K with or without IR 
treatment. (D) Expression of GFP-LANA (1-32a.a.) reduces RNF168-dependent 
H2AXK13/15ub. Experiments were performed and analyzed as in Figure 3.11A with the 
indicated constructs, with or without IR. Arrows indicate H2AXub protein species. e = 
endogenous; con = control GFP alone. (Panels B-D were provided by J.W.L.)  
To begin to address this question, we wanted to ask whether we could observe a 
decrease in H2AXub in cells expressing LANA peptide. We cloned and engineered a 
GFP-fusion of LANA containing only the first 32 amino acids (GFP-LANA (1-32a.a.), 
(118)). Next, we co-transfected our H2AX derivatives with GFP-LANA and analyzed 
H2AXub by western blotting. We observed that the ubiquitination of WT H2AX, H2AX-
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K118/119 only and H2AX-K13/15 only were reduced when co-expressed with GFP-
LANA in cells (Figure 3.13B-D). These results are in agreement with both our in vitro 
and in vivo data demonstrating that the nucleosome acidic patch of H2AX is required for 
K13/15 and K118/119 ubiquitination (Figure 3.2, 3.4).  
 
 
Figure 3.14 The acidic patch interaction region of LANA inhibits H2A ub in vitro 
Peptides derived from the KSHV acidic patch binding protein LANA compete with 
RING1B/BMI1-dependent H2Aub. In vitro Ub assays were performed (-) or (+) either 
LANA peptide or a mutant LANA peptide (8LRS10) that does not interact with the 
nucleosome acidic patch. Assays were performed as in Figure 3.4 with increasing 
concentrations of peptides (mM) as indicated (2 h reactions). 
The ability of LANA to inhibit H2AXub in vivo suggested that cells expressing LANA 
would exhibit impaired DNA damage signaling. If this were indeed the case, a clear 
prediction would be that cells expressing LANA would exhibit reduced 53BP1 IRIF due 
to H2AX/H2Aub inhibition from LANA blocking RNF168 through the acidic patch.  
To test this possibility, we expressed GFP-LANA in human U2OS and HEK293T cancer 
cells and analyzed 53BP1 IRIF with and without GFP-LANA. Upon DNA damage, we 
observed reduced 53BP1 IRIF in cells expressing GFP-LANA compared to GFP alone 
expressing cells (Figure 3.15A-B, 3.16). Importantly, the upstream DDR factor MDC1, 
as well as gH2AX, were unaffected by GFP-LANA expression (Figure 3.15A-C). This is 
consistent with RNF168 inhibition by LANA as RNF168 acts downstream of gH2AX 
and MDC1 (40, 151). To rule out any potential cell cycle effects due to GFP-LANA  
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Figure 3.15 Nucleosome acidic patch is required in vivo for DDR in human cells 
 (Figure legend for Figure 3.15 is on next page) 
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Figure 3.15 (A and B) In vivo expression of the acidic patch interacting portion of LANA 
(1-32 amino acids) reduces 53BP1, but not MDC1, IRIF (ionizing radiation induced-
foci). Human U2OS cells were transfected with GFP-LANA (1-32a.a.) followed by 2 Gy 
IR-treatment. Cells were analyzed by IF with the indicated antibodies 2 h post-IR. 
Representative IF images are shown. Nuclear DNA was visualized by Hoechst 33342 
staining. Quantification of A is shown in B. 53BP1 and MDC1 IRIF were counted and 
graphed for cells (-) or (+) GFP-LANA (1-32a.a.). N=3, > 100 cells analyzed/experiment, 
error bars = SEM. Student’s t-tests (paired) were performed and results indicated. *** = 
p-value < 0.001, ns = not significant (i.e. pvalue > 0.05). (C) IF analysis of DDR factor 
foci formation after IR treatment in GFP-LANA and GFP-LANA-8LRS10 expressing 
cells. Cells were treated with 2 Gy IR and processed for IF 2 h post-IR. IF analysis was 
performed as in A. (D) Quantification of 53BP1 IRIF from C. Graph represents values 
obtained from two independent experiments where foci from >100 cells were scored for 
GFP-LANA-8LRS10 expressing cells and non-GFP expressing cells. Error bars = SEM. 
Statistical analysis was performed as in B. (E) GFP-LANA (1-32a.a.) impairs recruitment 
of 53BP1 to laser damage. U2OS cells were transfected with GFPLANA (1-32a.a.) 
followed by laser micro-irradiation. Cells were fixed and stained with antibodies as 
indicated 2 h post-laser damage. Quantification of 53BP1 and MDC1 laser lines were 
obtained from > 50 damaged cells from two independent experiments. Error bars = SEM. 
(This figure was provided by F.G.)  
expression, we analyzed the cell cycle of GFP-LANA expressing cells. Analysis of these 
cells using FACS, DNA labeling by Hoechst and phospho-Histone H3 (S10) 
immunostaining, a histone mark specific for mitotic cells, did not reveal any detectable 
differences in cell cycle stage or DNA staining between control and GFP-LANA 
expressing cells (Figure 3.17A-D). In addition, expression of mutant GFP-LANA-
8LRS10, a mutation that is unable to bind the acidic patch, had no discernable effect on 
53BP1 IRIF showing that the effect of GFP-LANA on the DDR required its interaction 
 
 
Figure 3.16 In vivo expression of GFP-LANA reduces 53BP1 IRIF  
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 Figure 3.16 (A) HEK293T cells expressing GFP-LANA (1-32a.a) were analyzed as in 
Figure 3.10A. (B) Quantification of 53BP1 IRIF from A. Quantification and statistical 
analysis were performed as in Figure 3.10. (This figure was provided by J.W.L.) 
with the nucleosome acidic patch (Figure 3.15C-D). We also confirmed the inhibition of 
53BP1, but not MDC1, in GFP- LANA expressing cells by laser micro-irradiation 
(Figure 3.15E). We observed that cells expressing high levels of GFP-LANA were able  
 
Figure 3.17 GFP-LANA expression does not alter the cell cycle in U2OS cells  
(A) Cell cycle distributions of U2OS cells expressing GFP and GFP-LANA (1-32a.a) 
were analyzed by FACS and percentages of cells in G1, S, and G2/M are shown. GFP 
and GFP-LANA (1-32a.a) transfected cells were analyzed by Western blotting with 
indicated antibodies. (B) Mitotic index from empty vector and MYC-LANA (1-32a.a) 
transfected cells were analyzed by anti-phospho-H3S10 staining and quantified by flow 
cytometry. Graph represents triplicate experiments. Error bars = SEM. (C-D) U2OS cells 
expressing GFP-LANA (1-32a.a) do not exhibit detectable changes in H3S10p or nuclear 
DNA compaction. Untreated or IR-treated GFP-LANA (1-32a.a) transfected U2OS cells 
were analyzed as in Figure 3.15 with the indicated antibodies and DNA stain. (This figure 
was provided by J.W.L. and F.G.) 
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to fully inhibit 53BP1 recruitment to laser damage compared to cells expressing lower 
levels of GFP-LANA (Figure 3.15E). These results are consistent with GFP-LANA 
targeting the nucleosome acidic patch resulting in inhibition of 53BP1 recruitment to 
DNA damage.  
53BP1 functions in DNA double-strand break repair by both promoting NHEJ 
and inhibiting HR (reviewed in (152)). 53BP1 recruits the DDR factor RIF1 to DNA 
damage sites where it inhibits DNA end-resection and acts as the main effector of 53BP1-
dependent NHEJ (153-157). Consistent with GFP-LANA inhibiting RNF168-dependent 
53BP1 recruitment, we also observed reduced RIF1 accumulation at IRIF in GFP-LANA 
expressing cells (Figure 3.18A). RNF168 is also required for the recruitment of the HR 
factor BRCA1 to DNA damage sites (40, 151). Interestingly, GFP-LANA also impaired 
BRCA1 IRIF in S/G2 cells (Figure 3.18B; S/G2 cells were identified by CyclinA positive 
staining). Quantification of IRIF in GFP-LANA expressing cells revealed a greater than 
50% reduction in cells with greater than 10 foci for either RIF1 or BRCA1 (Figure 3.18C, 
D). The ability of GFP-LANA to impair IRIF of DDR factors appears to be dependent on 
expression levels. We observed that high LANA expressing cells displayed a greater 
reduction in DDR factor recruitment compared to low LANA expressing cells, which 
explains the incomplete inhibition of DDR factor recruitment to DNA damage sites by 
GFP-LANA (Figure 3.15E, 3.18B). 53BP1 also inhibits DNA-end resection in G1 to 
block HR and promote NHEJ (153, 155, 156, 158). Since expression of GFP-LANA 
impaired 53BP1 foci formation at DNA damage sites, we analyzed whether these cells 
exhibited functional inhibition of 53BP1 by monitoring DNA end-resection in G1 cells. 
RPA is recruited to, and binds, resected DNA, which is normally restricted to CyclinA-
positive S/G2 cells. As expected, in control cells that do not express GFP-LANA or cells 
expressing mutant GFP-LANA-8LRS10, RPA foci at laser damage were virtually 
undetectable using our experimental conditions (Figure 3.18E-F, quantified in G).  
Interestingly, GFP-LANA expressing cells readily formed RPA foci at laser damage in 
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CyclinA-negative G1 cells (Figure 3.18E-F, quantified in G). Thus, GFP-LANA 
expression resulted in DNA end-resection in G1 cells, which supports our previous 
results showing impaired 53BP1 recruitment to DNA damage by GFP-LANA. Taken 
together, these results are consistent with a role for the nucleosome acidic patch in 
promoting both 53BP1 and BRCA1 DDR pathways by mediating RNF168-dependent 
DNA damage signaling in vivo. 
 
 
Figure 3.18 Nucleosome acidic patch promotes RNF168-dependent DNA damage 
signaling and is required to inhibit DNA resection in G1 cells 
(Figure legend for Figure 3.18 is on next page) 
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Figure 3.18 (A and B) RIF1 and BRCA1 IRIF are impaired in GFP-LANA (1-32a.a.) 
expressing cells. Experiments were performed as in Figure 3.15A. Representative images 
are shown. CyclinA negative and High/Low LANA expressing cells are indicated in the 
merged image. Note: CyclinA marks S/G2 cells. (C and D) Quantification of RIF1 and 
BRCA1/CyclinA-positive IRIF from A and B. Graphs represent values obtained from 
two independent experiments where foci from >100 cells were quantified. Error bars = 
SEM. (E) GFP-LANA (1-32a.a.) expressing cells exhibit DNA end-resection as detected 
by RPA accumulation at laser damage in G1 (CyclinA-negative) cells. Experiments were 
performed as in Figure 3.10E with indicated antibodies after 4 h of micro-irradiation. (F) 
RPA32 laser lines in CyclinA-negative cells without or with GFP-LANA (1-32a.a.) 
expression are indicated by yellow and green dotted lines respectively. Enlarged images 
from each category are shown. All cells have been laser damaged. (G) Quantification of F 
and G from either WT GFP-LANA (1-32a.a.) or Mut GFPLANA-8LRS10 expressing 
cells. Laser damage CylclinA negative cells positive for LANA expression were scored 
for RPA laser line formation. Graph represents data obtained from >50 cells from two 
independent experiments. Error bars = SEM. (This figure was provided by F.G.) 
DISCUSSION 
Our results support a model whereby RNF168 and RING1B/BMI1 require the 
nucleosome acidic patch on H2AX/H2A to target these histones on site-specific lysines 
and that GFP-LANA can inhibit these processes (Figure 3.19). By overcoming the 
limitations of mutating the acidic patch of both H2A and H2AX through the expression 
of GFP-LANA, we have determined that the nucleosome acidic patch functions in vivo to 
promote RNF168-dependent DNA damage signaling. We have also created a novel tool 
that has the ability to silence DNA damage signaling at the level of RNF168 as well as 
inhibit RING1B/BMI1-dependent H2AX/H2Aub in vivo, which could be useful for 
studying these ubiquitin-dependent processes in cells. Of note, some viruses inactive the 
DDR by ubiquitin-dependent degradation mechanisms that target DDR factors, including 
RNF168 (159, 160). 
Our results suggest that viruses, including LANA expressing KSHV, could 
inactive the DDR through another means by interfering with the nucleosome acidic patch.  
This potential mechanism would inhibit H2A/H2AX ubiquitination and subsequent DNA 
damage responses whose inhibition can affect viral transcription and activation of latent 
viruses in mammalian cells (161).  Additionally, other nucleosome acidic patch binding 
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factors, including RCC1 and HMGN2, could also potentially affect the DDR. RCC1 and 
HMGN2 have opposing effects on chromatin dynamics with RCC1 promoting 
condensation of DNA prior to mitosis and HMGN2 decompacting chromatin through 
interactions with linker histone H1 (67). We envision that these factors could regulate the 
DDR in multiple ways including chromatin dynamics and/or competition with other 
nucleosome acidic patch interacting proteins including RNF168 and RING1B/BMI1. 
Additional studies are warranted to investigate the interplay between nucleosome 
interacting factors and the DDR. 
 
 
 
Figure 3.19 The nucleosome acidic patch and histone ubiquitination 
Summary of our results within the context of the nucleosome structure. The acidic patch 
is required for RNF168- and RING1B/BMI1-dependent histone ubiquitination and 
LANA inhibits these processes. Nucleosome structure was created in Pymol. 
To our knowledge, this study has identified the first nucleosome domain that 
participates in both H2A/H2AXub and the DDR in human cells. Most studies have 
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focused on the role of histone modifications, including ubiquitination, in the DDR. Our 
findings provide evidence that the DDR engages the nucleosome acidic patch, which 
participates in promoting histone ubiquitinations that mediate DDR factor interactions 
with chromatin including 53BP1. Chromatin interaction motifs within both RNF168 and 
RING1B/BMI1 have been identified. For example, RNF168 contains multiple ubiquitin-
binding domains that target RNF168 to chromatin (141) and the RING1B/BMI1 complex 
contains DNA binding activity that is critical for histone ubiquitination (117). Similar to 
the bivalent reading of histone marks by 53BP1, our results suggest that the histone 
ubiquitin writers, RNF168 and RING1B/BMI1, utilize multivalent chromatin 
interactions, including the nucleosome acidic patch, to write their “histone code.” 
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CHAPTER 4: CHROMATIN REGULATES GENOME TARGETING 
WITH CISPLATIN 
 
Emerging evidence indicates that functional interactions between small molecules and 
genomic DNA are influenced by chromatin features (104, 105). Platinum (Pt) drugs, 
including cisplatin and its derivatives represent some of the most commonly employed 
drugs in the clinical management of cancer (162). These drugs form covalent bonds with 
purine residues to produce toxic DNA-Pt including mono-adducts, inter- and intra-strand 
crosslinks. Thus, cellular responses to cisplatin are pleiotropic and inherently complex. 
For example, diverse repair mechanisms including nucleotide excision repair (NER), base 
excision repair (BER) and DNA crosslink repair involving the Fanconi anemia pathway 
can process DNA-Pt, and these lesions can also alter the structure of chromatin or be 
influenced by chromatin features (163). Alternatively, low-fidelity DNA polymerases 
(e.g. Polh) can bypass DNA-platinum lesions (DNA-Pt) through a mechanism known as 
translesion synthesis, enabling continued replication in the presence of DNA-Pt, 
conferring resistance to platinum drugs (164-168). 
To study DNA-Pt lesions, we sought to develop a surrogate probe that would 
allow for the chemical labeling of DNA-Pt crosslinks in cells. Visual detection of DNA-
Pt with high resolution at the single-cell level can potentially provide the means to 
monitor proteins at sites of lesions and to identify small molecules with a propensity to 
modulate targeting with cisplatin in an unbiased manner. Prior expertise in characterizing 
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mechanisms of action of small molecules prompted us to develop an azide-containing 
drug to label platinated DNA adducts by means of click-chemistry (105, 112, 169). 
Previous efforts towards the synthesis of clickable cisplatin derivatives suitable for cell 
imaging led to the development of an iminoacridine-Pt complex and a flexible alkyl-
azide-containing derivative (170, 171). 
With this in mind, our collaborators synthesized the cyclic azidoplatinum-
containing derivative we named 2-aminomethylpyridine (dichloro) PtII azide (APPA), 
(patent application no. PCT/EP2016/081166) on clickable cisplatin derivatives and 
protocols is filed). The design of APPA was inspired from the structures of cisplatin and 
picoplatin (Figure 4.1A), taking advantage of the aromatic methyl substituent to form a 
rigid five-membered ring with Pt. Thus, APPA exhibits a structure that can form bulky 
DNA lesions, where the ring prevents free rotation of the pyridine core chelated to Pt.  
This structural distinction was considered important given that the chemical nature of 
ligands bound to Pt at sites of lesions in cells can potentially affect how these lesions are 
detected and dealt with (172). Like cisplatin and picoplatin, APPA exhibited anti-
proliferative properties against human osteosarcoma U2OS cells (Figure 4.1B). Thus, we 
evaluated the reactivity of APPA towards DNA and our ability to label DNA-Pt with 
strained or terminal alkyne-containing fluorophores. A 26-mer hairpin-forming DNA oli- 
-gonucleotide containing a single 1,2-GG dinucleotide, prone to form an intra-strand 
crosslink upon treatment with Pt drugs, was incubated with APPA, purified and then 
incubated with a strained alkyne containing Alexa 488 (Figure 4.1C) (173, 174). The 
reaction products were then analyzed and characterized by mass spectrometry. We 
identified three ion peaks corresponding to the free unreacted hairpin along with the 
unlabeled and fluorescently labeled Pt adducts (Figure 4.1D). Next, we performed similar 
experiments in cells using APPA and the control compound 2-aminomethylpyridine 
(dichloro) PtII (APP, Figure 4.1E), a structurally related active analogue of APPA devoid 
of azide functionality and therefore not amenable to labeling. Labeled genomic DNA-Pt  
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Figure 4.1 APPA forms DNA-Pt cross-links in vitro and in vivo 
A) Molecular structures of APPA, cisplatin and picoplatin. B) Anti-proliferative activity 
of cisplatin derivatives against U2OS cells. C) Schematic representation of a DNA 
hairpin (hp), a 1,2-GG intrastrand DNA crosslink (hp-Pt) and chemical labeling of DNA-
Pt (hp-Pt-488). For clarity, a single regioisomer is shown for hp-Pt-488. D) Mass 
spectrometry detection of a free DNA hairpin, the corresponding DNAPt and its labeled 
counterpart. hp-Pt was observed as the molecular ion peak with loss of nitrogen. E) 
Molecular structure of APP and detection of genomic DNA platination by dot blot. DNA 
samples were purified from U2OS cells treated with APP (250 mM) or APPA (250 mM) 
for 3 h. EtBr (Ethidium bromide) stained gel of input DNA used as loading control. 
(Panels C and D were provided by E.Z.) 
obtained from APPA-treated cells displayed increased fluorescence compared to equal 
amounts of DNA collected from APP-treated cells as monitored by dot blot (Figure 
4.1E). This data demonstrated that APPA can form DNA-Pt with genomic DNA in cells.  
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Figure 4.2 Labeling and visualization of DNA-Pt in cells 
A) Detection of labeled DNA-Pt in U2OS cells. B) Schematic representation of a strategy 
for enhancing the detection of DNA-Pt in cells. C) Detection of labeled DNA-Pt in U2OS 
cells subjected to pre-extraction. Cells were treated with APPA (250 mM for 3 h). 
Zoomed images are 3X Scale bar, 20 mm. Unt., untreated. D) Visual detection of labeled 
DNA-Pt by fluorescence microscopy in U2OS cells showing colocalization with the 
nucleolar marker fibrillarin depicting APPA accumulates in nucleoli. Cells were treated 
with APPA (250 μM, 3 h). Scale bar, 20 μm. 
With this methodology in hand, we investigated the localization of DNA-Pt in 
cells. To this end, cells were treated with APPA and fixed with formaldehyde prior to 
labeling DNA-Pt using copper catalysis. Consistent with previous observations (170, 171, 
175, 176) labeled DNA-Pt exhibited a diffuse cytoplasmic and nuclear staining (Figure 
4.2A), which likely reflected the targeting of nuclear DNA as well as proteins and RNA. 
As a means to selectively detect DNA-Pt, we implemented a pre-extraction protocol to 
remove the background linked to soluble proteins and RNA targets of Pt drugs (Figure 
4.2B). This protocol allowed for the detection of labeled DNA-Pt in the nucleus with 
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some sub-nuclear regions displaying increased fluorescence intensity (Figure 4.2C). For 
instance, labeled DNA-Pt colocalized with fibrillarin (Figure 4.2D), in agreement with 
the idea that Pt drugs target rRNA in the nucleolus (171). Collectively, these data 
validated APPA as a functional clickable probe suitable for studying genome targeting 
with cisplatin derivatives in cells. Next, we searched for small molecule modulators of 
genomic DNA targeting with cisplatin derivatives, using APPA staining as a readout. We  
 
 
Figure 4.3 Effect on genome targeting with APPA in combination with chromatin 
modulators 
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Figure 4.3 A) Small molecules screened for effects on genome targeting with APPA. B) 
Flourescence microscopy detection of labeled DNA-Pt. Arrows indicate DNA-Pt foci. 
Scale bars, 20 mm. C) Quantification of B. >100 cells scored per condition; n=3; Foci 
were counted by means of visual inspection. D) Cisplatin competes with APPA for 
genome targeting. Zoomed images are 3X Scale bars, 20 mm. E) Heatmap of 
differentially expressed genes in SAHA and APPA cotreated cells. Genes were selected 
based on differential expression in SAHA and APPA cotreatment compared to untreated. 
Data from two independent experiments per condition are shown. Gene expression was 
monitored by RNA-Seq as described in Supporting Information. F) Scheme of DNA-Pt 
pull-down methodology. G) Quantification of DNA isolated by pull-down from samples 
treated as indicated; n=3. All experiments performed in U2OS cells. Cells were treated 
with APPA (250 mM for 3 h), APP (250 mm for 3 h), SAHA (2.5 mM for 5 h) and 
cisplatin (500 mM for 5 h). Error bars represent mean ± SD; ***P<0.001, Student’s t-
test; NS, not significant. (Panels A and D were provided by E.Z. and panel E was 
provided by N.A.) 
screened a defined set of small molecules that either operates at the level of chromatin or 
that are used in cancer treatment in conjunction with Pt drugs (Figure 4.3A). U2OS cells 
were cotreated independently with each small molecule and APPA, then subjected to 
chemical labeling and labeled DNA-Pt were analyzed by fluorescence microscopy. 
Treatment with the clinically approved DNA methyl transferase inhibitor azacytidine (5-
Aza) (177) and the histone deacetylase (HDAC) inhibitor SAHA (164, 178, 179) led to 
the occurrence of foci of DNA-Pt, indicating the presence of targeted clusters of purine 
residues at these sites that can include mono-adducts, 1,2-GG and 1,3-GTG intra-strand 
as well as inter-strand lesions (Figure 4.3B-C). Western blotting analysis confirmed that 
SAHA induced hyperacetylation of histone H4 (Figure 4.4A), an established marker of 
open chromatin (46). Furthermore, the structurally distinct Class I HDAC inhibitor MS-
275 (180) also led to increased number of DNA-Pt foci, implicating further the role of 
HDACS and chromatin in genome targeting with APPA ((Figure 4.4B). Importantly, the 
intensity of DNA-Pt foci was reduced when cells were cotreated with a two-fold excess 
of cisplatin acting as a competitor, indicating that both APPA and cisplatin target similar 
genomic loci (Figure 4.3D). These data suggested that chromatin relaxation resulting 
from SAHA treatment revealed de novo DNA targets of APPA. Interestingly, DNA-Pt 
occurring in SAHA-treated cells did not predominantly colocalize with the centromere  
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Figure 4.4 SAHA and MS-275 treatment in cells 
(A)Western blot analysis of U2OS cells treated as indicated showing SAHA induces 
hyperacetylation of H4 (B) MS-275 induces the formation of DNA-Pt foci. Visual 
detection of labeled DNA-Pt by fluorescence microscopy in U2OS cells. Cells were 
treated with APPA (250 μM for 3 h) and MS-275 (5 μM for 5 h) as indicated. Zoomed 
images are 3X. Scale bar, 20 μm. (Panel B was provided by E.Z.) 
 
 
Figure 4.5 DNA-Pt foci do not predominantly form at centromere and telomeres 
Visual detection of labeled DNA-Pt by fluorescence microscopy in osteosarcoma U2OS 
cells co-stained with markers of centromeres and telomeres. (A) Centromeric marker 
CENP-A. (B) Telomeric marker TRF1. Cells were treated with APPA (250 μM for 3 h) 
and SAHA (2.5 μM for 5 h) as indicated. Zoomed images are 3X. Scale bar, 20 μm.  
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and telomere markers CENP-A and TRF1, respectively, excluding these loci-containing 
repetitive sequences rich in 1,2-purine residues as primary targets of APPA under these 
conditions (Figure 4.5).  
Given that DNA-Pt can alter transcription, (181) we performed RNA-Seq analyses to 
evaluate whether SAHA treatment affected the transcriptional response induced by 
APPA. Our analysis identified a subset of genes that were up- or down-regulated by 
APPA compared to untreated cells (Figure 4.3E, 4.6). Interestingly, the transcriptional 
changes measured in cells cotreated with SAHA and APPA could be attributed to that 
observed either in SAHA or APPA independent treatments. This supported the idea that 
the DNA-Pt clusters detected in cotreated cells did not trigger additional transcriptional 
effects that were unique to this cotreatment.  
 
Figure 4.6 Transcriptional analysis in cells treated with platinum drugs 
Cisplatin and APPA treatment induce similar transcriptional effects. Analysis of top up- 
and down-regulated genes in APPA or cisplatin treated cells by qPCR. Bar graph 
represents data from three independent experiments. Cells were treated with APPA (250 
μM for 3 h) or cisplatin (10 μM for 3 h). Error bars represent s.e.m.  
Furthermore, qPCR experiments validated that cisplatin induced similar changes in gene 
expression compared to APPA, providing further evidence that APPA and cisplatin 
shared genomic targets. 
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Then, we developed a protocol to isolate DNA targets of APPA from cells (Figure 
4.3F). Cells were treated with APPA ± SAHA prior to being subjected to affinity pull-
down as previously performed for other classes of molecules (104, 182). The amount of 
DNA pulled down from cells was similar in both experimental conditions (Figure 4.3G). 
This result was in line with the idea that SAHA did not solely act by increasing the 
number of DNA targets per se, but rather induced a redistribution of DNA-Pt throughout 
the genome, potentiating DNA targeting at particular sites. This was consistent with the 
idea that chromatin relaxation induced by SAHA altered accessibility of the genome to 
APPA, providing additional insights into how HDAC inhibitors can sensitize cells to 
genotoxic drugs (109, 110). 
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Figure 4.7 Colocalization of labeled DNA-Pt with RAD18 in U2OS cells  
A) Cells were treated with APPA (250 mM for 3 h) and SAHA (2.5 mM for 5 h). 
Zoomed images are 3X. Scale bar, 20 mm. B) Western blot analysis of PCNA mono-
ubiquitination in U2OS cells. Cells were treated with APPA (250 mM) and SAHA (2.5 
mM) as indicated. C) Focal accumulation of Polη colocalizing with PCNA in U2OS 
cells. Cells were treated with cisplatin (10 mM for 3 h) and SAHA (2.5 mM for 5 h). 
Zoomed images are 6X. Scale bar, 20 mm. D) and E) Western blot analysis of apoptotic 
markers in WT and RAD18 KO HCT-116 cells. Cells were treated with APPA (250 
mM), SAHA (2.5 mM) and cisplatin (10 mM) as indicated. (Panel C was provided by 
E.Z.) (F) DNA-Pt colocalize with PCNA and RAD18. Visual detection of DNA-Pt, 
RAD18 and PCNA by fluorescence microscopy in osteosarcoma U2OS cells. Cells were 
treated with APPA (250 μM for 3 h) and SAHA (2.5 μM for 5 h) as indicated. Scale bar, 
20 μm. Quantification of DNA-Pt and RAD18 colocalizing foci is shown. 50 cells were 
scored per condition; n = 3. Foci were independently counted by two individuals in 
double-blinded experiments. Error bars represent mean ± SD. (Panel C was provided by 
E.Z.).  
The occurrence of DNA-Pt foci in SAHA-treated cells prompted us to determine 
whether clusters of lesions could act as physical roadblocks, potentially affecting DNA-
templated processes. Strikingly, DNA-Pt colocalized with RAD18, an E3 ubiquitin ligase 
that mediates mono-ubiquitination of the proliferating cell nuclear antigen PCNA in cells 
cotreated with SAHA and APPA (Figure 4.7A, F).  Moreover, clusters of DNA-Pt also 
colocalized with PCNA (Figure 4.7F). Cotreatment with SAHA and APPA led to mono-
ubiquitination of PCNA (Figure 4.7B), a mark that can promote the recruitment of low-
fidelity polymerases involved in TLS, (183) and cells cotreated with SAHA and cisplatin 
or APPA exhibited increased number of RAD18 foci (Figure 4.8). Furthermore, treatment 
with SAHA and cisplatin led to the focal accumulation of the TLS polymerase Polη (184) 
that colocalized with PCNA (Figure 4.7C, 4.9A). Altogether, these data were consistent 
with the notion that SAHA and cisplatin derivatives activated TLS synergistically.  
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It is noteworthy that levels of phosphorylated replication protein A (p-RPA) and 
CHK1 (p-CHK1) were similar in APPA-treated and cotreated cells indicating the absence 
of additional replication stress (Figure 4.9B). This was in agreement with the notion that 
HDAC inhibitors promoted a redistribution of DNA-Pt in contrast to a global increase in 
number of lesions. Remarkably, cotreatment with SAHA and APPA triggered apoptosis 
signaling as defined by the cleavage of PARP and the activation of caspase 3, in several 
cancer cell lines including colon carcinoma HCT-116, osteosarcoma U2OS and ovarian 
carcinoma A2780 cells (Figure 4.7D, 4.10). To evaluate whether RAD18 was directly  
 
Figure 4.8 SAHA and platinum drugs increase the number of RAD18 foci 
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Figure 4.8 (A) Visual detection of RAD18 by fluorescence microscopy in osteosarcoma 
U2OS cells. Cells were treated with cisplatin (10 μM for 3 h), APPA (250 μM for 3 h) 
and SAHA (2.5 μM for 5 h) as indicated. Zoomed images are 3X. Scale bar, 20 μm. (B) 
Quantification of A. 25 cells were scored per condition; n = 2; Foci were independently 
counted by two individuals in double blinded experiments. Error bars represent mean ± 
SD; ***P < 0.001, Student’s t-test. (Panel B was prepared together with E.Z.)  
 
 
Figure 4.9 Quantification of Polη foci and effect of replication stress 
A. U2OS cells were treated as indicated in Figure 4.7C. > 25 Polη positive cells were 
scored per condition; n = 2; Foci were computationally scored using Fiji software and the 
Analyze Particles function Error bars represent mean ± SD; ***P < 0.001, Student’s t-
test. (This figure was prepared together with E.Z.). (B) SAHA and APPA induce similar 
replication stress compared to APPA. Western blot analysis of osteosarcoma U2OS cells 
treated as indicated showing markers of replication stress. Cells were treated with HU (2 
mM), APPA (250 μM) and SAHA (2.5 μM) as indicated. 
 
involved in apoptotic signaling under these conditions, we performed similar experiments 
with matched HCT-116 RAD18 knockout (KO) cells. Western blotting indicated that 
cells devoid of RAD18 did not display PCNA mono-ubiquitination in response to SAHA 
and APPA cotreatment (Figure 4.7D). Additionally, markers of apoptosis were not 
detected in HCT-116 RAD18 KO cells even though DNA-Pt foci formed similarly in WT 
and RAD18 KO cells cotreated with SAHA and APPA (Figure 4.7D, 4.11). These results, 
along with the RAD18-dependent PCNA mono-ubiquitination implicated RAD18 in 
promoting apoptosis signaling in response to SAHA and APPA cotreatment. Comparable 
results were observed in SAHA and cisplatin cotreated WT and RAD18 KO cells, 
  A B 
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demonstrating that this response was a common feature of these cisplatin derivatives 
(Figure 4.7E). Although the induction of apoptosis signaling by RAD18 could be 
potentially counterintuitive owing to the well-established role of this factor in DNA 
repair processes and TLS, (164-168) HDAC inhibitors have been shown to re-sensitize 
cancer cells refractory to cisplatin (109, 110). Therefore, our results suggested that the 
 
Figure 4.10 SAHA and APPA induce apoptosis signaling 
Western blot analysis of cancer cells treated as indicated showing apoptotic markers. (A) 
Osteosarcoma U2OS cells. (B) Ovarian A2780 cells. Cells were treated with APPA (250 
μM) and SAHA (2.5μM) as indicated. 
 
Figure 4.11 RAD18 KO does not prevent the formation of DNA-Pt foci 
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Figure 4.11 Visual detection of labeled DNA-Pt by fluorescence microscopy in colon 
carcinoma HCT-116 WT and HCT-116 RAD18 KO cells. Cells were treated with APPA 
(250 μM for 3 h) and SAHA (2.5 μM for 5 h). Zoomed images are 4X. Scale bar, 10 μm. 
higher level of apoptosis signaling observed in RAD18 expressing cells in response to 
SAHA and cisplatin derivatives is due to the inability of polymerases to efficiently 
bypass DNA-Pt clusters. For instance, it is possible that chromatin relaxation mediated by 
SAHA favored the formation of 1,3-GTG intrastrand lesions, which have previously been 
shown to block TLS polymerases (185, 186). It is also conceivable that HDAC inhibition 
promoted lesion bypass at the expense of DNA repair (187), thereby leading to detectable 
clusters of DNA-Pt prone to trigger apoptosis through other mechanisms.  
DISCUSSION 
Engagement of the replication machinery with DNA-Pt can promote DNA breaks 
and cell death. However, cells can employ DNA damage tolerance pathways involving 
specialized low-fidelity polymerases to mono-ubiquitinated PCNA to bypass DNA-Pt 
(164-168, 188). These processes play a critical role in resistance to Pt drugs (108, 189-
193). To overcome these mechanisms, cisplatin derivatives containing bulkier ligands, or 
combination therapies with other drugs have been identified (194). Here, we have 
developed a versatile strategy to visualize DNA-Pt in cells with high resolution. This 
methodology has allowed unbiased identification of small molecule modulators of 
genome targeting with cisplatin derivatives. In particular, we have discovered that treati- 
-ng cells with the HDAC inhibitor SAHA and APPA resulted in detectable clusters of 
DNA-Pt and activation of a DNA damage response at these sites (Figure 4.12). While we 
cannot rule out a putative role of template switching and homologous recombination that 
could also be mediated by RAD18, the increase of Polh foci in cells cotreated with 
SAHA and cisplatin is consistent with activation of TLS. Thus, the response observed in 
these conditions comes in agreement with reports showing that clustered DNA lesions 
can impair DNA damage response pathways (195-197). This study has uncovered 
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unanticipated insights into how chromatin alterations can affect the targeting of genomic 
DNA and sensitization of cancer cells to cisplatin derivatives, establishing a robust exper- 
 
 
Figure 4.12 Model depicting influence of chromatin on genome targeting 
Treatment of cancer cells with cisplatin derivatives and a histone deacetylase inhibitor 
leads to the production of clusters of platinated DNA lesions that synergistically activate 
translesion synthesis and apoptosis signaling. These findings provide evidence for a role 
of chromatin in regulating genome targeting with cisplatin derivatives and associated 
cellular responses (111).   
-imental platform for basic and translational research relying on chromatin-targeting 
small molecules (98, 102). It is conceivable that these methods could be extended to the 
study of patient-derived xenografts, a step towards personalized medicine. 
 
 
 
 
 98 
CHAPTER 5: FUNCTIONAL ANALYSIS OF TRIM 
BROMODOMAIN PROTEINS IN THE DNA DAMAGE RESPONSE 
INTRODUCTION 
Histone posttranslational modifications (PTMs) are an integral part of the DDR 
machinery in human cells. One such PTM is acetylation and deacetylation of histones 
which is carried out by the concerted action of HAT (histone acetyltransferase) and 
HDAC (histone deacetylase) enzymes that recruit to sites of DNA damage to regulate and 
promote repair by modulating the chromatin states by altering interactions between DNA 
and histones. A class of proteins containing the conserved bromodomain (BRD) reader 
domain recognize and bind to acetylated lysine residue on proteins (79). Since BRD 
containing proteins also read the DDR-specific acetylation marks at sites of DNA 
damage, these have recently gained immense interest as an area of extensive research in 
current drug development. For instance, in addition to the existing pool of clinically 
approved small molecule inhibitors against HATs (eg. Curcumin) and HDACs (eg. 
Vornistat, Romidepsin) that target acetylation signaling, a wide range of small molecule 
inhibitors of that target proteins of the BRD family (e.g. BRD4 inhibitor JQ1, I-BET762, 
etc.) have been clinically approved for targeting DDR and tested for therapeutic 
applications for various cancer types including leukemia, myeloma, glioma and prostrate 
cancer (87, 89, 198-202).  
 Given the increasing potential of diverse screens for discovering novel DDR 
factors that could be effective anticancer drug targets, our group performed a 
comprehensive analysis of the dynamics of all the 42 human BRD-containing proteins 
which revealed that a third of these proteins relocalized upon DNA damage (82), some of 
which are known to be involved in various aspects of the DDR including reading specific 
acetylation changes at DNA damage sites (89, 91, 94, 203). They also found that 3 out of 
the 4 TRIM family BRD containing proteins, namely, TRIM24 (TIF1α), TRIM28 (TIF1β 
or KAP1) and TRIM33 (TIF1γ), which are generally classified as transcriptional 
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cofactors and constitute a Transcriptional Intermediary Factor 1 (TIF1) family, are 
recruited to sites of laser induced DNA damage (82). This is consistent with the 
previously known involvement of TRIM28 (92, 204) and TRIM33 proteins (205) in the 
DDR. 
In this study we investigated the DDR associated role and regulation of the TRIM 
BRD proteins, with a primary focus on TRIM24. Our data provides evidence that the 
multidomain protein TRIM24 binds acetylated chromatin and is involved in the DSB 
repair process in a TRIM28 and TRIM33 dependent manner. Damage recruitment of 
TRIM24 is mediated by histone acetylation by the HAT KAT6B to facilitate DNA repair 
in a PARP and SUV39H1 dependent manner. These functions require the bromodomain, 
PHD as well as the RING domain of TRIM24 revealing the potential importance of 
acetylation and ubiquitin signaling in this pathway. These findings will aid in gaining 
mechanistic insights on how acetylated chromatin and their reader domain containing 
TRIM-BRD proteins orchestrate DDR pathways, which can facilitate our understanding 
of how these proteins and pathways can be targeted for therapeutic purposes. 
RESULTS 
TRIM24 DNA damage recruitment is dependent on its RING, PHD-BRD domains 
One of the methods we implemented to study the TRIM DDR factors kinetics and 
localization upon induced DNA damage in live or fixed cells is by utilizing laser 
microirradiation followed by visualization of fluorescently tagged TRIM proteins by 
fluorescence confocal microscopy (Figure 5.1A). The TRIM-BRD proteins including 
TRIM24 are characterized by the presence of distinct structural features such as an N-
terminally located RING domain, two B-box zinc-binding domains and a leucine zipper 
coiled coil (CC) domain  (also called RBCC family) and a plant homeodomain finger and 
a bromodomain at the C-terminus (Figure 5.1B). These domains are involved in protein-
protein and protein-DNA interactions as characterized in other chromatin associated 
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proteins and transcription regulators (206, 207). Linked histone PTM reader modules 
such as tandem PHD finger and bromodomain are found frequently in proteins that 
interact with histones but not much is known about their mechanisms of action. Although 
several BRD proteins recruit to the sites of DNA damage, the requirement of BRD for its 
accumulation at damage site vary widely. For instance, the BRD containing TRIM28 
which shares many structural features with TRIM 24 recruits to DNA damage sites 
independent of BRD since it lacks acetyl-lysine binding (208). In contrast, the plant 
homeodomain (PHD)-BRD tandem domains of TRIM24 and TRIM33 can read 
methylated or acetylated histones (209, 210). Therefore we sought to investigate which 
domains in the newly identified DDR factor TRIM24 are required for its recruitment to 
damaged chromatin. We first observed that endogenous TRIM24 is rapidly recruited to 
sites of laser induced DNA damage marked by γH2AX (Figure 5.1C). By testing several 
ectopically expressed N-terminal GFP tagged TRIM24 constructs, for instance, WT 
TRIM24, PHD finger binding pocket mutant (C840W), bromodomain binding pocket 
mutant (F979A/N980A) or both PHD-BRD mutant (C840W/ F979A/N980A) (210) we 
found that TRIM24 rapidly accumulated to sites of laser induced damage and that 
TRIM24 required both PHD-BRD for this damage association (Fig 5.1D-E). TRIM24 is 
also reported to have E3 ubiquitin ligase activity, which modifies the tumor suppressor 
protein p53 mediated by its RING domain (211). We next tested whether deletion of the 
RING domain had an affect on its damage recruitment. However, RING deletion led to 
mislocalization of the nuclear protein TRIM24 in the cytoplasm (Figure 5.1 B, F-G). We 
therefore generated the catalytic dead RING mutant (C56A/C59A) to test its effect on 
damage recruitment (Figure 5.1B).  TRIM24 RING mutant is localized in the nucleus but 
has defective recruitment to DNA damage sites (Fig 5.1 H-I). Thus, these results indicate 
TRIM24 as a new DDR factor reliant on its RING, PHD-BRD domains for binding to 
damaged chromatin.  
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Figure 5.1 TRIM24 recruitment to damage requires its RING, PHD and BRD domains 
(Figure 5.1 legend is on the next page) 
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Figure 5.1 (A) DNA damage localization was studied using laser-induced damage and 
fluorescence microscopy (B) Domain structure of human BRD protein TRIM24 and 
generation of various mutants and deletion constructs. (C) Endogenous TRIM24 is 
recruited to laser induced damage sites and colocalizes with γH2AX. (D-I) TRIM24 
damage recruitment requires BRD, PHD and RING domains. White dashed circle 
represents laser induced DNA damage site (error bars represent S.E.M., n>10).  
TRIM24 is involved in maintaining genomic stability 
Our initial results showing that TRIM24 associates with damaged chromatin 
prompted us to further test its role in DNA damage signaling. TRIM24, also known as 
transcription intermediary factor 1-α (TIF1α), has been identified as a negative regulator 
of transcription factors including nuclear factors and p53 in human breast cancers (212). 
High levels of TRIM24 mRNA and overexpression negatively correlate with survival of 
breast cancer patients (210, 213). TRIM24 is abundantly localized in the nucleus of 
embryonic stem cells whose expression is downregulated during differentiation and 
organogenesis (214). A few reports highlight deregulation of TRIM24 expression as well 
as genomic alterations in human tumors such as papillary thyroid carcinoma and acute 
myeloid leukemia suggesting its functional significance (215-217). Moreover, the rapid 
recruitment of endogenous and GFP tagged TRIM24 to γH2AX-marked laser induced 
DSB sites (Figure 5.1C-D) indicated its role in another chromatin templated process, 
namely DNA repair.  These results corroborated with another method as endogenous 
TRIM24 increased chromatin association following DSB induction by ionizing radiation 
(IR) (Figure 5.2A). We then sought to characterize the role of TRIM24 in the DDR in 
human osteosarcoma U2OS cells by producing a TRIM24 knockout cell line (here 
referred to as TRIM24 KO and the parental cells (referred to as WT) using the CRISPR-
Cas9 technique. The TRIM24 knockout efficiency and specificity was confirmed by 
Western blotting (Figure 5.2B). TRIM24 knockout cells exhibited similar and 
comparable cell cycle profiles to parental U2OS cells containing TRIM24 (Figure 5.2C).  
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Further analysis showed that TRIM24 KO cells are hypersensitive to irradiation (IR), 
DNA cross-linking agent mitomycin C (MMC), topoisomerase I inhibitor camptothecin 
(CPT) and replication stress inducing compound hydroxyurea (HU), implicating that the  
 
Figure 5.2 TRIM24 participates in DNA damage repair 
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Figure 5.2 (A) Endogenous TRIM24 accumulated on chromatin following IR induced 
DNA damage. (B) TRIM24 KO cells verified by western blot. (C) Cell cycle distribution 
of 
WT and TRIM24 KO cells (D) Colony formation assays reveal hypersensitivity of 
TRIM24 KO cells in response to various DNA damaging agents (error bars indicate 
S.E.M., n=2) (E) Schematic of EU-labeling assay for nascent transcription analysis post 
damage (F) TRIM24 is not involved in transcription repression following laser induced 
DNA damage (G) TRIM24 recruitment is unaffected by DRB treatment (H) 
Quantification of G (Error bars = S.E.M., n>10) (I) Schematic for DR-GFP assay used to 
analyze HR efficiency (J) TRIM24 depletion alone or in combination with TRIM28 or 
TRIM33 does not impair HR-repair. siCtIP was used as a positive control for defective 
HR (error bars are S.E.M., n=3) (K) Random plasmid integration assay for analyzing 
NHEJ repair efficiency in WT and TRIM24 depleted U2OS cells. Data was normalized to 
siControl cells (siNC) and siLigaseIV (NHEJ factor) was used as a positive control for 
defective NHEJ (error bars, S.E.M., n=2). (L) Efficiency of siTRIM24 and siLigaseIV 
was assessed by quantitative PCR. Panel B TRIM24 KO U2OS cell line was made by 
F.G. Panel E was modified from (82).  Panel I was adapted from (82). 
DDR and DNA repair pathways are compromised in the absence of TRIM24 (Figure 
5.2D). These results confirm similar defects reported previously in cells depleted of 
TRIM28 and TRIM33 proteins which supports the involvement of these TRIM-BRD 
proteins in the DDR (94, 205). 
Since the TRIM family of proteins are generally classified as transcriptional 
regulators, this led us to hypothesize that this class of TRIM-BRD protein family 
members may have a role in transcription repression after DNA damage, a phenomenon 
known to occur as part of the DDR machinery to avoid conflicts between the 
transcription and repair pathways which can lead to genome-epigenome instability. We, 
therefore, tested whether TRIM24 repressed transcription after damage by utilizing EU-
labeling technique to monitor nascent transcription (Figure 5.2E) (82). We found that 
TRIM24 KO cells did not exhibit a reduction in transcription silencing at damaged sites 
(Figure 5.2 F). As both TRIM28 and TRIM33 have previously been demonstrated to be 
damage recruited, we assessed their roles in transcription inhibition following DNA 
damage as well. However, similar results were obtained using TRIM28 KO and TRIM33 
KO cells suggesting these DDR factors are not involved in transcription silencing at 
DNA damage sites (data not shown). We next examined whether TRIM24 required 
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transcriptionally active chromatin to mediate its recruitment to DNA damage. For these 
experiments, WT U2OS cells were treated with 5,6-dichlorobenzimidazole riboside 
(DRB), a chemical compound that inhibits transcription elongation, and TRIM24 damage 
recruitment was assayed. TRIM24 accumulation at sites of DNA damage was unaffected 
by DRB treatment indicating that its recruitment was not specific to transcriptionally 
active chromatin state in particular (Figure 5.2G-H).  
To further assess the role of TRIM24 in specific DSB repair pathways, we 
analyzed the efficiency of HR repair upon depletion of BRD-TRIM proteins using a HR 
reporter assay. As compared to control cells, there was no remarkable defect in HR 
efficiency following depletion of TRIM24 only or in cells co-depleted of TRIM24 and 
TRIM28 or TRIM33 (Figure 5.2I-J). This data is consistent with previous analysis of HR 
repair where 11 out of the 42 BRD proteins when depleted showed > 30% reduction of 
HR efficiency (data not shown). Using a random plasmid integration assay for NHEJ 
repair, we found that TRIM24 depletion impairs NHEJ repair (Figure 5.2K-L). Therefore, 
these preliminary data provide strong support for the involvement of TRIM24 in the 
DDR. However, further analyses to complement these findings through alternative 
experiments are warranted. 
TRIM24 regulates MDC1 expression levels in cells 
One of the distinctive features of DDR proteins is their discrete localization to the 
break sites that are microscopically detectable as foci. Since MDC1 (Mediator of DNA 
damage Checkpoint I) is one of the early DDR factors which promotes binding of DNA 
damage checkpoint and repair proteins to break sites, we investigated the focal 
accumulation of MDC1 to laser damage sites in TRIM24 depleted cells. Interestingly, we 
found a marked reduction in the number of MDC1 foci in TRIM24 KO cells. This 
defective MDC1 foci formation was also observed upon siRNA-mediated depletion of 
TRIM24 in U2OS cells. We then checked whether this decrease in MDC1 foci is due to a 
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reduction in the total levels of MDC1 produced. Both RNA analysis using qPCR and 
western blot using cell lysates from TRIM24 KO cells revealed a decrease in MDC1 
mRNA and protein levels respectively suggesting TRIM24 may play a role in regulating 
MDC1 expression. The formation of MDC1-γH2AX complex mediates retention of DDR 
factors in the vicinity of DNA lesions (30). As phosphorylation of histone H2AX 
(γH2AX) levels strongly increase following DNA damage to provide an initial signaling 
mechanism in the maintenance of DNA stability we expected to find higher levels of the 
γH2AX in TRIM24 KO cells exposed to genotoxic stresses. Unexpectedly, when 
TRIM24 KO and control U2OS cells were irradiated, or treated with HU, accumulation 
of γH2AX at various time points post-exposure was strongly reduced in the TRIM24 
deficient cells as compared to the WT cells indicating these cells have a defect in the 
DDR pathway (Figure 5.3F-G). The reduced γH2AX may be a downstream effect of the 
 
Figure 5.3 TRIM24 regulates MDC1 expression and foci formation  
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Figure 5.3 (A) MDC1 foci formation is partially defective in TRIM24KO cells upon laser 
damage treatment but not affected in WT cells (B) Quantification of A (P value <0.0001, 
n>50). (C) Quantification of MDC1 in siControl and siTRIM24 treated U2OS cells (P 
value <0.0001, n=85) (D) qPCR analysis for MDC1 mRNA levels using two different 
primer pairs (error bars = S.E.M., n=2). (E) Western blot for total MDC1 protein levels in 
WT and TRIM24KO U2OS cells. H2AX is used as a loading control. (F) Western blot 
for DNA damage signaling markers post IR damage. 
 
decreased MDC1 levels we observed in these cells as some studies implicate that MDC1 
masks the C-terminal region of γH2AX against premature dephosphorylation for efficient 
DNA repair to occur (30, 218). In TRIM24 KO cells, we observed reduced RPA2 
phosphorylation and ATM kinase mediated TRIM28 phosphorylation compared with 
wild- type cells after IR and HU treatment and reduced Chk1 phosphorylation after HU 
treatment (Figure 5.3F-G). Taken together, our data demonstrated a requirement of 
TRIM24 in maintaining genome integrity, which further highlights its relevance in the 
DDR. 
TRIM24 recruitment is PARP and ubiquitination dependent 
We next sought to determine the mechanisms that control TRIM24 recruitment to 
DNA lesions. We tested for the contribution of two important enzymes involved in early 
steps of the DDR: PARP and ATM. As known for a multitude of transcription factors that 
localize to damaged chromatin in a PARP dependent manner, we observed that 
recruitment of TRIM24 to damaged sites was partially PARP dependent (Figure 5.4A-B). 
This is in line with previously reported PARP dependency of TRIM33 recruitment as 
these three TRIM-BRD proteins are implicated to form heteromeric complexes (205). 
However, use of the ATM inhibitor KU-55933 revealed that ATM is dispensable for 
TRIM24 recruitment to damage sites (Figure 5.4C-D).  Similar results were obtained for 
ATM related kinase ATR inhibition (data not shown). We then tested whether regulatory 
ubiquitination events contributes to accumulation of TRIM24 on the damaged chromatin, 
we treated cells with the proteasome inhibitor MG132 which triggers translocation of the 
nuclear pool of ubiquitin-protein conjugates to the cytoplasm and subjected to laser 
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microirradiation (219). Remarkably, depletion of nuclear ubiquitin abrogated 
accumulation of TRIM24 recruitment to damaged sites suggesting regulatory 
ubiquitination is required for promoting recruitment of TRIM24 (Figure 5.4E-F).  
 
Figure 5.4 Factors affecting TRIM24 recruitment at damage sites 
 (A and B) Accumulation of GFP-TRIM24 to sites of laser microirradiation is attenuated 
upon PARPi treatment but not affected by (C and D) ATMi treatment (E and F) 
Treatment with MG132, proteasome inhibitor reduced TRIM24 DNA damage 
recruitment. 
TRIM24 accumulates to damaged chromatin in a SUV39H1 dependent manner 
Although the overall architecture of TIF1 family members including TRIM24, 
TRIM28, TRIM33 are similar, the extent of their functional similarity in the DDR 
pathway is not known. One function of TRIM28 is its association with heterochromatin-
associated factors HP1α, HP1β and HP1γ to promote the silencing of euchromatic genes 
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(220). In response to DNA damage, ATM kinase phosphorylates many histone and non-
histone proteins including the transcriptional regulator TRIM28 (94, 221-223). 
Phosphorylated TRIM28 promotes HR repair of DSBs in heterochromatic regions by 
chromatin decompaction, which allows the repair factors to access damaged sites (92, 
224). This is achieved by the formation of TRIM28-HP1-SUV39H1 complex, which 
rapidly recruits to damaged chromatin. H3K9 trimethylation is mediated by the 
methyltransferase SUV39H1 to promote additional binding of the TRIM28-HP1-
SUV39H1 repressive complex at DSB sites through interaction of H3K9me3 with HP1 
chromodomain, which facilitates the formation of heterochromatin and gene repression 
(225, 226). H3K9me3 activates the HAT TIP60, which then acetylates ATM and H4 
(212). This acetylated ATM activates the ATM kinase activity to promote DSB repair 
(227). siRNA-mediated depletion of TRIM28 blocked the recruitment of SUV39H1 to 
DSBs and vice versa. A high throughput histone peptide pull-down interaction screening 
platform to map the chromatin readers of the key activating and repressive histone 
modifications that serve as binding platform for the chromatin-associated proteins 
revealed that all the three TRIM-BRD proteins are specific binders of the repressive mark 
H3K9me3 which is mediated by SUV39H1 (228).  These studies support our premise to 
interrogate whether the TRIM-BRD proteins work in collaboration to orchestrate the 
DDR and therefore we examined the affect of SUV39H1 knockdown on TRIM24 
recruitment. Consistent with previous findings (212), both TRIM24 and TRIM28 
recruitment to DSBs required SUV39H1 (Figure 5.5A-F).  However, using the knockout 
cells that we generated for TRIM24 and TRIM28, we observed no defect in SUV39H1 
recruitment upon laser damage indicating SUV39H1 is an upstream factor that regulates 
the recruitment of TRIM-BRD proteins to the damaged chromatin (Figure 5.5D-E). 
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TRIM24 recognizes H3K23Ac catalyzed by KAT6B for damage recruitment 
Biophysical experiments by Tsai et al. showed that TRIM24 recognizes dual histone 
modifications, specifically, unmethylated H3K4 (H3K4me0) and the non-canonical 
histone mark H3K23Ac through its tandem PHD-BRD domain (210). In addition, 
immunohistochemical analysis of breast carcinoma samples showed that the levels of 
 
Figure 5.5 SUV39H1 regulates recruitment of BRD-TRIM proteins  
(A) U2OS cells were transfected with control siNC or siRNA to SUV39H1. Knockdown 
of SUV39H1 impairs TRIM24 to DSBs (B) Quantification of A (Error bars = S.E.M., 
n>10) (C and F) Western blot and mRNA levels showing siSUV39H1 efficiency (D and 
E) Depletion of SUV39H1 reduces TRIM28 recruitment to laser damage (Error bars = 
S.E.M., n>10) (G and H) Conversely, SUV39H1 recruitment is not affected in TRIM24 
or TRIM28 depleted cells. 
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TRIM24 expression positively correlated with H3K23Ac levels (229).  A similar PHD- 
BRD multivalent chromatin reader module was discovered in TRIM33 that recognizes 
histone H3 tail that is unmethylated at K4 and R2 and acetylated at two consecutive 
lysines, for instance, K18 and K23 (209). The histone mark H3K23Ac is catalyzed by the 
tumor suppressor HAT KAT6B (230). In order to assess whether these epigenetic marks 
are crucial for damage recruitment of the TRIM proteins, we depleted the cells of the 
HAT KAT6B and quantified their accumulation to damage sites. Notably, we observed a 
marked decrease in TRIM24 and TRIM33 accumulation upon KAT6B depletion (Figure 
5.6A-D). However, this dependency on KAT6B mediated H3K23Ac was not observed  
 
Figure 5.6 TRIM24 recognizes KAT6B mediated H3K23Ac mark for damage 
accumulation  
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Figure 5.6 (A and B) Knockdown of KAT6B HAT reduces the recruitment of TRIM24 
and  (C and D) TRIM33 whereas  (E and F) TRIM28 recruitment is not affected by 
depletion of KAT6B. (G) Quantification of qPCR showing efficient knockdown of 
KAT6B. (H and I) Cells treated with HDACi, TrichostatinA has impaired TRIM24 
accumulation to sites of damage. 
 
for TRIM28 recruitment to DNA lesions which is in line with previously identified non- 
BRD reader module recognition for TRIM28 to accumulate to damage sites (Figure 5.6E-
G). In striking contrast to the above data for TRIM24 and TRIM33 recruitment via 
KAT6B mediated acetylation recognition, chemical inhibition of HDACs (histone 
deacetylases) using Trichostatin A (TSA) completely abrogated TRIM24 accumulation at 
sites of laser induced damage (Figure 5.6H-I). This might be due to a drastic increase in 
the global acetylation levels on chromatin as a result of TSA treatment, which alters the 
TRIM-BRD association with damaged chromatin. Taken together, these data suggest that 
the recruitment of TRIM-BRD proteins to DNA damage sites is context specific and 
influenced by the damage site associated microenvironment.  
The TRIM-BRD proteins functionally interact to promote the DDR 
        Several non-DNA damage repair studies have shown that TRIM24, TRIM28 and 
TRIM33 have distinct functions (5-14). This is substantiated by the observation that     
TRIM28 and TRIM33 null mice are embryonic lethal at E8.5 and E9.5, respectively 
(15,16) whereas TRIM24 germline knockout mice are viable. Herquel et al. showed that 
HeLa cells overexpressing HA-tagged TRIM24 co-immunoprecipated TRIM28 and 
TRIM33 as interacting partners along with HDACs 1 and 2 and the HP1 proteins (17). In 
order to examine whether these 3 TRIM proteins interact functionally in the context of 
DNA damage to promote DDR signaling and repair, we generated TRIM28 KO and 
TRIM33 KO U2OS cell lines (Figure 5.7A-B). Over expressing GFP-TRIM24 in both 
TRIM28 KO and TRIM33 KO cells resulted in defective TRIM24 accumulation at laser 
damage sites (Figure 5.7C-D). Besides, TRIM28 recruitment was significantly reduced in 
the TRIM24 KO cells (Figure 5.7E-F). Our co-IP analysis using SFB-tagged TRIM33 
stably expressing 293T cells copurified TRIM24 and lower levels of TRIM28 (Figure 
5.7G), similar to previous reports where TRIM24 was found to be stoichiometric with 
TRIM33 in the complex but less abundant than the TRIM24, TRIM28 and TRIM33 tri-
 113 
member complex (17). We then sought to identify whether the interaction between 
TRIM24 and TRIM28 is mediated by TRIM33. To this end, we performed endogenous 
IP using the WT and TRIM KO cell lines. TRIM24 and TRIM28 interaction was not dep- 
 
Figure 5.7 TRIM24 damage accumulation is TRIM28 and TRIM33 dependent 
(A and B) Western Blot to confirm TRIM28 and TRIM33 KO U2OS cell lines generated 
using CRISPR-Cas9 respectively. (C and D) TRIM24 accumulation at damage sites is 
impaired in TRIM28 KO and TRIM33 KO cells (Error bars = SEM, n>10). (E and F) 
TRIM28 recruitment is reduced in TRIM28 KO cells (Error bars = SEM, n>10).  (G) 
Over expression of SFB-TRIM33 and affinity purification to validate that the 3 BRD-
TRIM proteins interact with each other. (H) Endogenous TRIM24 interacts with 
TRIM28. Western blot analysis of co-IP with TRIM24 antibody from WT and 
TRIM33KO U2OS cells. ( Panel A-B, TRIM28 and TRIM33 KO U2OS cell lines were 
generated by F.G. Panel G was provided by P.C. and panel H was prepared with 
assistance from M.K.) 
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-endent on the presence of TRIM33 as revealed by equal levels of TRIM28 co-purified 
from WT and TRIM33 KO U2OS cells (Figure 5.7H). Thus, we ascertained that the 
interaction between TRIM24 and TRIM28 was not mediated via TRIM33 and this 
interaction could be either direct or through other common partner proteins such as HP1. 
Sequential immunoprecipitations using TRIM24 KO and TRIM28 KO cells are 
warranted to test whether TRIM24 is required for TRIM28-TRIM33 interaction and 
TRIM28 requirement for TRIM24-TRIM33 interaction respectively. Further 
investigations are required to test whether the affinity between the individual TRIM 
proteins increases upon damage induction. These results implicate that the 3 TRIM-BRD 
proteins function as a complex and might act interdependently in the DDR.  
MCM complex interacts specifically with TRIM24 
To better understand the molecular function of TRIM24 in the DDR, we sought to 
identify its interacting protein partners. Expression vectors containing N’-SFB (S protein, 
2X flag, biotin) tagged TRIM-BRD genes were generated for TRIM-BRD proteins and 
stably expressed in HEK293T cells. Pull down of TRIM24, TRIM28 or TRIM33 
interacting proteins was carried out by a previously described two-step tandem affinity 
purification (TAP) method using streptavidin and S-protein beads (82) and purification 
efficiency was checked by silver stain (Figure 5.8A). These samples were then analyzed 
by mass spectrometry (MS) to identify the specific interactors of each of the TRIM-BRD 
proteins. Consistent with our identification of the TRIM-BRDs as chromatin interacting 
proteins, we identified all the core histones, H2AX, macroH2A in our MS results for 
BRD-TRIMs. We shortlisted ~15 proteins as potential TRIM24 interactors using the 
CRAPome database (a contaminant repository for affinity purification mass spectrometry 
data) to filter out common contaminants of MS analysis (Figure 5.8B). Consistent with 
previous findings and our analysis of TRIM proteins interactions and complex formation 
among TRIM24, TRIM28 and TRIM33, each of these proteins peptides appeared in the 
MS results for one another. Interestingly, we observed that, except for MCM5, peptides 
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corresponding to members of the hexameric MCM complex (e.g. MCM2, MCM3, 
MCM4, MCM6 and MCM7) were present as interactors of TRIM24 exclusively but not 
found in the TRIM28 or TRIM33 interactome. The eukaryotic MCM (minichromosome 
maintenance complex) proteins form a heterohexameric ring consisting of MCM2-
MCM7 that possesses DNA helicase activity and is activated during replication to 
unwind DNA and recruit DNA polymerases at the replication fork (231-233). In addition 
to its role in forming the pre-replication complex, the MCM complex has been implicated 
to be involved in DNA repair (234-237). The subunits MCM3 and MCM7 have been 
identified substrates for checkpoint kinases, ATM and ATR (238). A study showed that 
excess MCM complex bound to the chromatin safeguards the genome integrity under 
replication stress (239). A proteomics screen to identify proteins interacting with the 
MCM complex following etoposide induced DNA damage revealed ASF1 as an MCM2 
interactor, the levels of which increased upon DNA damage (235). Based on our MS 
results, we validated the MCM complex interaction with TRIM24 using GFP pull down 
experiments from cells over expressing GFP-tagged MCM4 (Figure 5.8C). In order to 
rule out the over expression effects, we confirmed these interactions with endogenous 
TRIM24, TRIM28, TRIM33, MCM2 and MCM4 from HEK293T cells (Figure 5.8D). In 
addition, we validated MCM complex interaction with reciprocal immunoprecipitation of 
endogenous TRIM24 (Figure 5.8E). Future work is required to map these interactions 
within the TRIM-BRD and MCM complex. It will be interesting to analyze whether the 
replicative helicase MCM complex cooperates with TRIM24 to promote signaling and 
repair of collapsed replication forks.  
FACT complex interacts with TRIM24 and TRIM33 
Our MS analysis also revealed interactions between the TRIM-BRD proteins and 
the histone chaperone complex FACT (Facilitates Chromatin Transcription) which is 
composed of the subunits, SUPT16H and SSRP1(240). We validated this interaction 
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using streptavidin immunoprecipitation from inducible HEK293T cells stably expressing 
SFB-TRIM33 (Figure 5.8F). Besides, our preliminary results indicate that SSRP1 is 
recruited to sites of DNA damage in WT U2OS cells but not in the TRIM33 or TRIM24  
 
Figure 5.8 TRIM24 interacts with the MCM and FACT complex 
(A) Identification of BRD-TRIM proteins interacting factors by mass spectrometry. (B) 
List of top proteins identified as TRIM24 interactors in MS analysis from three 
experiments. (C) MCM4 interacts with BRD-TRIM proteins, TRIM24, TRIM28 and 
TRIM33 directly or indirectly as analyzed by co-IP from HEK293T cells overexpressing 
GFP-MCM4. (D) Endogenous TRIM24 interacts with MCM2 and MCM4, core 
components of the MCM-complex. (E) WB analysis of endogenous reciprocal co-IPs 
with TRIM24 antibody from HEK293T cells. (F) TRIM33 interacts with FACT complex 
subunits, SSRP1 and SUPT16H (Panel A and F was provided by P.C.)  
KO cells (data not shown). It is conceivable that TRIM24 and TRIM33 are the upstream 
factors that regulate the accumulation of FACT complex to damaged chromatin. As 
discussed earlier, we validated that TRIM24 interacts with TRIM33 and that both 
TRIM24 and TRIM33 interact with the FACT and the MCM complex. We also 
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confirmed that SSRP1, a FACT complex component, reciprocally interacts with TRIM-
BRD proteins and the MCM complex. Previous data indicate that functional association 
of FACT-MCM complexes on DNA replication origins promotes replication initiation 
and DNA unwinding (241, 242). The functional basis of TRIM-BRD proteins interaction 
with the FACT and MCM complexes requires further investigation but it is possible that 
this interaction facilitates a very site-specific recruitment of the TRIM-BRD complex to 
active replication forks. Additional studies are required to evaluate how these complexes 
in association with TRIM-BRD proteins is involved in orchestrating their DDR function. 
It will be important to analyze any changes in abundance of the FACT and MCM 
components in the TRIM KO cell lines or changes in their interaction ability upon DNA 
damage to assess whether TRIMs are involved in regulating turnover of either complex. 
Besides, a host of zinc finger family proteins were also identified in the MS data some of 
which overlap among the three TRIM-BRD proteins. To better characterize the 
involvement of these factors in mediating the DDR functions of TRIMs, it is important to 
examine the effects on TRIM recruitment to DNA damage upon depletion of each 
putative TRIM-BRD interacting protein including MCM complex components and 
subunits of FACT complex.  
DISCUSSION 
Our work provides, for the first time, some preliminary insights into the role and 
regulation of TRIM24 in the DDR. Here we uncover that similar to previously known 
functions of TRIM28 and TRIM33 in promoting DNA repair, TRIM24 is a novel DDR 
factor. Specifically we have shown that TRIM24 accumulates at DNA damage sites and 
requires its PHD-BRD as well as the RING domain. Based on previous biochemical and 
structural studies indicating TRIM24 as a bivalent chromatin reader that recognizes 
unmodified H3K4 and H3K23Ac mediated by histone acetylation by the HAT KAT6B, 
we found that both TRIM24 and TRIM33 DNA damage recruitment is dependent on this 
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histone signature. This finding reveals the importance of acetylation signaling in the 
TRIM-BRD mediated repair pathway. Since this TIF1 family of proteins is categorized as 
transcription regulators, we first analyzed whether the TRIM-BRD protein family 
members were involved in transcription repression post DNA damage in order to avoid 
conflicts between the transcription and repair pathways and thereby promote the DDR. 
Strikingly, loss of TRIM24 did not reduce transcriptional silencing at damage sites 
indicating its involvement in other pathways. Further analysis revealed that TRIM24 
deficiency resulted in defective NHEJ repair efficiency, increased sensitivities to 
different damaging agents and had lower levels of the master regulator protein MDC1. 
Our work highlights how the newly identified TRIM24-dependent damaged chromatin 
recognition pathway is regulated to promote DNA repair.  
Future work is required to explore and comprehend mechanistically how these 
TRIM proteins orchestrate the DDR pathway in conjunction with the potential common 
and specific interactors of the TRIM-BRD proteins including MCM complex, FACT 
complex and Zn-finger proteins identified through proteomic analysis. Moreover, RNA-
seq and ChIP-seq analyses could reveal how TRIM-BRDs are involved in regulation of 
genes that are essential for cancer cell survival. ChIP-seq will allow to map the TRIM-
BRD occupancy throughout the genome. Nevertheless, it is important to analyze whether 
mutations in these three TRIM-BRD proteins that have been identified in cancer effect 
DNA damage repair by HR or NHEJ, which could point towards therapeutic 
opportunities. Detailed genetic and biochemical analysis to clarify functional redundancy 
between TRIM proteins would improve our understanding of the role of TRIM proteins 
in DDR. All these studies would provide a framework for elucidating chromatin-based 
DNA damage responses involving TRIM-BRD proteins that promote DNA repair and the 
DDR. It remains to be addressed whether the TRIM-BRD proteins act as key chromatin 
modulators of the DDR via a novel yet unidentified pathway to orchestrate the DDR in a 
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context specific damage associated microenvironment, for instance, active replication 
forks or heterochromatic DSB repair as implicated for TRIM28 (243).  
Our analysis of TRIM-BRD multi-protein complex as putative DDR factors has 
important implications for targeted anticancer therapy. Given the fast-paced development 
and clinical success of small molecule inhibitors of BET family of bromodomain proteins 
and increased application of DDR proteins targeted therapeutics, a comprehensive 
analysis of TRIM-BRD proteins in the DDR is potentially relevant to cancer. Two 
different groups have developed potent and selective small molecule inhibitors for 
TRIM24 BRD and BRPF1 family of proteins (244, 245), which can aid in further 
elucidating the DDR roles of TRIM24 and thereby utilize these inhibitors to target 
TRIM-BRD for anticancer therapy. Thus, knowledge gained from this study will be a 
stepping-stone towards therapeutic strategies for targeting TRIM-BRD proteins as 
mediators of DDR signaling. 
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CHAPTER 6: DISCUSSION 
 
CHROMATIN AND THE DNA DAMAGE RESPONSE 
Chromatin and the DDR participate in promoting cellular responses that are 
crucial for repairing damaged DNA across the chromatin landscape to ensure genome 
stability and cellular homeostasis. My thesis dissertation has contributed to this field in 
several ways. The first part of my thesis dissertation project identified the chromatin 
domain, the nucleosome acidic patch, as a critical region that modulates H2A and H2AX 
ubiquitinations that regulates DDR signaling. Secondly, altered chromatin dynamics 
occurring in diseases including cancer is known to influence DNA repair. This has been 
especially well established in cancer treatments as DNA damaging agents are used as 
frontline therapies to treat this disease and chromatin-based mechanisms have been 
identified as mediators of these responses. For example, cancer cells resistant to DNA 
damaging agents including cisplatin can be reversed to a drug-sensitive state through the 
reprogramming of chromatin by using the epigenetic drug that inhibits histone 
deacetylases (109). To gain mechanistic insights into how these events occur, the second 
part of my thesis focused on delineating how the chromatin modulator, SAHA (HDACi) 
in combination with the platinum drug influences genome targeting. These and other 
studies provide evidence that epigenetic drugs are promising anticancer agents and that 
 
Portions of this chapter have been published as follows: 
Ø Poonam Agarwal and Kyle M. Miller (2016) The nucleosome: orchestrating DNA 
damage signaling and repair within chromatin. Biochemistry and Cell Biology 
94: 1–15.    (Contributions: P.A. and K.M.M. wrote the manuscript together.) 
Ø Poonam Agarwal and Kyle. M. Miller  (2016) Book chapter: Chromatin 
Dynamics and DNA repair in Chromatin Regulation and Dynamics, Elsevier 
           (Contributions: P.A. and K.M.M. wrote the manuscript together). 
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drugs that alter chromatin dynamics have the potential to be combined with DNA 
damaging agents as novel therapeutic strategies to kill cancer cells (2, 97-99, 102, 104). 
Lastly, I have been focusing on characterizing the functions of TRIM-BRD proteins, 
which have currently gained importance as novel DDR factors. 
NUCLEOSOME ACIDIC PATCH 
Although our studies identified the nucleosome acidic patch as a key nucleosome 
feature that is utilized by the DDR factors RNF168 and RING1B/BMI1 to promote DNA 
damage signaling and repair, there are still numerous unanswered questions remaining 
about this chromatin region that need to be investigated. Several E3 ubiquitin ligases and 
other DDR factors promote the recruitment of RNF168 to damage sites. For example, 
RNF8 recruitment generates K-63-linked ubiquitin chains on H1 linker histones that are 
recognized by RNF168 via its UDM1 module, thus recruiting RNF168 to DSBs (39). 
Once on chromatin, RNF168 ubiquitinates histones, including H2A and H2AX on 
K13/15, which promotes the binding of the DDR factor 53BP1 to facilitate DSB repair by 
NHEJ (40, 41, 59, 62) (Figure 6.1A). 
RING1B/BMI1 catalyzes monoubiquitination of H2A/H2AX on the C-terminal lysines, 
K118 and K119 (129, 246) (Figure 6.1B). It is part of the Polycomb repressive complex1 
(PRC1) that compacts chromatin to promote transcriptional repression at various gene 
loci (129, 247, 248). In the DDR, several studies have shown that RING1B/BMI1 are 
recruited to sites of DNA damage (61, 123, 124, 249, 250). We and another group 
showed that the nucleosome acidic patch mediates the activity of the E3 ligase complex, 
RING1B/BMI1 (52, 142) (Figure 6.1B). Like RNF168, expression of the LANA 
(latency-associated nuclear antigen), a chromatin-interacting Kaposi’s sarcoma-
associated herpes virus (KSHV) peptide in cells or addition of LANA in biochemical 
peptide inhibition reactions interferes with these Ub reactions resulting in reduced 
H2A/H2AX ubiquitination by RING1B/BMI1. 
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Figure 6.1 The nucleosome acidic patch mediates multiple Ubs on H2A/X 
These Ub reactions are catalyzed by different E3 ligases for DDR signaling  (A) RNF168 
(B) BMI1/RING1B and (C) BRCA1(38). 
The use of the acidic patch to mediate DDR-dependent E3 Ub ligase activities 
does not seem to be limited to RNF168 and RING1B/BMI1. Another E3 Ub ligase 
involved in the DDR, BRCA1 (251), has recently been shown to ubiquitinate 
nucleosomal H2A K127/129 in an acidic patch-dependent reaction (252) (Figure 6.1C). 
The functional significance of H2A ubiquitination in the DDR by BRCA1 is still unclear. 
Previous work on mouse models of cancer has proposed that the E3 ligase activity of 
BRCA1 is dispensable for its tumor suppressive activity (253). Similar to RING1B/BMI1 
heterodimeric complex, the BRCA1/BARD1 forms a heterodimer to form a RING-type 
E3 ligase (254). Structural analysis and sequence alignment shows that the nucleosome-
interacting region of RING1B (including the lysine-arginine motif) and the corresponding 
region in BRCA1 are evolutionarily conserved. Furthermore, mutational disruption of 
this motif on BRCA1 or the nucleosome acidic patch eliminates H2A ubiquitylation by 
BRCA1 in vitro (142). Thus, like RNF168 and RING1B, BRCA1 appears to utilize the 
acidic patch on the nucleosome to promote its activity. Despite the large number of lysine 
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residues in the nucleosome, only a select few are ubiquitinated by RNF168, 
RING1B/BMI1, and BRCA1 E3 ubiquitin ligases and function within DSB signaling and 
repair. 
It is remarkable that all of these ubiquitination sites and their targeting enzymes 
require the nucleosome acidic patch. This raises an important question of how these 
enzymes are regulated at the level of the nucleosome to organize and promote the 
requisite activity at any given chromatin location without interference from a competing 
pathway. The nucleosome acidic patch on H2A/H2AX must therefore serve as a 
signaling hub that is able to accommodate and integrate a host of signals from different 
pathways that coordinate the chromatin activities that are essential for DSB signaling and 
repair (50, 52, 53, 255). Although structural and biochemical studies have provided key 
insights into enzyme-nucleosome interactions, additional experiments in cells are 
necessary to better understand mechanistically how the nucleosome acidic patch 
interacting network is set-up and regulated. For example, many of these pathways are 
implicated in diseases, including cancer (256-259). It will be interesting to know whether 
an imbalance of these, or other acidic patch interacting proteins, could negatively impact 
the function of other pathways reliant on this nucleosome surface motif. For example, 
cells infected with viruses or cancer cells that express high levels of acidic patch 
interacting proteins might impede the interactions of other factors that use the same 
interaction platform resulting in perturbation of these pathways. As more and more acidic 
patch interacting factors are identified, answers to these questions will be important to 
rationalize how chromatin functions to integrate these signals to promote genome 
stability and cellular homeostasis. 
NUCLEOSOME ACIDIC PATCH INTERACTING FACTORS 
In contrast to the prominent negatively charged surfaces of the NCP, the histone 
tails contain many arginine and lysine residues and carry a strong net positive charge. As 
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discussed earlier, the acidic patch domain is involved in nucleosome–nucleosome inter- 
actions via the basic histone H4 tail, a critical step for chromatin folding and compaction 
(57). In addition, the acidic patch is implicated as a crucial interaction platform for many 
nucleosome–protein complexes, some of which have been structurally demonstrated. For 
instance, the first complex structure of a nucleosome–peptide that was resolved and 
biochemically described was the viral peptide LANA from KSHV bound with the 
nucleosome (67, 118, 140). This pioneering work established how a viral protein 
interacted with the nucleosome through the acidic patch. Structural, computational 
modeling, and experimental analyses of other nucleosome binding proteins including 
HMGN2, RCC1, CENP-C, Sir3, IL-33, H4-tail, and the viral protein IE1 have revealed 
that these proteins interact with the acidic patch, which serves as the principal protein-
docking region for these proteins with the nucleosome (57, 149, 260-263) (Figure 6.2). 
It is intriguing that most of these proteins use a basic residue, generally an 
arginine or lysine, to make contact with one or more of the 8 negatively charged residues 
that constitute the nucleosomal acidic patch (66, 67, 149, 260, 262, 264) (Table 2)(38). 
Song Tan and colleagues published the co-crystal structure of the nucleosome-PRC1 
ubiquitylation module, which has provided a detailed mechanistic view of how the 
enzyme RING1B/BMI1 interacts with the acidic patch to facilitate its substrate 
recognition on the nucleosome (142). All 6 PCGF E3s of the PRC1 and PRC2 complexes 
including RING1B/BMI1, recognize the H2A/H2B acidic patch (142, 247, 265). Based 
on the identification of a host of nucleosome acidic patch interacting it seems highly 
likely that additional proteins will be identified that rely on interactions with the 
nucleosome acidic patch for their function, including those involved in the DDR, on 
chromatin. 
A key question to address in the future is how do chromatin features, including 
the nucleosome acidic patch, regulate specific interactions with DDR and chromatin 
factors in the presence of other nucleosome binding proteins that target the same acidic 
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Figure 6.2 Nucleosome acidic patch interacting proteins 
The acidic patch is a central hub for nucleosome interactions for multiple proteins 
involved in diverse biological processes. The crystal structure of NCP was retrieved from 
protein data bank (PDB code 1AOI) and modeled in Pymol. Color coding is as follows: 
DNA, grey; histones, pale cyan; acidic patch, red (38). 
pocket on the nucleosome. Chromatin is also highly modified, and an understanding of 
how additional modifications regulate interactions with chromatin factors and the 
nucleosome acidic patch are unknown. Another level of complexity is offered by the fact 
that in addition to the interactions between proteins and the nucleosome surface, 
negatively charged DNA also interacts electrostatically with specific basic regions of the 
histones and non-histone proteins in various chromatin templated processes, including 
DNA damage signaling. For example, the RING1B/BMI1-UbcH5c E3-E2 complex, 
forming the ubiquitin signaling module that is activated upon DSB induction, is known to 
interact with both the nucleosomal DNA and the acidic patch of the nucleosome (142). 
Given the weak interactions of many proteins with the nucleosome acidic patch, 
including DDR factors, these additional interactions between nucleosomal DNA and the 
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Table 6.1 Nucleosome acidic patch interacting factors  
protein could also contribute to their productive interactions with the nucleosome. 
Writing the histone-code involved in DSB signaling and repair thereby utilizes complex 
signaling events, including those occurring on the surface of the nucleosome that aid in 
recognizing, sensing, and repairing DSBs throughout the various chromatin environments 
that exist across the genome of mammalian cells. 
NUCLEOSOME ACIDIC PATCH AS A THERAPEUTIC TARGET 
Combining the above observations with the emerging paradigm that many 
proteins involved in DSB repair physically associate with the acidic patch to modulate 
chromatin dynamics, this unique chromatin interaction domain on the nucleosomal 
surface acts a central hub for DNA repair factor interactions with chromatin. Although 
cancer treatments have been “drugging” the DNA component of chromatin for over a 
half-century (i.e., cisplatin, ionizing radiation (2), or modifications of DNA or histones 
(i.e., FDA-approved inhibitors of DNA methylation or histone deacetylases) (98, 266, 
267), no therapy currently targets the unmodified histone protein component of chromatin 
within the nucleosome (95). Given the tremendous success of DNA targeting drugs as 
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therapeutic agents in cancer, the nucleosome surface represents a potentially attractive 
drug target (140, 266). Although both RING1B/BMI1 and RNF168 E3 ubiquitin ligases 
are involved in DDR signaling, overexpression and hyperactivation of these enzymes 
have been implicated in cancer initiation and development (158, 256-259). Supporting 
the potential for these pathways as therapeutic targets, small molecule inhibitors 
degrading or inhibiting RING1B/BMI1 ubiquitin ligase complex have been developed 
and show promise in anti-tumor activity in colorectal cancer models (268-270). 
The wealth of available structural and biochemical information on nucleosome 
and nucleosome acid patch-interacting proteins can be leveraged to design, synthesize, 
and test small molecule or peptide-derived inhibitors of nucleosome acidic patch 
interaction factors including RING1B/BMI1 and RNF168. The combination of genetic 
screens and in vitro structural and biochemical analyses is providing additional novel 
insights into how diverse chromatin-associated machineries interact with the nucleosome, 
in addition to the nucleosome acidic patch, to promote chromatin-based DDR activities. 
Several topological features beyond the charged acidic pocket exist on the nucleosomal 
surface that control and regulate nuclear processes, which could include DNA damage 
signaling and repair. Future work is required to understand whether these factors are 
mutually exclusive or act combinatorially on the nucleosome surface to write the 
requisite code for the DDR within a specific chromatin context. Studies furthering our 
mechanistic understanding of how chromatin proteins interact with the nucleosome to 
promote the DDR are warranted to have a better understanding of chromatin-based DDR 
pathways can be used to improve the development and application of DNA damaging 
agents and epigenetic drugs for the improved treatment of human diseases. 
CHROMATIN AND GENOME TARGETING CHEMOTHERAPEUTICS 
Chromatin targeting drugs constitute a major treatment for human cancer. The 
emerging roles of HDACs in DNA repair provide new opportunities for improving 
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traditional genotoxic drugs. Co-administration of HDAC inhibitors (HDACi) has been 
shown to enhance anticancer potency of drugs including cisplatin (110). The dynamic 
nature of genomes and epigenomes makes it challenging to predict and control 
chromatin-targeting drug responses. However, emerging evidence suggests that 
functional interactions between these drugs and the genome are non-stochastic and are 
influenced by a dynamic interplay between DNA sequences and chromatin states. 
Therefore, in the second part of my thesis project we screened a select few chromatin 
regulators or modulators of the chromatin states to assess how these influence targeting 
of anticancer Pt drugs used commonly as anticancer therapeutics. We developed a click-
chemistry based technique to visualize DNA-lesions in the cells and found that 
combination of an anticancer drug, cisplatin derivative, APPA that acts on the genome 
with an HDACi cotreatment with SAHA regulates its genome targeting capabilities to 
provide a unique drug response that induces hyper loading of platinum onto specific 
genomic loci promoting TLS dependent apoptosis and cell death. Our previous studies 
have shown that APPA preferentially targets the early S-phase cells. Damage induction in 
S-phase cells is known to activate translesion synthesis (TLS) pathway as a means to 
bypass the DNA lesion at stalled replication forks by recruitment of error-prone DNA 
polymerases including Polη and Polς mediated by monoubiquitination of PCNA. 
Translesion synthesis assays using human Polη has the ability to bypass cisplatin-GG 
adducts. Analyzing the changes in PCNA localization and RAD18 foci upon combined 
treatment of APPA with HDACi SAHA provided insights on the functional effects of 
chromatin reprogramming by these combination treatments. Our technique allows 
labeling of drugs with a tag while maintaining superior functionality of these small 
molecules that can be used for downstream applications including localization studies 
and genome-wide deep sequencing or proteomics to identify biologically relevant 
genomic target sites and drug-protein interactors (Figure 6.3). We believe knowledge 
gained from this study will have a transformative influence on our understanding, use and 
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development of combination therapies. These innovative approaches for identifying 
genomic target sites, responses and properties of genome and epigenome drugs could 
transform drug discovery by providing powerful methodologies to identify unanticipated 
and complex drug mechanisms. 
 
Figure 6.3 Click-chemistry based chemical labeling of DNA lesions in cells  
Visualizing DNA-Pt in cells enables to localize and identify genomic target sites of 
chromatin drugs. (This figure was provided by K.M.M.) 
Mechanistic details of the DDR and chromatin will provide insights into novel 
therapeutic targets and therapies because these pathways are currently targeted by anti-
cancer chemotherapeutic treatments in the clinic. Given the potential of combination 
therapies, a systematic analysis of cell populations from patient samples to study drug-
genome interactions could provide the basis to evaluate whether these patients would 
respond to treatment. For instance, using high throughput next generation sequencing, 
comparison of DNA-drug interactome between different cell lines could provide 
information about qualitative and quantitative differences in DNA targeting that could be 
exploited for therapeutic benefits. This technology could be extended to further study 
resistance mechanisms and to identify other small molecule modulators of cisplatin 
targeting by means of high throughput small molecule screening in an unbiased manner. 
For example, additional DNA damaging (Taxol) and chromatin regulating drugs 
including methylation inhibitors (5-azacytidine) that are relevant for biomedicine can be 
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combined with the Pt drugs. A key question to be addressed in the future is how 
orchestration of drug targeting by chromatin influences the intrinsic resistance or 
sensitivity of cancer cells to drug treatments and acquired drug resistance, which 
represent serious obstacles for therapeutic applications. Many chemotherapeutic 
compounds used as cancer therapies such as platinum drugs including cisplatin, 
oxaloplatin etc. readily result in chemoresistance through different mechanisms (108).  
Importantly, cisplatin resistant cancer cells can be resensitized to cisplatin by combined 
treatment with HDAC inhibitor treatments (109). Two FDA approved chromatin 
modulators; histone deacetylase inhibitors (HDACi) and DNA methylation inhibitor 5-
azacytidine are tested in phase trials for combinatorial use with other DNA damage for 
cancer treatments (110). Similar to genome-drug interactions, another key aspect that can 
be significantly informative is characterization of RNA targets of these platinum drugs 
including APPA, which could also contribute to the APPA-mediated alteration of gene 
expression. Furthermore, recent advancements in quantitative mass spectrometry along 
with our pull-down protocol may be employed to isolate and characterize proteins 
involved in the detection and processing of platinated DNA lesions in specific 
combinatorial treatment studies. Collectively, these studies will provide innovative tools 
and strategies for interrogating drug mechanisms and acquired drug resistance to better 
predict and control these responses in cancer and its treatments.  
BRD CONTAINING TRIM PROTEINS IN THE DDR 
Bromodomain (BRD) containing proteins are key mediators of chromatin based 
DDR mechanisms in eukaryotic cells via their potential to recognize and transmit signals 
that reside within acetylated chromatin. A host of BRD chromatin reader proteins have 
been unraveled that interact with damage associated acetylation to promote the DDR and 
thus maintain genome integrity. Some of the BRD containing proteins accumulate at sites 
of DNA lesions where they participate in the DDR whereas a few of them do not 
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accumulate at damage sites (82). A comprehensive analysis of all the human BRD 
proteins in the Miller Lab identified TRIM24 as a new DDR factor that recognizes DNA 
damage and recruits to damaged chromatin. Two other TRIM family proteins, TRIM28 
and TRIM33, which also contain the BRD, were identified to be recruited to DNA 
damage lesions. Another member of the TRIM-BRD protein family, TRIM66 is not 
studied here due to its tissue specific abundance and no recruitment to damage sites. 
However, TRIM24 is not well characterized in the context of DDR signaling and repair. 
How these three TRIM-BRD proteins collectively orchestrate the DDR in response to 
DNA breaks remains unclear.  
TRIM24 has previously been studied in specific cancer types where its elevated 
expression promotes progression of cancer including breast ((210, 213), head and neck 
(271), non-small cell lung (272), glioblastoma (273), cervical cancer (274) and HCC 
(275). Some studies highlight TRIM24 as a tumor suppressor in hepatocellular carcinoma 
(276, 277). It is known to serve as an E3 Ub ligase to regulate p53 levels resulting in p53 
degradation thereby affecting cell cycle arrest and apoptosis (211). It is also known as a 
transcriptional intermediary factor or transcriptional activator for various genes (278, 
279) and its interaction with several nuclear receptors (280). 
We showed that TRIM24 recruitment is affected upon down regulating the HAT 
KAT6B to facilitate DNA repair revealing the importance of acetylation signaling in this 
pathway. Cells depleted in TRIM24 showed defective NHEJ repair and had lower levels 
of the master regulator protein MDC1. Our proteomic and genetic analyses indicate that 
these three proteins, TRIM24, TRIM28 and TRIM33 functionally interact to orchestrate 
DDR signaling and repair. We found that both TRIM24 and TRIM33 interact with 
components of the histone chaperone complex, FACT. In addition, TRIM24 interacts 
with the replicative helicase MCM complex. Previous studies have established that the 
individual FACT and MCM subunits form at least two different and sequential 
subassemblies to coordinate origin establishment and progression of replication initiation 
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and S-phase (242). The physical association of the DDR factor TRIM24 with this 
complex hints towards a distinct function of this BRD protein in resolving damage at 
active replication regions such as the replication forks. Therefore, further mechanistic 
details of involvement of this protein complex in replication-associated DNA damage 
repair will illuminate critical pathways in which these are involved. Moreover, our data 
revealed that the recruitment of three BRD-TRIM proteins, TRIM24, TRIM28 and 
TRIM33 is regulated by the methyltransferase SUV39H1 that catalyzes the repressive 
histone mark, H3K9me3. It is therefore, plausible that these three factors display 
synergistic or redundant functions in the regulation of repair activities at specific 
chromatin states containing DNA-damage sites.  
A new cardiac role of TRIM24 was recently reported where it was shown to 
interact with cardiac Dysbindin and TRIM32 in cardiomyocytes. In this study, the 
differential expression of the two TRIM proteins, TRIM24 and TRIM32, was found to 
have opposing roles in regulating their common interactor Dysbindin protein levels and 
thereby cardiomyocyte hypertrophy. TRIM24 expression levels are higher than TRIM32 
levels in the heart and it protects Dysbindin from degradation by TRIM32 to promote 
cardiomyotrophy (281). It is conceivable that a similar mechanism exists in DDR 
involving the three BRD-TRIM proteins where they function and interact in a synergistic 
or antagonistic way to regulate specific steps and pathways involved in DNA repair based 
on their total levels in the complex formation. ATM mediated phosphorylation of 
TRIM24 at S768 has been shown to play an auto inhibitory role to promote TRIM24 
degradation during DNA damage (282). However, other PTMs on TRIM24 might have a 
role in the DDR that needs to be explored. Emerging evidence from our studies suggest 
that TRIM24 is an important component of the DDR pathway, however, it remains to be 
identified which pathway other than the gene silencing machinery is activated by 
TRIM24 to mount DDR signaling upon DNA damage. Collectively, the data provided 
here defines TRIM24 as a new player in cellular response to genotoxic insults. Further 
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work elucidating DDR functions for TRIM24 along with its chromatin associated 
interactors, MCM and FACT complex is warranted and essential for cancer research 
given that drugs targeting chromatin remodelers are currently being extensively explored 
for cancer therapies either alone or in conjunction with other DNA-damaging therapeutic 
agents. We anticipate that additional studies will have the potential to shed light on the 
various chromatin associated mechanisms of the DNA damage response, including those 
mediated by nucleosome interactions and BRD proteins, knowledge gained from which 
can be utilized to develop new or optimized existing therapeutic strategies and drugs to 
treat cancer. 
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